AU743798C - Genetic inhibition by double-stranded RNA - Google Patents

Genetic inhibition by double-stranded RNA

Info

Publication number
AU743798C
AU743798C AU19380/99A AU1938099A AU743798C AU 743798 C AU743798 C AU 743798C AU 19380/99 A AU19380/99 A AU 19380/99A AU 1938099 A AU1938099 A AU 1938099A AU 743798 C AU743798 C AU 743798C
Authority
AU
Australia
Prior art keywords
rna
cell
organism
target gene
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU19380/99A
Other languages
English (en)
Other versions
AU743798B2 (en
AU1938099A (en
Inventor
Samuel E. Driver
Andrew Fire
Stephen A. Kostas
Craig C. Mello
Mary K. Montgomery
Hiroaki Tabara
Lisa Timmons
Siqun Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carnegie Institution for Science
University of Massachusetts Amherst
Original Assignee
Carnegie Institution for Science
University of Massachusetts Boston
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26749094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU743798(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Carnegie Institution for Science, University of Massachusetts Boston, University of Massachusetts Amherst filed Critical Carnegie Institution for Science
Publication of AU1938099A publication Critical patent/AU1938099A/en
Application granted granted Critical
Publication of AU743798B2 publication Critical patent/AU743798B2/en
Publication of AU743798C publication Critical patent/AU743798C/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8285—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for nematode resistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/70—Invertebrates
    • A01K2227/703—Worms, e.g. Caenorhabdities elegans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU19380/99A 1997-12-23 1998-12-21 Genetic inhibition by double-stranded RNA Expired AU743798C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6856297P 1997-12-23 1997-12-23
US60/068562 1997-12-23
US09/215,257 US6506559B1 (en) 1997-12-23 1998-12-18 Genetic inhibition by double-stranded RNA
US09/215257 1998-12-18
PCT/US1998/027233 WO1999032619A1 (en) 1997-12-23 1998-12-21 Genetic inhibition by double-stranded rna

Publications (3)

Publication Number Publication Date
AU1938099A AU1938099A (en) 1999-07-12
AU743798B2 AU743798B2 (en) 2002-02-07
AU743798C true AU743798C (en) 2006-02-09

Family

ID=26749094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19380/99A Expired AU743798C (en) 1997-12-23 1998-12-21 Genetic inhibition by double-stranded RNA

Country Status (6)

Country Link
US (11) US6506559B1 (enExample)
EP (2) EP2267131B1 (enExample)
JP (4) JP5148028B2 (enExample)
AU (1) AU743798C (enExample)
CA (1) CA2311999C (enExample)
WO (1) WO1999032619A1 (enExample)

Families Citing this family (2156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465188B1 (en) * 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US20040033977A1 (en) * 1990-08-14 2004-02-19 Bennett C. Frank Oligonucleotide modulation of cell adhesion
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
CA2135646A1 (en) * 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
US5639647A (en) * 1994-03-29 1997-06-17 Ribozyme Pharmaceuticals, Inc. 2'-deoxy-2'alkylnucleotide containing nucleic acid
US6156535A (en) * 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
US20040142895A1 (en) * 1995-10-26 2004-07-22 Sirna Therapeutics, Inc. Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
US6274369B1 (en) * 1996-02-02 2001-08-14 Invitrogen Corporation Method capable of increasing competency of bacterial cell transformation
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US20080119427A1 (en) * 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US7812149B2 (en) * 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US20060008448A1 (en) * 1996-06-11 2006-01-12 Minzhen Xu Inhibition of li expression in mammalian cells
US6586661B1 (en) 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
US7709454B2 (en) * 1997-06-20 2010-05-04 New York University Methods and compositions for inhibiting tumorigenesis
US20040072345A1 (en) * 1997-06-20 2004-04-15 Altaba Ariel Ruiz I. Method and compositions for inhibiting tumorigenesis
US6238876B1 (en) * 1997-06-20 2001-05-29 New York University Methods and materials for the diagnosis and treatment of sporadic basal cell carcinoma
US7351578B2 (en) 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
DE69836092T2 (de) * 1997-10-24 2007-05-10 Invitrogen Corp., Carlsbad Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
FR2782325B1 (fr) 1998-08-12 2002-05-24 Proteus Procede d'identification de sequences polynucleotidiques et/ou des proteines correspondantes a partir d'un echantillon d'acides nucleiques
US20040045056A1 (en) * 1998-02-26 2004-03-04 Zhizheng Chen Transformation of Brassica
US20060260005A1 (en) * 1998-02-26 2006-11-16 Zhizhen Chen Transformation of Brassica
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CN101818145A (zh) * 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
DK1068311T3 (da) † 1998-04-08 2011-08-08 Commw Scient Ind Res Org Fremgangsmåder og midler til opnåelse af modificerede fænotyper
US20040214330A1 (en) * 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
US8598332B1 (en) * 1998-04-08 2013-12-03 Bayer Cropscience N.V. Methods and means for obtaining modified phenotypes
US20030228597A1 (en) * 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
CA2326823A1 (en) * 1998-04-20 1999-10-28 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US7078224B1 (en) * 1999-05-14 2006-07-18 Promega Corporation Cell concentration and lysate clearance using paramagnetic particles
AR020078A1 (es) * 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
US7019195B1 (en) * 1998-05-26 2006-03-28 Syngenta Participations Ag Method for conferring resistance or tolerance aganist furovirus, potyvirus, tospovirus, and cucomovirus to plant cells
US7005423B1 (en) * 1999-07-02 2006-02-28 Devgen Nv Characterization of gene function using double stranded RNA inhibition
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
US20060172925A1 (en) * 1998-10-26 2006-08-03 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US20040242521A1 (en) * 1999-10-25 2004-12-02 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US6759574B1 (en) 1998-11-05 2004-07-06 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Plants having enhanced gall resistance and methods and compositions for producing same
US6939712B1 (en) * 1998-12-29 2005-09-06 Impedagen, Llc Muting gene activity using a transgenic nucleic acid
AU776150B2 (en) * 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
AU2008202208C1 (en) * 1999-01-30 2014-04-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6987025B1 (en) 1999-02-11 2006-01-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Dwf4 polynucleotides, polypeptides and uses thereof
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
JP2002541822A (ja) * 1999-04-14 2002-12-10 エム ユー エス シー ファンデーション フォー リサーチ ディベロップメント 組織特異的および病原体特異的毒性物質ならびにリボザイム
IL145778A0 (en) * 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
EP1801215B1 (en) * 1999-05-10 2013-02-27 Syngenta Participations AG Regulation of viral gene expression
WO2000073493A2 (en) * 1999-05-27 2000-12-07 Pharmacia & Upjohn A nematode drug screen for modulators of mammalian disorders
US7485715B2 (en) 1999-06-18 2009-02-03 Ceres, Inc. Sequence-determined DNA encoding AP2 domain polypeptides
US7479555B2 (en) 1999-07-21 2009-01-20 Ceres, Inc. Polynucleotides having a nucleotide sequence that encodes a polypeptide having MOV34 family activity
US20040002153A1 (en) * 1999-07-21 2004-01-01 Monia Brett P. Modulation of PTEN expression via oligomeric compounds
US6639121B1 (en) 1999-07-29 2003-10-28 Dana-Farber Cancer Institute, Inc. Inducible cancer model to study the molecular basis of host tumor cell interactions in vivo
US6924109B2 (en) * 1999-07-30 2005-08-02 Agy Therapeutics, Inc. High-throughput transcriptome and functional validation analysis
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6822086B1 (en) * 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7531718B2 (en) 1999-08-26 2009-05-12 Monsanto Technology, L.L.C. Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7067722B2 (en) 1999-08-26 2006-06-27 Monsanto Technology Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
CN1378602A (zh) * 1999-08-26 2002-11-06 卡尔根尼有限公司 含修饰的多不饱和脂肪酸的植物
US20040106567A1 (en) * 1999-09-07 2004-06-03 Hagstrom James E. Intravascular delivery of non-viral nucleic acid
US20020006664A1 (en) * 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US20040157327A1 (en) * 1999-10-22 2004-08-12 Wyeth Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto
GB9925459D0 (en) * 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
DE10160151A1 (de) * 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20050229272A1 (en) * 1999-12-30 2005-10-13 Monica Driscoll Compositions and methods for gene silencing
EP1242609A2 (en) * 1999-12-30 2002-09-25 Novartis AG Novel colloid synthetic vectors for gene therapy
US6531644B1 (en) * 2000-01-14 2003-03-11 Exelixis, Inc. Methods for identifying anti-cancer drug targets
US20020055479A1 (en) * 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US7179796B2 (en) * 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
CA2398282A1 (en) * 2000-02-11 2001-08-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
US20050233329A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. Inhibition of gene expression using duplex forming oligonucleotides
US20080039414A1 (en) * 2002-02-20 2008-02-14 Sima Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050032733A1 (en) * 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en) * 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US8202846B2 (en) * 2000-03-16 2012-06-19 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
EP1728862A1 (en) * 2000-03-16 2006-12-06 Genetica, Inc. Methods and compositions for RNA interference
JP2003526367A (ja) * 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Ｒｎａ干渉の方法とｒｎａ干渉組成物
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
CN1426466A (zh) * 2000-03-17 2003-06-25 贝尼泰克澳大利亚有限公司 遗传沉默
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
EP2796553B1 (en) † 2000-03-30 2019-06-19 Whitehead Institute for Biomedical Research RNA sequence-specific mediators of RNA interference
US7691991B2 (en) 2000-04-17 2010-04-06 Ceres, Inc. Sequence-determined DNA fragments encoding cytochrome P450 proteins
GB0012233D0 (en) 2000-05-19 2000-07-12 Devgen Nv Vector constructs
US20100305186A1 (en) * 2000-05-30 2010-12-02 Johnson & Johnson Research Pty Limited Methods for mediating gene suppression
JP2002306183A (ja) * 2000-06-02 2002-10-22 Mitsubishi Chemicals Corp 遺伝子機能同定法
WO2001096584A2 (en) * 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
CA2408326A1 (en) 2000-06-23 2002-01-03 E.I. Dupont De Nemours And Company Recombinant constructs and their use in reducing gene expression
US7662791B2 (en) 2000-08-02 2010-02-16 University Of Southern California Gene silencing using mRNA-cDNA hybrids
US8044259B2 (en) * 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
CA2456008A1 (en) * 2000-08-19 2002-02-28 Axordia Limited Stem cell differentiation
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
WO2002018607A2 (en) 2000-08-30 2002-03-07 North Carolina State University Transgenic plants containing molecular decoys that alter protein content therein
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20080032942A1 (en) 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20060247194A1 (en) * 2000-08-30 2006-11-02 Sirna Therapeutics , Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
WO2002022858A1 (en) * 2000-09-14 2002-03-21 The Regents Of The University Of California Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
US20020165192A1 (en) * 2000-09-19 2002-11-07 Kerr William G. Control of NK cell function and survival by modulation of ship activity
AU2001292753A1 (en) * 2000-09-19 2002-04-02 University Of South Florida Control of nk cell function and survival by modulation of ship activity
US7691821B2 (en) * 2001-09-19 2010-04-06 University Of South Florida Inhibition of SHIP to enhance stem cell harvest and transplantation
BR0114618B1 (pt) * 2000-10-12 2014-06-10 Univ New Jersey Med Método para facilitar a coalescência de dois membros selecionados do grupo que consiste de células, vesículas de bicamada de lipídeo e lipossomas
CA2427347C (en) 2000-10-31 2011-01-18 Commonwealth Scientific And Industrial Research Organisation Method and means for producing barley yellow dwarf virus resistant cereal plants
EP1368467B1 (en) 2000-11-07 2007-04-25 North Carolina State University Putrescine-n-methyltransferase promoter
US20020173478A1 (en) * 2000-11-14 2002-11-21 The Trustees Of The University Of Pennsylvania Post-transcriptional gene silencing by RNAi in mammalian cells
CH695778A5 (de) * 2000-11-29 2006-08-31 Hoffmann La Roche Hemmung der Transkription eines Zielgens in einer Zelle oder in Geweben.
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
JP2004532616A (ja) * 2000-12-28 2004-10-28 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 二本鎖ｒｎａ仲介遺伝子抑制
US7385046B2 (en) 2001-01-03 2008-06-10 Ceres, Inc. Sequence-determined DNA fragments encoding ethylene responsive element binding proteins
US7423142B2 (en) * 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
JP2002208294A (ja) * 2001-01-12 2002-07-26 Toshiba Corp リダンダンシーシステムを有する半導体記憶装置
EP1860199B1 (en) 2001-01-12 2014-03-05 Exelixis, Inc. Modulating insulin receptor signaling
JP4454934B2 (ja) 2001-01-26 2010-04-21 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 組換えクローニングを用いて効率のよいサイレンシング構築物を作製する方法および手段
US20020132257A1 (en) * 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
AU2002250034A1 (en) * 2001-02-08 2002-08-19 Sequitur, Inc. Methods of light activated release 0f ligands from endosomes
GB0104948D0 (en) * 2001-02-28 2001-04-18 Novartis Res Foundation Novel methods
US7563618B2 (en) * 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
US20040006035A1 (en) * 2001-05-29 2004-01-08 Dennis Macejak Nucleic acid mediated disruption of HIV fusogenic peptide interactions
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050191618A1 (en) * 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050176664A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US20050176666A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050182006A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
US20050159378A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
EP3231445A1 (en) 2001-05-18 2017-10-18 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050130181A1 (en) * 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20070270579A1 (en) * 2001-05-18 2007-11-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050137155A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20040219671A1 (en) * 2002-02-20 2004-11-04 Sirna Therapeutics, Inc. RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20060019913A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20040019001A1 (en) * 2002-02-20 2004-01-29 Mcswiggen James A. RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050164966A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050233344A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20080188430A1 (en) * 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050054596A1 (en) * 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050176665A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20050159379A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US20050136436A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) * 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050079610A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20060142226A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
US20050182009A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20050124568A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050054598A1 (en) * 2002-02-20 2005-03-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20090299045A1 (en) * 2001-05-18 2009-12-03 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition Of Interleukin and Interleukin Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2003072590A1 (en) * 2002-02-20 2003-09-04 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2003070197A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050159380A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
US20070049543A1 (en) * 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20060142225A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US20050164224A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20050170371A1 (en) * 2001-05-18 2005-08-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20050153914A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US20050233996A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20050267058A1 (en) * 2001-05-18 2005-12-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
US20050164967A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20050124567A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
US20050191638A1 (en) * 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20070093437A1 (en) * 2001-05-18 2007-04-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of xiap gene expression using short interfering nucleic acid (sina)
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050159376A1 (en) * 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20050187174A1 (en) * 2001-05-18 2005-08-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US8008472B2 (en) 2001-05-29 2011-08-30 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
WO2002099083A2 (en) 2001-06-05 2002-12-12 Exelixis, Inc. Gfats as modifiers of the p53 pathway and methods of use
SG132542A1 (en) 2001-06-08 2007-06-28 Vector Tobacco Ltd Modifying nicotine and nitrosamine levels in tobacco
US20030190312A1 (en) * 2001-06-22 2003-10-09 The Regents Of The University Of California Eukaryotic genes involved in adult lifespan regulation
US20040126867A1 (en) * 2001-07-06 2004-07-01 Crooke Stanley T. Human RNase III and compositions and uses thereof
ES2192945B1 (es) * 2001-07-06 2005-03-01 Consejo Superior De Investigaciones Cientificas Un metodo para interferir con la infeccion de virus en plantas.
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
BR0211079A (pt) * 2001-07-10 2005-08-30 Johnson & Johnson Res Pty Ltd Processos para a modificação genética de células hematopoiéticas progenitoras e empregos das células modificadas
WO2003006614A2 (en) 2001-07-12 2003-01-23 Exelixis, Inc. UBE2s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
BR0211111A (pt) * 2001-07-12 2004-06-22 Univ Massachusetts Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula
US8022272B2 (en) 2001-07-13 2011-09-20 Sungene Gmbh & Co. Kgaa Expression cassettes for transgenic expression of nucleic acids
US10590418B2 (en) * 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
WO2003010180A1 (en) * 2001-07-23 2003-02-06 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for rnai mediated inhibition of gene expression in mammals
US7612194B2 (en) * 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
GB0118223D0 (en) * 2001-07-26 2001-09-19 Univ Sheffield Stem loop RNA
US20050037989A1 (en) * 2001-08-27 2005-02-17 Lewis David L. Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US7456335B2 (en) 2001-09-03 2008-11-25 Basf Plant Science Gmbh Nucleic acid sequences and their use in methods for achieving pathogen resistance in plants
CA2457282C (en) 2001-09-13 2015-01-13 California Institute Of Technology Method for expression of small antiviral rna molecules within a cell
US7195916B2 (en) * 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
EP1446503A2 (en) 2001-09-27 2004-08-18 University Of Delaware Composition and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration
EP2428570B1 (en) * 2001-09-28 2018-05-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microrna molecules
GB0123401D0 (en) * 2001-09-28 2001-11-21 Novartis Forschungsstiftung Methods of inducing gene expression
DE10163098B4 (de) 2001-10-12 2005-06-02 Alnylam Europe Ag Verfahren zur Hemmung der Replikation von Viren
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
WO2003034985A2 (en) * 2001-10-22 2003-05-01 University Of Rochester Telomerase interference
DE10230996A1 (de) * 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Behandlung eines Pankreaskarzinoms
DE10230997A1 (de) * 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
WO2003035083A1 (de) * 2001-10-26 2003-05-01 Ribopharma Ag Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
US20050119202A1 (en) * 2001-10-26 2005-06-02 Roland Kreutzer Medicament to treat a fibrotic disease
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
JP2005527639A (ja) * 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
US7659391B2 (en) * 2001-11-05 2010-02-09 Janssen Pharmaceutica N.V. Method for the in vitro synthesis of short double stranded RNAs
US20030150017A1 (en) * 2001-11-07 2003-08-07 Mesa Jose Ramon Botella Method for facilitating pathogen resistance
US20030148519A1 (en) * 2001-11-14 2003-08-07 Engelke David R. Intracellular expression and delivery of siRNAs in mammalian cells
WO2003043580A2 (en) * 2001-11-19 2003-05-30 Proteologics, Inc. Methods for identifying and validating potential drug targets
KR100990055B1 (ko) * 2001-11-21 2010-10-26 사이고 가오루 유전자 발현 억제 방법
AU2002343792A1 (en) * 2001-11-28 2003-06-10 Center For Advanced Science And Technology Incubation, Ltd. siRNA EXPRESSION SYSTEM AND PROCESS FOR PRODUCING FUNCTIONAL GENE-KNOCKDOWN CELLS AND THE LIKE USING THE SAME
US20040138163A1 (en) * 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070203333A1 (en) * 2001-11-30 2007-08-30 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050075304A1 (en) * 2001-11-30 2005-04-07 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
GB0130199D0 (en) * 2001-12-17 2002-02-06 Syngenta Mogen Bv New nematode feeding assay
US7294504B1 (en) * 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
AU2012261651B2 (en) * 2002-01-22 2015-09-24 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
DE10202419A1 (de) * 2002-01-22 2003-08-07 Ribopharma Ag Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens
AU2008246266B2 (en) * 2002-01-22 2012-09-06 Cold Spring Harbor Laboratory Methods and compositions for RNA interference
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP1478656B1 (en) † 2002-02-01 2009-09-16 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US20030166282A1 (en) * 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
US20050096289A1 (en) * 2002-02-07 2005-05-05 Hans Prydz Methods and compositions for modulating tissue factor
US20050202428A1 (en) * 2002-02-13 2005-09-15 Axordia Limited Pluripotential stem cells
JP2005527198A (ja) * 2002-02-14 2005-09-15 シティ・オブ・ホープ 哺乳動物細胞において、干渉ｒｎａ分子を産生する方法、および該干渉ｒｎａ分子の療法的使用
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8067575B2 (en) 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US7662952B2 (en) * 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
WO2003106476A1 (en) * 2002-02-20 2003-12-24 Sirna Therapeutics, Inc Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US7935812B2 (en) 2002-02-20 2011-05-03 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
US7910724B2 (en) 2002-02-20 2011-03-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20090253773A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7683165B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US7667029B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US7691999B2 (en) 2002-02-20 2010-04-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US7678897B2 (en) 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US7700760B2 (en) 2002-02-20 2010-04-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US8258288B2 (en) 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US7897752B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US7928218B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US7667030B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
JP2005517427A (ja) 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＣ型肝炎ウイルス（ＨＣＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1476459A4 (en) * 2002-02-20 2005-05-25 Sirna Therapeutics Inc INHIBITION OF RNA INTERFERENCE-INDUCED CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
CA2477014A1 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of tnf and tnf receptor superfamily gene expression using short interfering nucleic acid (sina)
US7928219B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
US20090253774A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7897757B2 (en) 2002-02-20 2011-03-01 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US8013143B2 (en) 2002-02-20 2011-09-06 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US20050137153A1 (en) * 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
US7928220B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US7893248B2 (en) * 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20090137510A1 (en) * 2002-02-20 2009-05-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/ REL-A GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2005517450A (ja) * 2002-02-20 2005-06-16 サーナ・セラピューティクス・インコーポレイテッド 短干渉核酸（ｓｉＮＡ）を用いるＲＮＡ干渉媒介性標的発見および標的評価
US20090137513A1 (en) * 2002-02-20 2009-05-28 Sirna Therapeutics, Inc. RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA)
US7795422B2 (en) 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
AU2003215161A1 (en) * 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TELOMERASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1448590A4 (en) * 2002-02-20 2004-12-15 Sirna Therapeutics Inc Inhibition of the myc and myb genes mediated by RNA interference mediated or genes of the corresponding synthetic pathways
CN100549171C (zh) * 2002-02-22 2009-10-14 大塚制药株式会社 靶基因用多核苷酸
US20050176008A1 (en) * 2002-02-22 2005-08-11 Mikio Suzuki Polynucleotide for target gene
AUPS078002A0 (en) * 2002-02-27 2002-03-21 Unisearch Limited Dnazyme therapeutics
WO2003073991A2 (en) 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
US7274703B2 (en) * 2002-03-11 2007-09-25 3Com Corporation Stackable network units with resiliency facility
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
AU2003218181A1 (en) * 2002-03-15 2003-09-29 Multicell Immunotherapeutics, Inc. Immunostimulatory double stranded RNA and methods of inducing, enhancing or modulating the immune response
WO2003079025A2 (en) 2002-03-19 2003-09-25 Novartis Ag Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof
DE10212893A1 (de) * 2002-03-20 2003-10-16 Basf Plant Science Gmbh Verfahren zum Erhöhen des Ölgehaltes in Pflanzen
DE10212892A1 (de) 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
US7166771B2 (en) * 2002-06-21 2007-01-23 Monsanto Technology Llc Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
US7566813B2 (en) * 2002-03-21 2009-07-28 Monsanto Technology, L.L.C. Nucleic acid constructs and methods for producing altered seed oil compositions
WO2003080802A2 (en) * 2002-03-21 2003-10-02 Monsanto Technology Llc Nucleic acid constructs and methods for producing altered seed oil compositions
DK1490490T3 (da) 2002-03-27 2009-09-07 Aegera Therapeutics Inc Antisense IAP--nukleobase-oligomerer og anvendelser deraf
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
EP1352960A1 (en) * 2002-04-12 2003-10-15 Viruvation B.V. Antiviral therapy on the basis of RNA interference
US20050222061A1 (en) * 2002-04-18 2005-10-06 Schulte Ralf W Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
EP1497418B1 (en) 2002-04-19 2012-10-17 Verenium Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
EP1497437A4 (en) 2002-05-01 2005-11-16 Cell Genesys Inc LENTIVIRAL VECTOR PARTICLES RESISTANT TO THE INACTIVATION OF A COMPLEMENT
CA2524569C (en) 2002-05-03 2013-10-22 Duke University A method of regulating gene expression
CA2487274A1 (en) 2002-05-06 2003-11-13 Nucleonics Inc. Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent
US20030228691A1 (en) * 2002-05-17 2003-12-11 Lewis David L. Processes for inhibiting gene expression using polynucleotides
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US20040121353A1 (en) * 2002-05-23 2004-06-24 Ceptyr, Inc. Modulation of TCPTP signal transduction by RNA interference
GB0212302D0 (en) * 2002-05-28 2002-07-10 Isis Innovation Method of selecting targets for gene silencing by RNA interference
GB0212303D0 (en) * 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
US20040019008A1 (en) * 2002-05-28 2004-01-29 Lewis David L. Compositions and processes using siRNA, amphipathic compounds and polycations
FR2840217B1 (fr) * 2002-06-03 2005-06-24 Oreal Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
CA2388441A1 (en) * 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
WO2003106630A2 (en) * 2002-06-12 2003-12-24 Ambion, Inc. Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20100075423A1 (en) * 2002-06-12 2010-03-25 Life Technologies Corporation Methods and compositions relating to polypeptides with rnase iii domains that mediate rna interference
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
MXPA04012614A (es) 2002-06-14 2005-12-14 Diversa Corp Xilanasas, acidos nucleicos que las codifican, y metodos para hacerlas y usarlas.
AU2003251579B2 (en) * 2002-06-21 2008-04-03 Monsanto Technology Llc Intron double stranded RNA constructs and uses thereof
EP1516186B1 (en) * 2002-06-26 2010-02-17 University Of Louisville Research Foundation, Inc. A method for the detection of apoptosis
CA2491034A1 (en) * 2002-06-26 2004-01-08 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
WO2004005485A2 (en) * 2002-07-10 2004-01-15 Kansas State University Research Foundation Compositions and methods for controlling parasitic nematodes
US7655790B2 (en) 2002-07-12 2010-02-02 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
US20040219516A1 (en) * 2002-07-18 2004-11-04 Invitrogen Corporation Viral vectors containing recombination sites
DE10233327A1 (de) * 2002-07-22 2004-02-05 Basf Ag Verfahren zum Erreichen einer Pathogenresistenz in Pflanzen
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US7399851B2 (en) 2002-07-25 2008-07-15 Dana Farber Cancer Institute, Inc. Composition and method for imaging cells
ATE405658T1 (de) 2002-07-26 2008-09-15 Basf Plant Science Gmbh Neue selektionsverfahren
JP4709545B2 (ja) * 2002-07-26 2011-06-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 修飾された低分子干渉ｒｎａ分子および使用方法
US20050239728A1 (en) * 2002-07-31 2005-10-27 Pachuk Catherine J Double stranded rna structures and constructs, and methods for generating and using the same
WO2004013288A2 (en) 2002-08-01 2004-02-12 City Of Hope Methods and kits for synthesis of sirna expression cassettes
US20050106731A1 (en) * 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
US20050255086A1 (en) * 2002-08-05 2005-11-17 Davidson Beverly L Nucleic acid silencing of Huntington's Disease gene
US20080274989A1 (en) 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
US20080176812A1 (en) * 2002-08-05 2008-07-24 Davidson Beverly L Allele-specific silencing of disease genes
US20040241854A1 (en) * 2002-08-05 2004-12-02 Davidson Beverly L. siRNA-mediated gene silencing
US20040023390A1 (en) * 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
US20050042646A1 (en) * 2002-08-05 2005-02-24 Davidson Beverly L. RNA interference suppresion of neurodegenerative diseases and methods of use thereof
SG166672A1 (en) * 2002-08-06 2010-12-29 Intradigm Corp Methods of down regulating target gene expression in vivo by introduction of interfering rna
AU2003261449A1 (en) 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
EP1529112A2 (en) 2002-08-07 2005-05-11 BASF Plant Science GmbH Nucleic acid sequences encoding proteins associated with abiotic stress response
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
CN1685063B (zh) * 2002-08-12 2011-12-21 新英格兰生物实验室公司 与基因沉默相关的方法和组合物
EP1534832A2 (en) * 2002-09-04 2005-06-01 Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Compositions and methods for tissue specific or inducible inhibition of gene expression
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
AU2003268531A1 (en) 2002-09-06 2004-03-29 University Of South Florida Materials and methods for treatment of allergic diseases
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
EA008940B1 (ru) * 2002-09-13 2007-10-26 Репликор, Инк. Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
AU2003270734A1 (en) * 2002-09-16 2004-04-30 University Of Southern California Rna-mediated gene modulation
US7476777B2 (en) 2002-09-17 2009-01-13 Ceres, Inc. Biological containment system
EP1546344A4 (en) * 2002-09-18 2007-10-03 Isis Pharmaceuticals Inc EFFICIENT PRODUCTION OF TARGET RNAS USING SINGLE AND DOUBLE-STRONG OLIGOMER COMPOUNDS
WO2004029212A2 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
AU2003277005A1 (en) * 2002-09-26 2004-04-19 The Regents Of The University Of California Conditional gene expression using rnai
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20070224124A1 (en) * 2002-09-30 2007-09-27 University Of South Florida Novel SH2containing inositol 5'-phosphatase isoform that partners with the Grb2 adapter protein
AU2003275449A1 (en) * 2002-10-07 2004-05-04 Wei Liu Compositions, organisms and methodologies employing a novel human kinase
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
WO2004032870A2 (en) * 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US7255860B2 (en) * 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
EP1549749A4 (en) * 2002-10-10 2007-08-22 Wyeth Corp COMPOSITIONS, ORGANISMS AND METHODS USING A NEW HUMAN KINASE
US7122361B2 (en) * 2002-10-10 2006-10-17 Wyeth Compositions employing a novel human kinase
WO2004036221A2 (en) * 2002-10-18 2004-04-29 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
CA2503491A1 (en) * 2002-10-24 2004-05-06 Wyeth Calcineurin-like human phosphoesterase
WO2004042024A2 (en) 2002-11-01 2004-05-21 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF HIF-1 ALPHA
US7892793B2 (en) * 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
CA2504694C (en) 2002-11-05 2013-10-01 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
GB0225799D0 (en) * 2002-11-05 2002-12-11 Novartis Forschungsstiftung Tel/etv6-mediated inhibition of cell proliferation
US8604183B2 (en) * 2002-11-05 2013-12-10 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004044138A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US9150606B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7635770B2 (en) * 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US20100113307A1 (en) * 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7691998B2 (en) * 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7592442B2 (en) * 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7977471B2 (en) * 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US7612196B2 (en) * 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US7619081B2 (en) * 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US20090227780A1 (en) * 2002-11-14 2009-09-10 Dharmacon, Inc. siRNA targeting connexin 43
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
WO2004046324A2 (en) * 2002-11-15 2004-06-03 University Of Massachusetts Allele-targeted rna interference
CA2505416A1 (en) * 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
US7365186B2 (en) * 2002-11-22 2008-04-29 Arborgen, Llc Vascular-preferred promoter sequences and uses thereof
WO2004047764A2 (en) * 2002-11-22 2004-06-10 University Of Massachusetts Modulation of hiv replication by rna interference
US7297779B2 (en) * 2002-11-24 2007-11-20 Daiichi Pharmaceutical Co., Ltd. Colon cancer metastasis inhibitor
EP2112229A3 (en) 2002-11-25 2009-12-02 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
US7217807B2 (en) * 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US7605249B2 (en) * 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20050048641A1 (en) * 2002-11-26 2005-03-03 Medtronic, Inc. System and method for delivering polynucleotides to the central nervous system
RU2379056C2 (ru) 2002-11-27 2010-01-20 Айрм Ллс Способы и композиции для индукции апоптоза раковых клеток
WO2004050831A2 (en) 2002-11-27 2004-06-17 Wyeth Compositions, organisms and methodologies employing a novel human kinase
US20040110698A1 (en) * 2002-12-10 2004-06-10 Kimron Veterinary Institute Oligonucleotides and methods using same for treating cox-ll associated diseases
CA2509494A1 (en) * 2002-12-11 2004-06-24 University Of Massachusetts Method of introducing sirna into adipocytes
US7544499B2 (en) 2002-12-16 2009-06-09 Halozyme, Inc. Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
US20040176293A1 (en) * 2002-12-18 2004-09-09 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
CN1301263C (zh) * 2002-12-18 2007-02-21 北京昭衍新药研究中心 一组抗hiv感染及防治艾滋病的核苷酸序列及其应用
US7078234B2 (en) 2002-12-18 2006-07-18 Monsanto Technology Llc Maize embryo-specific promoter compositions and methods for use thereof
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK1575517T3 (da) * 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
AU2003303589B2 (en) 2002-12-26 2008-04-24 Syngenta Participations Ag Cell proliferation-related polypeptides and uses therefor
US20040248299A1 (en) * 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
DE602004015064D1 (de) * 2003-01-06 2008-08-28 Wyeth Corp Zusammensetzungen und verfahren zur diagnose und behandlung von kolonkrebs
JP2007524349A (ja) * 2003-01-16 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法
EP1583832B1 (en) 2003-01-17 2010-12-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inducible small interfering rna (sirna) expression constructs for targeted gene silencing
JP3792655B2 (ja) * 2003-01-20 2006-07-05 日本電気株式会社 新規な癌遺伝子、該癌遺伝子由来の組換えタンパク質、およびそれらの用途
AU2004206250B8 (en) 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
US20040147027A1 (en) * 2003-01-28 2004-07-29 Troy Carol M. Complex for facilitating delivery of dsRNA into a cell and uses thereof
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
WO2004070025A2 (en) * 2003-02-05 2004-08-19 Juan Saus Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders
AU2004211949A1 (en) * 2003-02-05 2004-08-26 University Of Massachusetts RNAi targeting of viruses
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
US20040171118A1 (en) * 2003-02-13 2004-09-02 City Of Hope Methods for directing DNA methylation in mammalian cells using homologous short double stranded RNAs
JP2007524362A (ja) 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
JP2006523103A (ja) * 2003-02-21 2006-10-12 ザ ペン ステイト リサーチ ファウンデーション Ｒｎａ干渉組成物および方法
US20040261149A1 (en) * 2003-02-24 2004-12-23 Fauquet Claude M. siRNA-mediated inhibition of gene expression in plant cells
WO2004076639A2 (en) * 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
EP2311948A1 (en) 2003-02-28 2011-04-20 Onco Therapy Science, Inc. RNA-interference for ZNFN3A1-gene as a method for inhibiting cancer cell growth
WO2004078995A2 (en) 2003-03-04 2004-09-16 Neurogenetics, Inc. Methods of modulating and of identifying agents that modulate intracellular calcium
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
NZ542665A (en) * 2003-03-05 2008-05-30 Senesco Technologies Inc Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1604022A2 (en) * 2003-03-06 2005-12-14 Oligo Engine, Inc. Modulation of gene expression using dna-rna hybrids
WO2004091544A2 (en) * 2003-03-06 2004-10-28 Diversa Corporation Amylases, nucleic acids encoding them and methods for making and using them
EP2194133B1 (en) 2003-03-06 2015-12-02 BASF Enzymes LLC Amylases, nucleic acids encoding them and methods for making and using them
CA2515583C (en) 2003-03-07 2015-07-14 Diversa Corporation Hydrolases, nucleic acids encoding them and methods for making and using them
EP1601382A4 (en) * 2003-03-13 2006-11-22 Univ Utah Res Found PHOSPHOLIPID SCRAMBLASE 3
AU2004221760B2 (en) 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
WO2004087901A2 (en) 2003-03-25 2004-10-14 Wyeth Brain-localized protein kinases homologous to homeodomain-interacting protein kinases
JP2006522806A (ja) * 2003-03-26 2006-10-05 マルチセル・イミュノセラピューティクス，インコーポレイテッド 細胞死及び／又はアポトーシスを誘導するための、選択されたｒｎａモチーフ
AU2004225483B2 (en) 2003-03-28 2009-07-23 Monsanto Technology, Llc Novel plant promoters for use in early seed development
US20040265961A1 (en) * 2003-03-28 2004-12-30 Wei Liu Novel proteins homologous to kinase suppressor of Ras
CA2520987A1 (en) * 2003-04-01 2004-10-21 Intradigm Corporation Targets for tumor growth inhibition
WO2004087862A2 (en) * 2003-04-01 2004-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Tak1-mediated inhibition of osteogenesis
EP1608733B1 (en) * 2003-04-02 2011-12-07 Dharmacon, Inc. Modified polynucleotides for use in rna interference
US20070167384A1 (en) * 2003-04-02 2007-07-19 Dharmacon, Inc. Modified polynucleotides for use in rna interference
US8158420B2 (en) 2003-04-04 2012-04-17 The Trustees Of Columbia University In The City Of New York Methods for inhibiting the differentation of proliferative telencephalic cells in vitro by addition of ATF5
EP1613733B1 (en) 2003-04-04 2015-06-03 BASF Enzymes LLC Pectate lyases, nucleic acids encoding them and methods for making and using them
EP1615611B1 (en) * 2003-04-09 2013-02-13 Alnylam Pharmaceuticals Inc. iRNA CONJUGATES
JP4912873B2 (ja) * 2003-04-09 2012-04-11 アルナイラム ファーマシューティカルズ， インコーポレイテッド ｉＲＮＡ複合体
WO2004091515A2 (en) * 2003-04-09 2004-10-28 Alnylam Pharmaceuticals, Inc. iRNA CONJUGATES
US20070270360A1 (en) * 2003-04-15 2007-11-22 Sirna Therapeutics, Inc. Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid
EP1469070A1 (en) * 2003-04-15 2004-10-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Livin-specific siRNAs for the treatment of therapy-resistant tumors
AU2004233043A1 (en) * 2003-04-18 2004-11-04 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2
IL155561A0 (en) * 2003-04-24 2006-12-31 Yeda Res & Dev Oligonucleotides that block toll-like receptors
ES2398110T3 (es) 2003-04-29 2013-03-13 Biocrine Ab ApoCIII y tratamiento y diagnóstico de la diabetes
WO2004098634A2 (en) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
EP3222294A1 (en) 2003-04-30 2017-09-27 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
JP2007515940A (ja) * 2003-05-08 2007-06-21 ワイス 関節炎及びその他の炎症性疾患の薬物標的としてのプロテインキナーゼｃゼータ
US7619068B2 (en) 2003-05-09 2009-11-17 Diadexus, Inc. Ovr110 antibody compositions and methods of use
EP1623032A2 (en) * 2003-05-09 2006-02-08 University of Pittsburgh of the Commonwealth System of Higher Education Small interfering rna libraries and methods of synthesis and use
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
CN1780920B (zh) * 2003-05-12 2012-03-28 波多玛克制药有限公司 基因表达抑制剂
WO2005018534A2 (en) * 2003-05-16 2005-03-03 Rosetta Inpharmatics, Llc Methods and compositions for rna interference
US20070027099A1 (en) * 2003-05-19 2007-02-01 Lin Marie C Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA)
JP2007516230A (ja) 2003-05-19 2007-06-21 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 心臓組織の変性を治療及び予防するための組成物及び方法並びにその用途
US20050119210A1 (en) * 2003-05-20 2005-06-02 Xiaobing Be Compositions and methods for diagnosing and treating cancers
AU2004244626A1 (en) * 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20050042641A1 (en) * 2003-05-27 2005-02-24 Cold Spring Harbor Laboratory In vivo high throughput selection of RNAi probes
WO2004106515A1 (ja) 2003-05-28 2004-12-09 Scimedia Ltd. 抗ｂａｍｂｉ抗体、及びそれを含有する大腸癌及び肝臓癌の診断剤又は治療剤
WO2005001110A2 (en) * 2003-05-29 2005-01-06 The Salk Institute For Biological Studies Transcriptional regulation of gene expression by small double-stranded modulatory rna
EP1635858A4 (en) * 2003-05-29 2009-08-26 Scripps Research Inst TARGETED DELIVERY TO LEGUMAIN EXPRESSING CELLS
WO2004106511A1 (ja) 2003-05-30 2004-12-09 Nippon Shinyaku Co., Ltd. Ｂｃｌ−２の発現抑制をするオリゴ二本鎖ＲＮＡとそれを含有する医薬組成物
CA2527958C (en) * 2003-06-02 2014-04-08 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of rnai
US7750144B2 (en) * 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
CA2528012C (en) * 2003-06-02 2015-11-24 University Of Massachusetts Methods and compositions for controlling efficacy of rna silencing
JP4579911B2 (ja) 2003-06-03 2010-11-10 アイシス・ファーマシューティカルズ・インコーポレイテッド スルビビン発現の調節
US20050059044A1 (en) * 2003-06-03 2005-03-17 Graham Michael Wayne Double-stranded nucleic acid
CN1860231A (zh) * 2003-06-06 2006-11-08 阿博根有限公司 转录因子
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DK2270162T3 (en) 2003-06-12 2019-01-21 Alnylam Pharmaceuticals Inc PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING
WO2004113573A2 (en) * 2003-06-19 2004-12-29 The Samuel Roberts Noble Foundation, Inc. Methods and compositions for analysis of plant gene function
WO2005044976A2 (en) * 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
WO2005009346A2 (en) * 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US20080131874A1 (en) * 2003-06-24 2008-06-05 Amitava Mitra Method for efficient post-transcriptional gene silencing using intrinsic direct repeat sequences and utilization thereof in functional genomics
JP5248014B2 (ja) * 2003-06-25 2013-07-31 ゲンシア コーポレーション 細胞小器官トランスフェクションのための改質ベクター
JP5183064B2 (ja) * 2003-07-02 2013-04-17 エムユーエスシー ファウンデイション フォー リサーチ デべロップメント 甲殻類動物、及び他の無脊椎動物における、ｄｓＲＮＡで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体
CN103484486B (zh) 2003-07-02 2018-04-24 维莱尼姆公司 葡聚糖酶，编码它们的核酸以及制备和使用它们的方法
US20050019927A1 (en) * 2003-07-13 2005-01-27 Markus Hildinger DECREASING GENE EXPRESSION IN A MAMMALIAN SUBJECT IN VIVO VIA AAV-MEDIATED RNAi EXPRESSION CASSETTE TRANSFER
CA2532312A1 (en) 2003-08-01 2005-02-17 Basf Plant Science Gmbh Process for the production of fine chemicals in plants
EP1660010B1 (en) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with her2 antagonists
US20050026290A1 (en) * 2003-08-01 2005-02-03 Ciardi Joseph Anthony Inhibiting gene expression with dsRNA
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP2927318B1 (en) 2003-08-08 2020-05-20 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
US7741089B2 (en) 2003-08-11 2010-06-22 Verenium Corporation Laccases, nucleic acids encoding them and methods for making and using them
EP1651674B1 (en) 2003-08-14 2010-09-29 Exelixis, Inc. Ups as modifiers of the beta catenin pathway and methods of use
US20050112763A1 (en) * 2003-08-21 2005-05-26 Cold Spring Harbor Laboratory RNAI-based modification of heterochromatin
IL157538A0 (en) * 2003-08-21 2004-03-28 Bar Ilan Res & Dev Company Ltd Plant resistant to cytoplasm-feeding parasites
CA2536026A1 (en) * 2003-08-22 2005-05-06 Nucleonics Inc. Eukariotic expression systems for expression of inhibitory rna in multiple intracellular compartments
CN1845993B (zh) * 2003-08-28 2010-06-23 诺瓦提斯公司 具有平端和3＇修饰的干扰rna双链体
EP1670924A1 (en) * 2003-08-28 2006-06-21 Aveo Pharmaceuticals, Inc. Tumor-specific expression of reporter genes
WO2005026322A2 (en) * 2003-09-11 2005-03-24 Clontech Laboratories, Inc. siRNA ENCODING CONSTRUCTS AND METHODS FOR USING THE SAME
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
WO2005027980A1 (en) * 2003-09-12 2005-03-31 University Of Massachusetts Rna interference for the treatment of gain-of-function disorders
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
CA2568603A1 (en) * 2003-09-12 2005-03-24 Commonwealth Scientific And Industrial Research Organisation Modified gene-silencing nucleic acid molecules and uses thereof
EP1682573B1 (en) * 2003-09-15 2014-01-01 Cenix Bioscience GmbH The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases
WO2005025611A1 (en) * 2003-09-16 2005-03-24 Pharmacia Corporation Inhibitors of pace4 for the treatment of arthritis
EP1670955A2 (en) * 2003-09-22 2006-06-21 Rosetta Inpharmatics LLC. Synthetic lethal screen using rna interference
US20050282168A1 (en) * 2003-09-29 2005-12-22 Wyeth Cell surface molecules as markers and therapeutic agents against kidney cancers
KR20060100370A (ko) * 2003-09-30 2006-09-20 다카라 바이오 가부시키가이샤 ＲｎａｓｅⅢ 활성을 가지는 폴리펩티드
US20070218551A1 (en) * 2003-10-02 2007-09-20 Chuan-Yuan Li Novel Sirna-Based Approach to Target the Hif-Alpha Factor for Gene Therapy
EP1687410A4 (en) * 2003-10-07 2008-04-09 Isis Pharmaceuticals Inc ANTISENSE OLIGONUCLEOTIDE OPTIMIZED FOR KIDNEY TARGETING
WO2005035769A2 (en) * 2003-10-09 2005-04-21 E. I. Du Pont De Nemours And Company Gene silencing by using micro-rna molecules
BRPI0415771A (pt) 2003-10-23 2006-12-26 Illumigen Biosciences Inc detecção de mutações em um gene associado à resistência a infecção viral, oas1
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8062891B2 (en) * 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8507277B2 (en) * 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
AU2004297533B2 (en) * 2003-10-24 2010-04-29 Gencia Corporation Methods and compositions for delivering polynucleotides
ES2687645T3 (es) 2003-10-27 2018-10-26 Merck Sharp & Dohme Corp. Método de diseño de ARNip para el silenciamiento de genes
US8012944B2 (en) * 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
US7553822B2 (en) * 2003-10-30 2009-06-30 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for inhibiting translation of a Mect1-MAML2 chimeric gene
US20070083943A1 (en) * 2003-10-31 2007-04-12 Hannah L C Materials and methods for improved sweet corn
WO2005042782A1 (en) * 2003-10-31 2005-05-12 The Trustees Of Columbia University In The City Of New York Methods for reducing seizure-induced neuronal damage
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
GB2422607A (en) * 2003-11-10 2006-08-02 Univ Utah Res Found Improved methods and compositions for RNA interference
WO2005049838A2 (en) * 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
US7763592B1 (en) 2003-11-20 2010-07-27 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
US7807646B1 (en) * 2003-11-20 2010-10-05 University Of South Florida SHIP-deficiency to increase megakaryocyte progenitor production
CN103397019A (zh) 2003-11-21 2013-11-20 雷维维科公司 干扰rna在生产转基因动物中的用途
WO2005054439A2 (en) * 2003-12-01 2005-06-16 North Carolina State University Small interfering rna (sirna)-mediated heritable gene manipulation in plants
DE602004027538D1 (de) * 2003-12-01 2010-07-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
CN1922320B (zh) 2003-12-03 2013-04-24 科达治疗（新西兰）有限公司 靶向连接蛋白的反义化合物及其使用方法
WO2005059102A2 (en) * 2003-12-10 2005-06-30 University Of Utah Research Foundation METHOD FOR OBTAINING AN ENRICHED POPULATION OF siRNA-EXPRESSING CELLS
US20080021205A1 (en) * 2003-12-11 2008-01-24 Helen Blau Methods and Compositions for Use in Preparing Hairpin Rnas
JP4753130B2 (ja) * 2003-12-12 2011-08-24 独立行政法人産業技術総合研究所 インターフェロン応答が軽減された長い干渉用二重鎖ｒｎａ
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
US20050164970A1 (en) * 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
WO2005062937A2 (en) * 2003-12-22 2005-07-14 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirna
EP1716238B1 (fr) * 2003-12-23 2017-12-06 Bayer S.A.S. Methode pour modifier l'expression genique d' un champignon phytopathogene
FR2872383B1 (fr) * 2004-07-02 2015-10-16 Bayer Cropscience Sa Methode pour modifier l'expression genetique d'un champignon phytopathogene
AU2004304665B2 (en) 2003-12-24 2009-03-12 Novo Nordisk A/S Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR
JP4682152B2 (ja) 2003-12-31 2011-05-11 ザ・ペン・ステート・リサーチ・ファンデーション 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法
EP1778858A4 (en) * 2004-01-15 2009-08-19 Univ Washington USING DROSOPHILA TO PHARMACEUTICS, HIGH-PERFORMANCE SCREENING
WO2005070044A2 (en) * 2004-01-22 2005-08-04 The Cbr Institute For Biomedical Research, Inc. Systems and methods for short rna expression
WO2005090606A2 (en) * 2004-01-23 2005-09-29 Dharmacon, Inc. Identification of toxic nucleotide sequences
WO2005072272A2 (en) 2004-01-23 2005-08-11 New England Biolabs, Inc. Compositions and methods for generating short double-stranded rna using mutated rnase iii
WO2005073378A1 (en) * 2004-01-30 2005-08-11 Santaris Pharma A/S MODIFIED SHORT INTERFERING RNA (MODIFIED siRNA)
WO2005072057A2 (en) * 2004-01-30 2005-08-11 Quark Biotech, Inc. Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
AU2005213464A1 (en) 2004-02-06 2005-08-25 Wyeth Diagnosis and therapeutics for cancer
WO2005078094A2 (en) * 2004-02-06 2005-08-25 Dharmacon, Inc. Stabilized rnas as transfection controls and silencing reagents
US20090280567A1 (en) * 2004-02-06 2009-11-12 Dharmacon, Inc. Stabilized sirnas as transfection controls and silencing reagents
US7683237B2 (en) * 2004-02-10 2010-03-23 Monsanto Technology Llc Maize seed with synergistically enhanced lysine content
AR047598A1 (es) 2004-02-10 2006-01-25 Monsanto Technology Llc Semilla de maiz transgenica con mayor contenido de aminoacidos
US20060075515A1 (en) * 2004-08-11 2006-04-06 Luethy Michael H Enhanced zein reduction in transgenic corn seed
US7855323B2 (en) * 2004-02-10 2010-12-21 Monsanto Technology Llc Recombinant DNA for gene suppression
ATE452188T1 (de) * 2004-02-10 2010-01-15 Sirna Therapeutics Inc Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
WO2005078848A2 (en) 2004-02-11 2005-08-25 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase dnazymes
EP1766032B1 (en) 2004-02-13 2012-10-10 Monsanto Technology, LLC In vivo assembly of transcription units
EP1727556A2 (en) * 2004-02-17 2006-12-06 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US7622301B2 (en) * 2004-02-24 2009-11-24 Basf Plant Science Gmbh Compositions and methods using RNA interference for control of nematodes
WO2005082415A2 (en) 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
US20060003956A1 (en) * 2004-03-03 2006-01-05 Casadome David O Materials and methods for the derepression of the E-cadherin promoter
US8569474B2 (en) * 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
ES2423060T3 (es) 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
US20070265220A1 (en) * 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
MXPA06010667A (es) * 2004-03-19 2007-07-04 Penn State Res Found Metodos combinatorios y composiciones para el tratamiento de melanoma.
US7851452B2 (en) * 2004-03-22 2010-12-14 The Trustees Of The University Of Pennsylvania Methods of use of bcl-6-derived nucleotides to induce apoptosis
EP2343384A3 (en) * 2004-03-23 2012-01-04 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancer
TW200533376A (en) 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
DE602005023426D1 (de) * 2004-03-25 2010-10-21 California Inst Of Techn Hybridisierungskettenreaktion
EP1734996B1 (en) 2004-04-02 2013-05-22 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
KR101637908B1 (ko) * 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
ES2547381T3 (es) 2004-04-09 2015-10-05 Monsanto Technology, Llc Composiciones y procedimientos de control de infestaciones de insectos en plantas
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
US20070031417A2 (en) * 2004-04-14 2007-02-08 University Of Massachusetts Dicer interacting proteins and uses therefor
US20050233994A1 (en) * 2004-04-16 2005-10-20 Ajamete Kaykas Methods and vectors for expressing siRNA
CA2564616C (en) * 2004-04-20 2016-08-30 Nastech Pharmaceutical Company Inc. Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
CA3056110C (en) 2004-04-22 2020-07-14 Surinder Pal Singh Synthesis of long-chain polyunsaturated fatty acids by recombinant cells
WO2005103254A1 (en) * 2004-04-22 2005-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem UNIVERSAL TARGET SEQUENCES FOR siRNA GENE SILENCING
CA2557532A1 (en) * 2004-04-23 2005-11-10 Angela M. Christiano Inhibition of hairless protein mrna
US7897839B2 (en) 2004-04-23 2011-03-01 Ceres, Inc. Methods for modifying plant characteristics
US8076304B2 (en) * 2004-04-26 2011-12-13 The Regents Of The University Of Colorado Methods and compositions for the diagnosis and treatment of cyclin A-1 associated conditions
CA2562833A1 (en) 2004-04-27 2005-11-03 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20060035815A1 (en) * 2004-05-04 2006-02-16 Nastech Pharmaceutical Company Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
US20060040882A1 (en) * 2004-05-04 2006-02-23 Lishan Chen Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
US20060010513A1 (en) * 2004-05-11 2006-01-12 Melville Mark W Oligonucleotide arrays to monitor gene expression and methods for making and using same
US7605250B2 (en) * 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
WO2005113571A2 (en) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds
EP2322665A1 (en) 2004-05-14 2011-05-18 Rosetta Genomics Ltd MicroRNAs and uses thereof
US8563252B2 (en) * 2004-05-14 2013-10-22 Rosetta Genomics Ltd. Methods for distinguishing between lung squamous carcinoma and other non small cell lung cancers
CA2566519C (en) 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US20050265927A1 (en) * 2004-05-17 2005-12-01 Yale University Intranasal delivery of nucleic acid molecules
US7563885B1 (en) * 2004-05-24 2009-07-21 Isis Pharmaceuticals, Inc. Modulation of Tudor-SN expression
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7964196B2 (en) * 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
EP2471924A1 (en) * 2004-05-28 2012-07-04 Asuragen, INC. Methods and compositions involving microRNA
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US20060040876A1 (en) * 2004-06-10 2006-02-23 Rong-Hwa Lin Modulation of peroxisome proliferator-activated receptors
AU2005264938B2 (en) 2004-06-16 2011-11-24 Verenium Corporation Compositions and methods for enzymatic decolorization of chlorophyll
US20060010505A1 (en) * 2004-06-18 2006-01-12 Washington University High throughput cancer pharmaceutical screening using drosophila
US20060156421A1 (en) * 2004-06-18 2006-07-13 Cagan Ross L High throughput screening methods for anti-metastatic compounds
ES2415665T3 (es) 2004-06-21 2013-07-26 Proteome Sciences Plc Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
ATE501252T1 (de) 2004-06-22 2011-03-15 Univ Illinois Verfahren zur inhibierung von tumorzellwachstum mit foxm1 sirns
WO2006069610A2 (en) 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
US8680062B2 (en) 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US7968762B2 (en) * 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
WO2006014755A2 (en) * 2004-07-20 2006-02-09 Wyeth Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease
US20100132058A1 (en) 2004-07-23 2010-05-27 Diatchenko Luda B Methods and materials for determining pain sensitivity and predicting and treating related disorders
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
DE102004036456A1 (de) * 2004-07-28 2006-03-23 Basf Plant Science Gmbh Verfahren zur Herstellung von transgenen Pflanzen mit erhöhter Pathogenresistenz durch Veränderung des Gehalts und/oder der Aktivität von Actin-depolymerisierenden Faktoren
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
EP1781784A2 (en) 2004-08-02 2007-05-09 BASF Plant Science GmbH Method for isolation of transcription termination sequences
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
AR050211A1 (es) 2004-08-13 2006-10-04 Basf Plant Science Gmbh Composiciones y metodos que usan interferencia de arn para el control de nematodos
NZ553162A (en) 2004-08-16 2010-03-26 Quark Biotech Inc Double stranded siRNA compounds that inhibit RRTP801
WO2006017932A1 (en) 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
EP2169072A1 (en) 2004-08-23 2010-03-31 Alnylam Pharmaceuticals, Inc Multiple RNA polymerase III promoter expression constructs
US20060046248A1 (en) * 2004-08-25 2006-03-02 Avigenics, Inc. RNA interference in avians
US20080222743A1 (en) * 2004-08-25 2008-09-11 Avigenics, Inc. RNA interference and disease resistance in avians
US20090313712A1 (en) * 2004-08-25 2009-12-17 Leandro Christmann RNA interference and disease resistance in avians
US20060046247A1 (en) * 2004-08-25 2006-03-02 Rapp Jeffrey C Protecting avians from pathogens
US7323310B2 (en) * 2004-08-31 2008-01-29 Qiagen North American Holdings, Inc. Methods and compositions for RNA amplification and detection using an RNA-dependent RNA-polymerase
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US20060059585A1 (en) 2004-09-14 2006-03-16 Boris Jankowski Modulating plant sugar levels
WO2006031859A2 (en) 2004-09-14 2006-03-23 Ceres Inc. Modulation of amino acid and sugar content in plants
FI20041204A0 (fi) 2004-09-16 2004-09-16 Riikka Lund Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi
JP5085326B2 (ja) 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
US10583094B2 (en) 2004-09-18 2020-03-10 University Of Maryland Therapeutic methods that target the NCCA-ATP channel
US7456338B2 (en) 2004-09-22 2008-11-25 Arborgen Llc Modification of plant lignin content
US7402428B2 (en) * 2004-09-22 2008-07-22 Arborgen, Llc Modification of plant lignin content
US7799906B1 (en) 2004-09-22 2010-09-21 Arborgen, Llc Compositions and methods for modulating lignin of a plant
EP1794304B1 (en) 2004-09-24 2013-06-19 BASF Plant Science GmbH Plant cells and plants with increased tolerance to environmental stress
JP4991547B2 (ja) * 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
WO2006039399A2 (en) * 2004-09-29 2006-04-13 University Of Rochester Staufen 1 (stau1) - mediated mrna decay
WO2006039582A2 (en) * 2004-09-30 2006-04-13 The Regents Of The University Of California Compositions and methods for diagnosing and treating brain cancer and identifying neural stem cells
EP1796732B1 (en) * 2004-10-01 2013-10-30 Novartis Vaccines and Diagnostics, Inc. Modified small interfering rna molecules and methods of use
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
US20060247197A1 (en) 2004-10-04 2006-11-02 Van De Craen Marc Method for down-regulating gene expression in fungi
WO2006070227A2 (en) * 2004-10-04 2006-07-06 Devgen Nv Method for down-regulating gene expression in fungi
CN101056981A (zh) * 2004-10-04 2007-10-17 德福根有限公司 负调节真菌中基因表达的方法
EP2163632A1 (en) 2004-10-05 2010-03-17 SunGene GmbH Constitutive expression cassettes for regulation of plant expression
AU2005295948A1 (en) * 2004-10-12 2006-04-27 The Rockefeller University MicroRNAs
JP2008515458A (ja) 2004-10-13 2008-05-15 ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド 線虫抵抗性の遺伝子組換え植物
US20060089325A1 (en) * 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of PTP1B expression
US7429692B2 (en) 2004-10-14 2008-09-30 Ceres, Inc. Sucrose synthase 3 promoter from rice and uses thereof
NZ582988A (en) * 2004-10-21 2011-07-29 Venganza Inc Methods and materials for conferring resistance to pests and pathogens of plants
US7592322B2 (en) * 2004-10-22 2009-09-22 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US8772254B2 (en) * 2004-10-25 2014-07-08 Devgen N.V. Method and constructs for delivering double stranded RNA to pest organisms
WO2006047687A2 (en) * 2004-10-27 2006-05-04 Schering Corporation Compositions and methods for short interfering nucleic acid inhibition of nav1.8
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
ES2534300T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
EP1812016A4 (en) * 2004-11-17 2010-07-14 Univ Maryland HIGH-BRANCHED HK-PEPTIDES AS EFFECTIVE CARRIER FROM SIRNA
EP1813289B1 (en) * 2004-11-19 2010-03-03 Miyagi Ken Medicinal composition for treating cancer or diabetes
US20060166234A1 (en) * 2004-11-22 2006-07-27 Barbara Robertson Apparatus and system having dry control gene silencing compositions
US7935811B2 (en) * 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
EP1662000B1 (en) 2004-11-25 2011-03-30 SunGene GmbH Expression cassettes for guard cell-preferential expression in plants
WO2006060454A2 (en) * 2004-12-02 2006-06-08 B-Bridge International, Inc. Methods of designing small interfering rnas, antisense polynucleotides, and other hybridizing polynucleotides
EP1666599A3 (en) 2004-12-04 2006-07-12 SunGene GmbH Expression cassettes for mesophyll- and/or epidermis-preferential expression in plants
US9758790B2 (en) 2004-12-08 2017-09-12 Ceres, Inc. Modulating the level of components within plants
WO2008069878A2 (en) 2006-10-27 2008-06-12 Ceres, Inc. Modulating lignin in plants
WO2006062971A2 (en) 2004-12-08 2006-06-15 Ceres Inc. Modulating plant carbon levels
WO2007089610A1 (en) 2006-01-26 2007-08-09 Ceres, Inc. Modulating plant oil levels
EP1669455B1 (en) 2004-12-08 2009-10-28 SunGene GmbH Expression cassettes for vascular tissue-preferential expression in plants
EP1669456A3 (en) 2004-12-11 2006-07-12 SunGene GmbH Expression cassettes for meristem-preferential expression in plants
WO2006065552A2 (en) 2004-12-16 2006-06-22 Ceres Inc. Modulating plant nitrogen levels
EP2096177A3 (en) 2004-12-17 2010-01-13 Metanomics GmbH Process for the production of lutein
US8404927B2 (en) * 2004-12-21 2013-03-26 Monsanto Technology Llc Double-stranded RNA stabilized in planta
US20060200878A1 (en) 2004-12-21 2006-09-07 Linda Lutfiyya Recombinant DNA constructs and methods for controlling gene expression
WO2006069064A2 (en) 2004-12-22 2006-06-29 Nucleonics, Inc. Conserved hbv and hcv sequences useful for gene silencing
NZ556158A (en) * 2004-12-22 2010-04-30 Auckland Uniservices Ltd Trefoil factors and methods of treating proliferation disorders using same
US7335760B2 (en) 2004-12-22 2008-02-26 Ceres, Inc. Nucleic acid sequences encoding zinc finger proteins
US20060142228A1 (en) * 2004-12-23 2006-06-29 Ambion, Inc. Methods and compositions concerning siRNA's as mediators of RNA interference
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
TWI386225B (zh) * 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
EP2003205B1 (en) 2004-12-28 2013-05-01 Pioneer Hi-Bred International, Inc. Improved grain quality through altered expression of seed proteins
JP2008526213A (ja) * 2004-12-30 2008-07-24 トッド エム． ハウザー， 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
EA017847B1 (ru) * 2005-01-07 2013-03-29 Элнилэм Фармасьютикалз, Инк. Композиция для лечения респираторных синцитиальных вирусов
DK1841793T3 (da) 2005-01-07 2010-07-19 Diadexus Inc Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
WO2006076423A2 (en) 2005-01-12 2006-07-20 Monsanto Technology, Llc Genes and uses for plant improvement
EP1846442B1 (en) 2005-01-13 2010-04-21 Pioneer Hi-Bred International, Inc. Maize cyclo1 gene and promoter
ES2429430T3 (es) 2005-01-14 2013-11-14 University Of Guelph Gen y proteína para la detección de azúcares regulados por nitrógeno y modulación de los mismos
US7718625B2 (en) * 2005-01-27 2010-05-18 University Of South Florida Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
CN101573131B (zh) 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
EP2163633A1 (en) 2005-02-09 2010-03-17 BASF Plant Science GmbH Expression cassettes for regulation of expression in monocotyledonous plants
WO2006088925A2 (en) * 2005-02-14 2006-08-24 Wyeth Use of il17-f in diagnosis and therapy of airway inflammation
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
CN101218254A (zh) * 2005-02-14 2008-07-09 惠氏公司 白介素-17f抗体及其它il-17f信号传递拮抗剂和它们的用途
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
AU2006217847B2 (en) 2005-02-26 2011-04-07 Basf Plant Science Gmbh Expression cassettes for seed-preferential expression in plants
US7727721B2 (en) * 2005-03-08 2010-06-01 California Institute Of Technology Hybridization chain reaction amplification for in situ imaging
EP2166102B1 (en) 2005-03-08 2012-12-19 BASF Plant Science GmbH Expression enhancing intron sequences
MX2007010922A (es) 2005-03-10 2007-10-12 Genentech Inc Metodos y composiciones para modular la integridad vascular.
EP1869174B1 (en) 2005-03-10 2015-02-18 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
CA2598234A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
US8999943B2 (en) * 2005-03-14 2015-04-07 Board Of Regents, The University Of Texas System Antigene oligomers inhibit transcription
DE102005011648A1 (de) * 2005-03-14 2006-09-21 IPK-Institut für Pflanzengenetik und Kulturpflanzenforschung Verfahren zur Erhöhung der Pilzresistenz in transgenen Pflanzen durch wirtsinduzierte Unterdrückung der Genexpression in Pilzpathogenen
EA018577B1 (ru) 2005-03-15 2013-09-30 Верениум Корпорейшн Целлюлазы, нуклеиновые кислоты, кодирующие их, и способы их получения и применения
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
US20060223777A1 (en) * 2005-03-29 2006-10-05 Dharmacon, Inc. Highly functional short hairpin RNA
JP4131271B2 (ja) * 2005-03-30 2008-08-13 ソニー株式会社 情報処理装置および方法、並びにプログラム
PL1866414T3 (pl) 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
BRPI0609485A2 (pt) * 2005-03-31 2010-04-13 Ronen Kahana criação de aves domésticas e outros animais resistentes a doenças virais
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
US20060234973A1 (en) * 2005-04-14 2006-10-19 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof
US8895717B2 (en) * 2005-04-15 2014-11-25 The Board Of Regents Of The University Of Texas System Delivery of siRNA by neutral lipid compositions
EP2098593B1 (en) 2005-04-15 2011-12-28 National University Corporation Tottori University hTERT expression regulatory gene
WO2006112879A2 (en) * 2005-04-15 2006-10-26 The Trustees Of The University Of Pennsylvania Hunk, a snf1-related kinase essential for mammary tumor metastasis
US20090203055A1 (en) * 2005-04-18 2009-08-13 Massachusetts Institute Of Technology Compositions and methods for RNA interference with sialidase expression and uses thereof
US20060269556A1 (en) * 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
EP1874936B1 (en) 2005-04-19 2013-10-30 BASF Plant Science GmbH Improved methods controlling gene expression
ATE552343T1 (de) 2005-04-19 2012-04-15 Basf Plant Science Gmbh Endosperm-spezifische expression und/oder expression in keimenden embryos monokotyledoner pflanzen
AU2006245701B2 (en) 2005-05-10 2011-04-28 Basf Plant Science Gmbh Expression cassettes for seed-preferential expression in plants
CA2605508A1 (en) 2005-05-12 2006-11-23 Wisconsin Alumni Research Foundation Blockade of pin1 prevents cytokine production by activated immune cells
US8669236B2 (en) * 2005-05-12 2014-03-11 The General Hospital Corporation Biotinylated compositions
WO2007001684A2 (en) * 2005-05-19 2007-01-04 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibiting dna polymerase beta to enhance efficacy of anticancer agents
FR2885808B1 (fr) 2005-05-19 2007-07-06 Oreal Vectorisation de dsrna par des particules cationiques et utilisation topique.
WO2007053184A2 (en) 2005-05-31 2007-05-10 Cold Spring Harbor Laboratory Methods for producing micrornas
CA2610644A1 (en) 2005-05-31 2006-12-07 Devgen Nv Rnai for control of insects and arachnids
CN101213300B (zh) 2005-06-01 2013-01-23 聚加转染股份有限公司 用于rna干扰的寡核苷酸及其生物学应用
MX2007015454A (es) * 2005-06-06 2008-02-25 Wyeth Corp Perfiles de expresion de las celulas mononucleares de sangre periferica para las enfermedades inflamatorias del intestino.
US20070014776A1 (en) * 2005-06-09 2007-01-18 Gimeno Ruth E Identification of adiponutrin-related proteins as esterases and methods of use for the same
US20070299029A1 (en) * 2005-06-09 2007-12-27 Agency For Science, Technology And Research Hepatic stellate cell specific promoter and uses thereof
US7863251B2 (en) * 2005-06-09 2011-01-04 Agency For Science, Technology And Research Hepatic stellate cell specific promoter and uses thereof
US8124111B2 (en) * 2005-06-10 2012-02-28 Children's Hospital & Research Center At Oakland Immunomodulation by altering sphingosine 1-phosphate lyase (SPL) activity
US20100266574A1 (en) * 2005-06-10 2010-10-21 Orna Mor Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ES2267390B1 (es) * 2005-06-16 2008-03-16 Universidad Politecnica De Valencia Aislamiento y caracterizacion de mutante csb3-1 de arabidopsis thaliana, y su uso como regulador de la resistencia en plantas a enfermedades producidas por patogenos biotroficos.
AU2006260924B2 (en) 2005-06-23 2011-03-03 Basf Plant Science Gmbh Improved methods for the production of stably transformed, fertile zea mays plants
US20080280843A1 (en) 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
WO2007005613A2 (en) * 2005-07-01 2007-01-11 Promega Corporation Network of buoyant particles for biomolecule purification
AU2006267841B2 (en) * 2005-07-07 2011-12-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19, and methods of using same
WO2007011702A2 (en) 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
EP1913149A4 (en) * 2005-07-26 2009-08-05 Sangamo Biosciences Inc TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES
EP1907580A2 (en) * 2005-07-28 2008-04-09 Oncotherapy Science, Inc. Method for diagnosing and treating renal cell carcinoma
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
EP2239328A3 (en) 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
AU2006279325B2 (en) 2005-08-18 2013-06-27 Accelalox, Inc. Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
TW200801201A (en) * 2005-08-23 2008-01-01 Illumigen Biosciences Inc Detection of mutations in a gene associated with resistance to viral infection, OAS2 or OAS3
US8029989B2 (en) * 2005-08-26 2011-10-04 The Trustees Of The University Of Pennsylvania Method using snail transcriptional repressor
WO2007028147A2 (en) * 2005-09-01 2007-03-08 Philadelphia Health & Education Corporation D.B.A. Drexel University College Of Medicin Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer
CA2620803A1 (en) 2005-09-01 2007-03-08 Suntory Limited Tryptophan transporter gene and use thereof
WO2007030167A1 (en) * 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
EP2272968A3 (en) 2005-09-08 2011-08-31 Chromatin, Inc. Plants modified with mini-chromosomes
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP1764091B1 (en) 2005-09-15 2017-08-30 Marina Biotech, Inc. Improvements in or relating to amphoteric liposomes
BRPI0616181B1 (pt) 2005-09-16 2024-03-05 Monsanto Technology Llc Construção de polinucleotídeo isolada, sequência de ribonucleotídeo de fita dupla, microrganismo transgênico, seu método de produção, e métodos para controle de infestação por coleóptero praga, para melhorar o rendimento e a tolerância a estiagem de um cultivo, e para produção de um produto comercial, alimento ou ração
CA2622660C (en) 2005-09-16 2017-11-07 Devgen Nv Transgenic plant-based methods for plant pests using rnai
WO2007039454A1 (en) 2005-09-20 2007-04-12 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siran
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2660661A1 (en) 2005-09-26 2007-04-05 The Trustees Of Columbia University In The City Of New York Side population cells in cardiac repair
CA2622772A1 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
US20070079396A1 (en) * 2005-10-03 2007-04-05 Malvar Thomas M Transgenic plant seed with increased lysine
WO2007044727A2 (en) 2005-10-07 2007-04-19 California Institute Of Technology Pkr activation via hybridization chain reaction
EP1934348B1 (en) * 2005-10-11 2018-05-02 Ben-Gurion University Of The Negev Research And Development Authority Compositions for silencing the expression of vdac1 and uses thereof
WO2007047706A2 (en) * 2005-10-17 2007-04-26 Children's Hospital Methods and compositions for regulating gene expression
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
EP1947925B1 (en) 2005-10-20 2013-12-25 Commonwealth Scientific And Industrial Research Organisation Cereals with altered dormancy
US20080274469A1 (en) 2005-10-21 2008-11-06 The Regents Of The University Of California C-Kit Oncogene Mutations in Melanoma
DK1945665T3 (da) * 2005-10-21 2012-02-06 Genzyme Corp Antistof-baserede terapimidler med forhøjet ADCC-aktivitet
US7723314B1 (en) 2005-10-28 2010-05-25 Transderm, Inc. Methods and compositions for treating pachyonychia congenita
EP2325315B1 (en) 2005-10-28 2014-05-07 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of huntingtin gene
US7723477B2 (en) * 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP1945754B1 (en) * 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP2500360B1 (en) 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
AU2006311725B2 (en) 2005-11-04 2011-11-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of NAV1.8 gene
CA2628505A1 (en) 2005-11-08 2007-05-18 Basf Plant Science Gmbh Use of armadillo repeat (arm1) polynucleotides for obtaining resistance to pathogens in plants
CA2626690A1 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
CN100447243C (zh) * 2005-11-15 2008-12-31 中国人民解放军第四军医大学 HBV特异性干涉靶位点基因及其siRNA和其在抗HBV感染中的应用
CA2629664A1 (en) 2005-11-17 2007-08-02 Board Of Regents, The University Of Texas System Modulation of gene expression by oligomers targeted to chromosomal dna
US8916530B2 (en) * 2005-11-18 2014-12-23 Gradalis, Inc. Individualized cancer therapy
US8603991B2 (en) * 2005-11-18 2013-12-10 Gradalis, Inc. Individualized cancer therapy
EP1960778A2 (fr) * 2005-11-25 2008-08-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Procede pour la mise en evidence de la presence ou de l'absence de marqueurs (eef1a1 ou mark3 ) associes a la presence et/ou a la chimiosensibilite des tumeurs
WO2007064759A2 (en) * 2005-11-29 2007-06-07 The Scripps Research Institute Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain
JP4737531B2 (ja) 2005-12-05 2011-08-03 サントリーホールディングス株式会社 形質転換酵母を用いるセラミドの製造方法
US20090317802A1 (en) * 2005-12-09 2009-12-24 Bhatia Sangeeta N Compositions and Methods to Monitor RNA Delivery to Cells
WO2007065878A2 (en) 2005-12-09 2007-06-14 Basf Plant Science Gmbh Nucleic acid molecules encoding polypeptides involved in regulation of sugar and lipid metabolism and methods of use viii
WO2007070381A2 (en) 2005-12-09 2007-06-21 Promega Corporation Nucleic acid purification with a binding matrix
US9267937B2 (en) * 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
CA2636070A1 (en) 2006-01-06 2007-08-02 North Carolina State University Cyst nematode resistant transgenic plants
US8906876B2 (en) 2006-01-12 2014-12-09 Devgen Nv Methods for controlling pests using RNAi
WO2007080143A1 (en) * 2006-01-12 2007-07-19 Basf Plant Science Gmbh Use of stomatin (stm1) polynucleotides for achieving a pathogen resistance in plants
EP1971688B1 (en) 2006-01-12 2012-03-14 Devgen NV Dsrna as insect control agent
EP2348115A3 (en) 2006-01-12 2012-01-18 deVGen N.V. Transgenic plant-based methods for plant pests using RNAi
CN100562342C (zh) * 2006-01-17 2009-11-25 奥林格斯技术有限公司 防治流感病毒感染的寡核苷酸药物
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
MX2008009220A (es) * 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
UY30097A1 (es) * 2006-01-20 2007-08-31 Atugen Ag Usos terapeuticos de inhibidores de rtp801
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
WO2007085485A2 (en) * 2006-01-27 2007-08-02 Santaris Pharma A/S Lna modified phosphorothiolated oligonucleotides
EP2526968A3 (en) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo receptor antagonists
EP1987142A4 (en) 2006-02-02 2009-07-15 Verenium Corp ESTERASES AND ASSOCIATED NUCLEIC ACIDS AND METHODS
US20080022423A1 (en) * 2006-02-03 2008-01-24 Monsanto Technology Llc IN PLANTA RNAi CONTROL OF FUNGI
WO2007095469A2 (en) 2006-02-10 2007-08-23 Monsanto Technology Llc Identification and use of target genes for control of plant parasitic nematodes
NZ595502A (en) 2006-02-10 2013-11-29 Verenium Corp Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
CN101421406B (zh) 2006-02-13 2016-08-31 孟山都技术有限公司 用于产生改变的种子油组成的核酸构建体和方法
AU2007214547B2 (en) * 2006-02-13 2012-09-20 Monsanto Technology Llc Selecting and stabilizing dsRNA constructs
ES2682284T3 (es) 2006-02-14 2018-09-19 Bp Corporation North America Inc. Xilanasas, ácidos nucleicos que las codifican y métodos para elaborarlas y usarlas
US20070293657A1 (en) * 2006-02-17 2007-12-20 Nastech Pharmaceutical Company Inc. Complexes and methods of forming complexes of ribonucleic acids and peptides
JP2009165352A (ja) * 2006-02-24 2009-07-30 Suntory Liquors Ltd アシルＣｏＡ：エタノールＯ−アシルトランスフェラーゼ／エステラーゼ遺伝子及びその用途
WO2007120989A2 (en) 2006-02-24 2007-10-25 Ceres, Inc. Shade regulatory regions
KR100929997B1 (ko) 2006-02-24 2009-12-07 산토리 홀딩스 가부시키가이샤 효모의 응집 특성의 원인이 되는 단백질을 인코딩하는유전자 및 이의 용도
WO2007097097A1 (en) 2006-02-24 2007-08-30 Suntory Limited Ammonia transporter gene and use thereof
KR100929998B1 (ko) 2006-02-24 2009-12-07 산토리 홀딩스 가부시키가이샤 효모의 응집성을 초래하는 단백질을 암호화하는 유전자 및그의 용도
JPWO2007097093A1 (ja) * 2006-02-27 2009-07-09 サントリーホールディングス株式会社 分枝アミノ酸トランスポーター遺伝子及びその用途
JPWO2007097095A1 (ja) * 2006-02-27 2009-07-09 サントリーホールディングス株式会社 芳香族アミノ酸トランスポーター遺伝子及びその用途
EP1996730A4 (en) * 2006-03-08 2010-03-03 Promega Corp CLEANING OF SMALL RNA
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
US20100068172A1 (en) * 2006-03-16 2010-03-18 Devgen N.V. Nematode Control
EP1999257B1 (en) 2006-03-20 2011-06-22 Novozymes, Inc. Polypeptides having endoglucanase activity and polynucleotides encoding same
ES2556128T3 (es) * 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
FR2898908A1 (fr) 2006-03-24 2007-09-28 Agronomique Inst Nat Rech Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
EP2004817A2 (en) 2006-03-30 2008-12-24 Novozymes, Inc. Polypeptides having endoglucanase activity and polynucleotides encoding same
WO2007123777A2 (en) 2006-03-30 2007-11-01 Duke University Inhibition of hif-1 activation for anti-tumor and anti-inflammatory responses
JP5704741B2 (ja) 2006-03-31 2015-04-22 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇ５遺伝子発現の抑制のための組成物および方法
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
AU2007299219A1 (en) 2006-04-05 2008-03-27 Metanomics Gmbh Process for the production of a fine chemical
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
JP2009533350A (ja) * 2006-04-07 2009-09-17 キメロス， インコーポレイテッド Ｂ細胞悪性疾患を処置するための組成物および方法
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US7625874B2 (en) * 2006-04-11 2009-12-01 The Regents Of The University Of California Compositions and methods for treating diseases associated with T-box and N-Myc
US20100055116A1 (en) * 2006-04-13 2010-03-04 Liou Hsiou-Chi Methods and Compositions for Targeting c-Rel
KR20090010194A (ko) 2006-04-13 2009-01-29 노바티스 백신즈 앤드 다이아그노스틱스, 인크. 암의 치료, 진단 또는 검출 방법
MX2008013455A (es) * 2006-04-19 2008-10-30 Wyeth Corp Duplex de acido ribonucleico interfiriente corto dirigido a una secuencia del sitio de entrada del ribosoma interno y usos del mismo.
EP2010910A2 (en) 2006-04-21 2009-01-07 Wyeth Differential expression profiling analysis of cell culture phenotypes and the uses thereof
EP2051585A4 (en) * 2006-04-28 2010-06-02 Univ South Florida MATERIALS AND METHODS OF SUPPRESSING INFLAMMATION THROUGH INHIBITION OF THE VORHOF RECEPTOR FOR NATRIURETIC PEPTIDES
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
US20070281900A1 (en) * 2006-05-05 2007-12-06 Nastech Pharmaceutical Company Inc. COMPOSITIONS AND METHODS FOR LIPID AND POLYPEPTIDE BASED siRNA INTRACELLULAR DELIVERY
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US7605251B2 (en) 2006-05-11 2009-10-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
GB0609498D0 (en) * 2006-05-12 2006-06-21 Oncomethylome Sciences S A Novel methylation marker
US20090239936A1 (en) 2006-05-15 2009-09-24 Yoshikazu Sugimoto Prophylactic and Therapeutic Agent for Cancer
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
EP3196311B1 (en) 2006-05-16 2019-12-04 Monsanto Technology LLC Use of non-agrobacterium bacterial species for plant transformation
US20070286863A1 (en) * 2006-05-17 2007-12-13 Christopher Sinal CMKLR regulation of adipogenesis and adipocyte metabolic function
WO2007137117A2 (en) * 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
US20070269892A1 (en) * 2006-05-18 2007-11-22 Nastech Pharmaceutical Company Inc. FORMULATIONS FOR INTRACELLULAR DELIVERY dsRNA
EP2392583A1 (en) 2006-05-19 2011-12-07 Alnylam Europe AG. RNAi modulation of Aha and therapeutic uses thereof
RU2469090C2 (ru) * 2006-05-19 2012-12-10 Алькон Рисерч, Лтд. iPHK-ОПОСРЕДОВАННОЕ ИНГИБИРОВАНИЕ СВЯЗАННЫХ С ФАКТОРОМ НЕКРОЗА ОПУХОЛИ АЛЬФА СОСТОЯНИЙ
US7888498B2 (en) 2006-05-22 2011-02-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
US20070275923A1 (en) * 2006-05-25 2007-11-29 Nastech Pharmaceutical Company Inc. CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
EP2024495A2 (en) * 2006-05-25 2009-02-18 Wyeth Expression of the cysteine protease legumain in vascular and inflammatory diseases
US8153369B2 (en) 2006-06-05 2012-04-10 Cancer Care Ontario Assessment of risk for colorectal cancer
EP2044204B1 (en) 2006-06-07 2014-04-30 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Plant expression constructs and methods of utilizing same
WO2007141796A2 (en) * 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
JP2009540011A (ja) * 2006-06-12 2009-11-19 エクセジェニックス、インク．ディー／ビー／エー オプコ ヘルス、インク． 血管新生のｓｉＲＮＡ阻害のための組成物及び方法
CA2651846C (en) 2006-06-13 2019-11-12 The Rockefeller University Use of p11 to diagnose a p11/5-ht related disorder
WO2007147067A2 (en) * 2006-06-14 2007-12-21 Rosetta Inpharmatics Llc Methods and compositions for regulating cell cycle progression
CA2655990A1 (en) * 2006-06-22 2007-12-27 Tai June Yoo Restoration of hearing loss
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US8097596B2 (en) * 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
WO2008029295A2 (en) 2006-06-30 2008-03-13 Rosetta Genomics Ltd A method for detecting nucleic acids
US20130191941A1 (en) 2006-07-05 2013-07-25 Shing Kwok Modulating light response pathways in plants, increasing light-related tolerances in plants, and increasing biomass in plants
US9131648B2 (en) * 2006-07-07 2015-09-15 Washington State University Genes encoding chavicol/eugenol synthase from the creosote bush Larrea tridentata
WO2008054561A2 (en) 2006-07-11 2008-05-08 University Of Medicine And Dentistry Of New Jersey Proteins, nucleic acids encoding the same and associated methods of use
US8536429B2 (en) 2006-07-12 2013-09-17 Commonwealth Scientific And Industrial Research Organisation Polynucleotides encoding a NAX2 polypeptide and methods for enhancing salinity tolerance in plants
DK2447275T3 (en) 2006-07-13 2015-06-29 Univ Iowa Res Found Methods and reagents for the treatment of age-related macular degeneration
JP5693004B2 (ja) 2006-07-28 2015-04-01 チルドレンズ メモリアル ホスピタル ヒト胚性幹細胞の微小環境を使用して腫瘍細胞の悪性度を抑制する方法
PL380335A1 (pl) * 2006-07-31 2008-02-04 Instytut Chemii Bioorganicznej Pan W Poznaniu Sekwencja dwunicowego ATN-RNA, interwencja interferencyjnym RNA ( iRnAi) oraz zastosowanie sekwencji dwunicowego ATN-RNA w terapii guzów mózgu
CN106222185B (zh) 2006-08-04 2021-12-03 维莱尼姆公司 葡聚糖酶、编码它们的核酸及制备和使用它们的方法
JP2010500029A (ja) 2006-08-11 2010-01-07 ダウ アグロサイエンシィズ エルエルシー ジンクフィンガーヌクレアーゼ媒介相同組換え
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
CA2669812A1 (en) 2006-08-30 2008-03-06 Basf Plant Science Gmbh Method for increasing resistance to pathogens in transgenic plants
WO2008028121A1 (en) 2006-08-31 2008-03-06 Monsanto Technology Llc Plant transformation without selection
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
WO2008030605A2 (en) * 2006-09-08 2008-03-13 The Regents Of The University Of Michigan Herv group ii viruses in lymphoma and cancer
JPWO2008032876A1 (ja) 2006-09-15 2010-01-28 学校法人東海大学 Ｅｒ陰性およびｈｅｒ２陰性である乳癌の予防または治療剤およびそのスクリーニング方法
WO2008036638A2 (en) 2006-09-18 2008-03-27 Alnylam Pharmaceuticals, Inc. Rnai modulation of scap and therapeutic uses thereof
WO2008036741A2 (en) * 2006-09-19 2008-03-27 Asuragen, Inc. Mir-200 regulated genes and pathways as targets for therapeutic intervention
EP2145001A2 (en) * 2006-09-19 2010-01-20 Asuragen, Inc. Mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p regulated genes and pathways as targets for therapeutic intervention
EP2057274B1 (en) 2006-09-21 2013-12-11 DSM IP Assets B.V. Phospholipases, nucleic acids encoding them and methods for making and using them
US8877478B2 (en) 2006-09-21 2014-11-04 Verenium Corporation Phytases, nucleic acids encoding them and methods for making and using them
US20090209478A1 (en) 2006-09-21 2009-08-20 Tomoko Nakayama Compositions and methods for inhibiting expression of the hamp gene
EP2081949B1 (en) * 2006-09-22 2014-12-10 GE Healthcare Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
ES2531391T3 (es) 2006-10-06 2015-03-13 Basf Plant Science Gmbh Delta-5 desaturasas y procedimiento para la preparación de ácidos grasos poliinsaturados en organismos transgénicos no humanos
CN101802215A (zh) 2006-10-12 2010-08-11 孟山都技术有限公司 植物微rna及其使用方法
AU2007306556B2 (en) 2006-10-13 2014-04-10 Marina Biotech, Inc. Improvements in or relating to amphoteric liposomes
AU2007310982A1 (en) 2006-10-18 2008-04-24 Marina Biotech, Inc. Nicked or gapped nucleic acid molecules and uses thereof
ES2425179T3 (es) 2006-10-25 2013-10-11 The Rockefeller University Métodos para el tratamiento de trastornos relacionados con beta-amiloide y composiciones para los mismos
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
EP2078079B1 (en) * 2006-11-01 2011-05-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Adipocyte-specific constructs and methods for inhibiting platelet-type 12 lipoxygenase expression
DK2094086T3 (da) 2006-11-08 2013-11-25 Veritas Bio LLC Indgivelse in vivo af dobbeltstrenget rna til en målcelle
US8758998B2 (en) 2006-11-09 2014-06-24 Gradalis, Inc. Construction of bifunctional short hairpin RNA
US8906874B2 (en) 2006-11-09 2014-12-09 Gradalis, Inc. Bi-functional shRNA targeting Stathmin 1 and uses thereof
US8252526B2 (en) * 2006-11-09 2012-08-28 Gradalis, Inc. ShRNA molecules and methods of use thereof
US20100247552A1 (en) 2006-11-10 2010-09-30 Massachusetts Institute Of Technology Pak modulators
RU2542471C2 (ru) 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
WO2008064128A2 (en) 2006-11-22 2008-05-29 Ceres, Inc. Broadly expressing regulatory regions
JP2010510772A (ja) 2006-11-27 2010-04-08 パトリス リミテッド 新生細胞における新規なグリコシル化ペプチド標的
AU2007325283B2 (en) 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
CN101595214B (zh) 2006-11-29 2013-06-12 诺维信股份有限公司 改进向细菌细胞中导入dna的方法
EP2099818A2 (en) 2006-11-29 2009-09-16 Novozymes Inc. Bacillus licheniformis chromosome
CN101195821A (zh) * 2006-12-04 2008-06-11 中国科学院上海生命科学研究院 利用RNAi技术改良植物抗虫性的方法
US8481506B2 (en) * 2006-12-05 2013-07-09 Rosetta Genomics, Ltd. Nucleic acids involved in viral infection
WO2008073856A2 (en) * 2006-12-08 2008-06-19 Massachusetts Institute Of Technology Delivery of nanoparticles and/or agents to cells
EP2104737B1 (en) * 2006-12-08 2013-04-10 Asuragen, INC. Functions and targets of let-7 micro rnas
CN101622348A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
WO2008067840A1 (en) 2006-12-08 2008-06-12 Swetree Technologies Ab Plants having improved growth characteristics and method for making the same
EP2104735A2 (en) * 2006-12-08 2009-09-30 Asuragen, INC. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CA2669746C (en) * 2006-12-14 2017-05-16 Dow Agrosciences Llc Optimized non-canonical zinc finger proteins
PL3101128T3 (pl) 2006-12-21 2019-09-30 Basf Enzymes Llc Amylazy i glukoamylazy, kwasy nukleinowe kodujące te związki oraz sposoby wytwarzania tych związków oraz stosowania ich
US20100028949A1 (en) * 2006-12-22 2010-02-04 Vincent Beuger Shrna-mediated inhibition of expression of alpha 1,6-fucosyltransferase
US20100129358A1 (en) 2006-12-22 2010-05-27 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
WO2008089103A2 (en) 2007-01-12 2008-07-24 University Of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
EP2057273A2 (en) 2007-01-15 2009-05-13 BASF Plant Science GmbH Use of subtilisin (rnr9) polynucleotides for achieving a pathogen resistance in plants
EP2111449B1 (en) * 2007-01-16 2012-03-07 Yissum Research Development Company of the Hebrew University of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
US20100204300A1 (en) * 2007-01-17 2010-08-12 Stephen Mark Tompkins Anti-viral methods and compositions
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008092099A2 (en) * 2007-01-26 2008-07-31 Rosetta Genomics, Ltd. Compositions and methods for treating hematopoietic malignancies
CA2676143A1 (en) 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
WO2008094937A2 (en) * 2007-01-29 2008-08-07 Joslin Diabetes Center, Inc. Methods of modulating angiogenesis
CN104212822A (zh) 2007-01-30 2014-12-17 Bp法人北美有限公司 用于处理木质纤维素的酶、编码它们的核酸及其制备和应用方法
BRPI0807350A2 (pt) 2007-02-05 2014-05-06 Univ Singapore Receptor de quitocina putativa e métodos para uso do mesmo
CA2674494A1 (en) 2007-02-06 2008-08-14 Basf Plant Science Gmbh Compositions and methods using rna interference for control of nematodes
CA2674562A1 (en) 2007-02-08 2008-08-14 Basf Plant Science Gmbh Compositions and methods using rna interference of opr3-like gene for control of nematodes
ES2373614T3 (es) 2007-02-09 2012-02-07 Basf Plant Science Gmbh Composiciones y métodos que utilizan interferencia de arn de tipo cdpk para el control de nemátodos.
US9217129B2 (en) * 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
DE102007008596B4 (de) 2007-02-15 2010-09-02 Friedrich-Schiller-Universität Jena Biologisch wirksame Moleküle auf Grundlage von PNA und siRNA, Verfahren zu deren zellspezifischen Aktivierung sowie Applikationskit zur Verabreichung
KR20090119910A (ko) 2007-02-16 2009-11-20 바스프 플랜트 사이언스 게엠베하 외떡잎 식물에서 배-특이적 발현의 조절을 위한 핵산 서열
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
EP2115141A4 (en) 2007-02-20 2010-08-04 Monsanto Technology Llc miRNA FROM INVERTEBRATES
WO2008106102A2 (en) * 2007-02-26 2008-09-04 Quark Pharmaceuticals, Inc. Inhibitors of rtp801 and their use in disease treatment
US9006206B2 (en) 2007-02-27 2015-04-14 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
WO2008104974A2 (en) * 2007-02-27 2008-09-04 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
WO2008104978A2 (en) * 2007-02-28 2008-09-04 Quark Pharmaceuticals, Inc. Novel sirna structures
WO2008106658A2 (en) * 2007-03-01 2008-09-04 California Institute Of Technology TRIGGERED RNAi
US9340601B2 (en) * 2007-03-01 2016-05-17 The Board Of Trustees Of The Leland Stanford Junior University Splice variants of the EGF receptor
WO2008109432A2 (en) * 2007-03-02 2008-09-12 The Board Of Regents Of The University Of Texas System Therapeutic targeting of interleukins using sirna in neutral liposomes
AU2008222563A1 (en) 2007-03-05 2008-09-12 Cancer Care Ontario Assessment of risk for colorectal cancer
US8080648B1 (en) 2007-03-09 2011-12-20 The United States Of America, As Represented By The Secretary Of Agriculture Pesticidal double stranded RNA composition and method of use thereof
WO2008112218A2 (en) 2007-03-12 2008-09-18 Antigen Express, Inc. Li-rnai involved li suppression in cancer immunotherapy
WO2008112988A2 (en) 2007-03-14 2008-09-18 Novartis Ag Apcdd1 inhibitors for treating, diagnosing or detecting cancer
ES2538217T3 (es) 2007-03-21 2015-06-18 Brookhaven Science Associates, Llc Composiciones combinadas antisentido de horquilla y métodos para modular la expresión
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
PE20090064A1 (es) 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
WO2008118957A2 (en) 2007-03-26 2008-10-02 The Government Of U.S.A As Represented By The Secretary Of The Department Of Health & Human Services Methods for modulating embryonic stem cell differentiation
WO2012070037A2 (en) 2010-11-22 2012-05-31 Rosetta Genomics Ltd. Methods and materials for classification of tissue of origin of tumor samples
US20100273172A1 (en) * 2007-03-27 2010-10-28 Rosetta Genomics Ltd. Micrornas expression signature for determination of tumors origin
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
JP5350360B2 (ja) 2007-03-29 2013-11-27 アルナイラム ファーマシューティカルズ， インコーポレイテッド エボラ由来の遺伝子の発現を阻害するための組成物および方法
EP1985295A1 (en) * 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
US20090226525A1 (en) * 2007-04-09 2009-09-10 Chimeros Inc. Self-assembling nanoparticle drug delivery system
US20100150944A1 (en) * 2007-04-16 2010-06-17 Modgene, Llc Methods and compositions for diagnosis and treatment of depression and anxiety
CA2584934A1 (en) 2007-04-17 2008-10-17 University Of Guelph Nitrogen-regulated sugar sensing gene and protein and modulation thereof
CN101686939B (zh) * 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
PL2144633T4 (pl) 2007-04-23 2015-02-27 Sabag Rfa Ltd Układ do transportu czynników terapeutycznych do żywych komórek i jąder komórkowych
EP2377952A1 (en) 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Methods for diagnosing and treating astrocytomas
EA019514B1 (ru) 2007-04-27 2014-04-30 Те Риджентс Оф Те Юниверсити Оф Калифорния Сенсоры coрастений, нуклеиновые кислоты, кодирующие их, способы их получения и применение
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
EP2152877A2 (en) * 2007-05-02 2010-02-17 Sirna Therapeutics Inc. RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIC NUCLEOTIDE TYPE 4 PHOSPHODIESTERASE ( PDE4B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2607477B1 (en) 2007-05-03 2020-09-23 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
EP3434259A1 (en) 2007-05-04 2019-01-30 Marina Biotech, Inc. Amino acid lipids and uses thereof
US20100115635A1 (en) * 2007-05-04 2010-05-06 Abbott Laboratories Methods for Assessing the Delivery of Exogenous Agents
EP2492346A3 (en) 2007-05-04 2013-03-27 BASF Plant Science GmbH Seed enhancement by combinations of pyruvate kinases
US20100251392A1 (en) * 2007-05-04 2010-09-30 Abbott Laboratories Methods for assessing the delivery of exogenous agents
WO2008137993A1 (en) * 2007-05-08 2008-11-13 Duke University Compositions and methods for characterizing and regulating olfactory sensation
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
BRPI0721697A2 (pt) 2007-05-11 2014-08-05 Univ Jefferson " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2."
US20080313773A1 (en) * 2007-05-14 2008-12-18 The Rockefeller University Production of artificial micrornas using synthetic microrna precursors
EP1992699A1 (en) * 2007-05-15 2008-11-19 Genoplante-Valor Method for increasing the resistance of a plant to endoparasitic nematodes
WO2008144562A1 (en) 2007-05-16 2008-11-27 California Institute Of Technology A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways
NZ580712A (en) 2007-05-22 2011-12-22 Marina Biotech Inc Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers
AU2008252998A1 (en) 2007-05-22 2008-11-27 Basf Plant Science Gmbh Plant cells and plants with increased tolerance and/or resistance to environmental stress and increased biomass production-KO
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090131354A1 (en) * 2007-05-22 2009-05-21 Bader Andreas G miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
EP2152885B1 (en) 2007-05-23 2014-06-18 Syngenta Participations AG Polynucleotide markers
CA2688417C (en) 2007-05-24 2017-04-25 Calcimedica, Inc. Calcium channel proteins and uses thereof
WO2009023059A2 (en) 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
AU2008261951A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. miR-34 regulated genes and pathways as targets for therapeutic intervention
WO2008157299A2 (en) * 2007-06-15 2008-12-24 Wyeth Differential expression profiling analysis of cell culture phenotypes and uses thereof
US20100273854A1 (en) * 2007-06-15 2010-10-28 Hagar Kalinski Compositions and methods for inhibiting nadph oxidase expression
WO2008157263A2 (en) 2007-06-15 2008-12-24 Arkansas State University Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
DE102007029471A1 (de) 2007-06-20 2008-12-24 Novosom Ag Neue fakultativ kationische Sterole
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
SI2170403T1 (sl) * 2007-06-27 2014-07-31 Quark Pharmaceuticals, Inc. Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
CA2728571A1 (en) * 2007-06-29 2009-01-08 Boston Biomedical, Inc. Bacteria-mediated gene modulation via microrna machinery
EP2170395A1 (en) * 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
EP2184353A4 (en) 2007-07-03 2010-09-08 Kyorin Seiyaku Kk FLU TREATMENT
EP2319926B1 (en) 2007-07-05 2016-08-31 Arrowhead Research Corporation DSRNA for treating viral infection
WO2009008990A2 (en) * 2007-07-06 2009-01-15 Intradigm Corporation Methods and compositions for treatment of cancer and other angiogenesis - related diseases
CA2692441C (en) 2007-07-06 2020-01-21 The Regents Of The University Of Michigan Solute carrier family 45 member 3 (slc45a3) and ets family gene fusions in prostate cancer
WO2009007934A2 (en) 2007-07-10 2009-01-15 Neurim Pharmaceuticals (1991) Ltd. Cd44 splice variants in neurodegenerative diseases
US9689031B2 (en) 2007-07-14 2017-06-27 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
WO2009012263A2 (en) 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
EP2185719B1 (en) 2007-08-02 2013-11-13 NovImmune SA Anti-rantes antibodies and methods of use thereof
US20090044296A1 (en) * 2007-08-07 2009-02-12 Cornell Research Foundation, Inc. Hrpn interactors and uses thereof
JP5855828B2 (ja) 2007-08-13 2016-02-09 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 低レベルのホルデインを有するオオムギ
US20110131668A1 (en) 2007-08-14 2011-06-02 Commonwealth Scientific And Industrial Research Organisation Improved gene silencing methods
EP2597464B1 (en) 2007-08-16 2015-02-25 The Regents of the University of Michigan Metabolomic profiling of prostate cancer
CA2697363A1 (en) 2007-08-23 2009-03-05 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptogenesis
WO2009026660A1 (en) 2007-08-30 2009-03-05 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
WO2009033027A2 (en) * 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
US8361714B2 (en) 2007-09-14 2013-01-29 Asuragen, Inc. Micrornas differentially expressed in cervical cancer and uses thereof
US20100280097A1 (en) * 2007-09-18 2010-11-04 Intradigm Corporation Compositions comprising hif-1 alpha sirna and methods of use thereof
EP2190995A2 (en) * 2007-09-18 2010-06-02 Intradigm Corporation Compositions comprising k-ras sirna and methods of use
JP5723154B2 (ja) 2007-09-19 2015-05-27 アプライド バイオシステムズ リミテッド ライアビリティー カンパニー ＲＮＡｉにおけるオフターゲット表現型の影響を減少させるためのＳｉＲＮＡ配列非依存性修飾フォーマットおよびその安定化型
ES2585157T3 (es) 2007-09-27 2016-10-04 Dow Agrosciences Llc Proteínas de dedo de cinc de diseño que se dirigen a los genes de 5-enolpiruvil shikimato-3-fosfato sintasa
CA2701845A1 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
NZ601191A (en) 2007-10-03 2014-01-31 Verenium Corp Xylanases, nucleic acids encoding them and methods for making and using them
AU2008308499A1 (en) * 2007-10-04 2009-04-09 Board Of Regents, The University Of Texas System Modulating gene expression with agRNA and gapmers targeting antisense transcripts
US20100280098A1 (en) * 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
EP2200649A4 (en) 2007-10-19 2012-09-26 Univ California COMPOSITIONS AND METHODS FOR TREATING CNS INFUSION, PSYCHOSIS, DELIRE, PTSD OR PTSS
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
WO2009064590A2 (en) 2007-11-12 2009-05-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer
EP2065037A1 (en) 2007-11-27 2009-06-03 DKFZ Deutsches Krebsforschungszentrum Means and methods for treating or preventing brain tumors based on the nuclear receptor tailless (Tlx)
UA113829C2 (uk) 2007-11-27 2017-03-27 Коммонвелс Сайнтіфік Енд Індастріал Рісерч Організейшн Генетично модифікована рослина зі збільшеним потенціалом продуктивності
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
US7968525B1 (en) 2007-12-03 2011-06-28 University Of Florida Research Foundation, Inc. Use of RNA interference to validate new termiticide target sites and a method of termite control
ES2490608T3 (es) 2007-12-06 2014-09-04 Novozymes A/S Polipéptidos con actividad de esterasa de acetilxilano y polinucleótidos que codifican los mismos
WO2009076400A2 (en) 2007-12-10 2009-06-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor vii gene
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20110105584A1 (en) * 2007-12-12 2011-05-05 Elena Feinstein Rtp80il sirna compounds and methods of use thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
NZ585784A (en) * 2007-12-13 2012-09-28 Alnylam Pharmaceuticals Inc siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
US20110041215A1 (en) * 2007-12-17 2011-02-17 Basf Plant Science Gmbh Lipid Metabolism Protein And Uses Thereof I (BZIP Transcription Factor)
EP2072528A1 (en) 2007-12-19 2009-06-24 Labeit, Mr. Siegfried A host cell deficient for MuRF1 and MuRF2
EP2235173A2 (en) 2007-12-19 2010-10-06 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
US20090192114A1 (en) * 2007-12-21 2009-07-30 Dmitriy Ovcharenko miR-10 Regulated Genes and Pathways as Targets for Therapeutic Intervention
WO2009080743A2 (en) 2007-12-21 2009-07-02 Basf Plant Science Gmbh Plants with increased yield (ko nue)
WO2009086215A2 (en) * 2007-12-21 2009-07-09 Wyeth Pathway analysis of cell culture phenotypes and uses thereof
EP2237795A2 (en) * 2007-12-21 2010-10-13 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
CA2710380A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
EP2554674B1 (en) 2007-12-21 2014-11-05 Keygene N.V. Trichome specific promoters
AU2008343754A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of surgical adhesions
CN101960012B (zh) 2007-12-28 2014-03-12 瑞典树木科技公司 具有改善生长特征的木本植物以及使用转录因子制备它们的方法
WO2009088837A2 (en) * 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
AU2008347234B2 (en) 2008-01-03 2015-05-28 Basf Enzymes Llc Transferases and oxidoreductases, nucleic acids encoding them and methods for making and using them
CA2710922A1 (en) 2008-01-03 2009-07-16 Verenium Corporation Isomerases, nucleic acids encoding them and methods for making and using them
WO2009097077A2 (en) * 2008-01-07 2009-08-06 Coda Therapeutics, Inc. Wound healing compositions and treatments
TW200930398A (en) * 2008-01-11 2009-07-16 Univ Chang Gung RNAi sequence, inhibitor, and inhibition method that specifically inhibits expression of 78-kDA glucose-regulated protein
WO2009090639A2 (en) * 2008-01-15 2009-07-23 Quark Pharmaceuticals, Inc. Sirna compounds and methods of use thereof
EP2245464B1 (en) 2008-01-25 2016-12-14 MultiVir Inc. P53 biomarkers
WO2009093254A2 (en) 2008-01-27 2009-07-30 Rosetta Genomics Ltd. Methods and compositions for diagnosing complications of pregnancy
EP2245167A1 (en) 2008-02-05 2010-11-03 Pioneer Hi-Bred International Inc. Maize leaf- and stalk-preferred promoter
WO2009100430A2 (en) * 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
EP3643782A1 (en) * 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
DE102009043743B4 (de) 2009-03-13 2016-10-13 Friedrich-Schiller-Universität Jena Zellspezifisch wirksame Moleküle auf Grundlage von siRNA sowie Applikationskits zu deren Herstellung und Verwendung
US8497364B2 (en) * 2008-02-27 2013-07-30 California Institute Of Technology Triggered RNAi
CN105267233B (zh) 2008-03-05 2019-07-26 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因表达的组合物和方法
US20090233297A1 (en) * 2008-03-06 2009-09-17 Elizabeth Mambo Microrna markers for recurrence of colorectal cancer
EP2250265A1 (en) * 2008-03-12 2010-11-17 Intradigm Corporation Compositions comprising notch1 sirna and methods of use thereof
RU2010138558A (ru) * 2008-03-20 2012-03-27 Кварк Фармасьютикалс. Инк, (Us) Новые соединения миphk для ингибирования rtp801
US20090253780A1 (en) * 2008-03-26 2009-10-08 Fumitaka Takeshita COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
JP2011516065A (ja) 2008-04-04 2011-05-26 カランド ファーマシューティカルズ， インコーポレイテッド Ｅｐａｓ１阻害剤の組成物および使用
WO2009126726A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
US8901373B2 (en) 2008-04-10 2014-12-02 Monsanto Technology Llc Methods and compositions for root knot nematode control
WO2009125401A2 (en) 2008-04-10 2009-10-15 Rosetta Genomics Ltd. Compositions and methods for enhancing oil content in plants
CA2720903C (en) 2008-04-14 2019-01-15 Sangamo Biosciences, Inc. Linear donor constructs for targeted integration
WO2009144704A2 (en) * 2008-04-15 2009-12-03 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS FOR INHIBITING NRF2
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
US8518884B2 (en) 2008-04-25 2013-08-27 Northwestern University Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
US8258111B2 (en) * 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
US20100021904A1 (en) * 2008-05-21 2010-01-28 Pierce Niles A Shielded cross-linking probes
WO2009143391A2 (en) * 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Methods for modulation expression of creb
US20100021901A1 (en) * 2008-05-22 2010-01-28 Peng Yin Compositions and methods for detecting analytes
US8241854B2 (en) * 2008-05-22 2012-08-14 California Institute Of Technology Triggered RNAi
CA2726052A1 (en) 2008-06-04 2009-12-10 The Board Of Regents Of The University Of Texas System Modulation of gene expression through endogenous small rna targeting of gene promoters
US8431692B2 (en) 2008-06-06 2013-04-30 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
JP5764822B2 (ja) 2008-08-27 2015-08-19 オンコセラピー・サイエンス株式会社 がんの治療および診断の標的遺伝子としてのｐｒｍｔ１
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
EP2690175B1 (en) 2008-09-02 2016-12-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression
AU2009290625B2 (en) 2008-09-10 2014-12-11 University Of Bradford Compositions and methods for modulating skin pigmentation
AU2009290563A1 (en) 2008-09-15 2010-03-18 Genentech, Inc. Compositions and methods for regulating cell osmolarity
US20110263478A1 (en) 2008-09-16 2011-10-27 Simard J Marc Sur1 inhibitors for therapy
EP2165710A1 (en) 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US8546554B2 (en) 2008-09-25 2013-10-01 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
EP2331136B1 (en) 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
CA2738474C (en) 2008-09-29 2020-05-12 Monsanto Technology Llc Soybean transgenic event mon87705 and methods for detection thereof
US8298794B2 (en) 2008-10-09 2012-10-30 Ceres, Inc. Cinnamyl-alcohol dehydrogenases
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
EP2353012B1 (en) * 2008-10-16 2017-04-05 Cytonics Corporation Biomarkers and methods for detecting and treating spinal and joint pain
CN104382853A (zh) 2008-10-16 2015-03-04 玛瑞纳生物技术有限公司 基因沉默治疗剂的脂质体有效递送方法和组合物
EP2937418B1 (en) 2008-10-20 2017-10-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
WO2010048590A1 (en) * 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
EP2363148B1 (en) 2008-10-31 2014-11-26 Japan Science and Technology Agency Method for selectively controlling function of helper t cell
BRPI0921746A2 (pt) 2008-11-03 2015-09-01 Swetree Technologies Ab Material vegetal, plantas e um método de produção de uma planta tendo propriedades de ligna alteradas
EP2350264A4 (en) 2008-11-06 2012-08-29 Univ Johns Hopkins TREATMENT OF CHRONIC INFLAMMATION OF THE RESPIRATORY TRACT
CN102272157B (zh) 2008-11-07 2015-11-25 研究发展基金会 用于抑制cripto/grp78复合物形成和信号的组合物和方法
WO2010054264A1 (en) * 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
CA2742278A1 (en) * 2008-11-10 2010-05-14 Wyeth Llc Temperature-induced polynucleotides and uses therefor
EP2352847B1 (en) 2008-11-10 2014-01-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Gene signature for predicting prognosis of patients with solid tumors
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010059413A2 (en) 2008-11-20 2010-05-27 Novozymes, Inc. Polypeptides having amylolytic enhancing activity and polynucleotides encoding same
CA2744093A1 (en) 2008-12-03 2010-06-10 Marina Biotech, Inc. Una oligomer structures for therapeutic agents
EP2370092A1 (en) 2008-12-03 2011-10-05 Research Development Foundation Modulation of olfml-3 mediated angiogenesis
US7771983B2 (en) 2008-12-04 2010-08-10 Novozymos, Inc. Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
JP5832293B2 (ja) 2008-12-04 2015-12-16 オプコ ファーマシューティカルズ、エルエルシー 血管新生促進ｖｅｇｆイソ型を選択的に抑制する組成物および方法
US8497075B2 (en) 2008-12-09 2013-07-30 Novartis Ag Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands
EP2373382B1 (en) 2008-12-10 2017-02-15 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
AU2009326129B2 (en) 2008-12-12 2016-05-12 Basf Plant Science Gmbh Desaturases and process for the production of polyunsaturated fatty acids in transgenic organisms
US20110296557A1 (en) 2008-12-12 2011-12-01 Novozymes, Inc. Polypeptides Having Lipase Activity And Polynucleotides Encoding Same
WO2010068800A1 (en) 2008-12-12 2010-06-17 Novozymes, Inc. Polypeptides having aspartic endopeptidase activity and polynucleotides encoding same
WO2010074972A1 (en) 2008-12-15 2010-07-01 Novozymes, Inc. Polypeptides having catalase activity and polynucleotides encoding same
US20110271407A1 (en) 2008-12-16 2011-11-03 Novozymes, Inc. Polypeptides Having Alpha-Mannosidase Activity And Polynucleotides Encoding Same
WO2010074955A1 (en) 2008-12-16 2010-07-01 Novozymes, Inc. Polypeptides having carboxypeptidase activity and polynucleotides encoding same
US20100233172A1 (en) * 2008-12-16 2010-09-16 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
AU2009333863B2 (en) 2008-12-17 2015-02-05 Corteva Agriscience Llc Targeted integration into the Zp15 locus
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010074783A1 (en) 2008-12-23 2010-07-01 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
AU2010203474B2 (en) * 2009-01-08 2015-11-19 Northwestern University Inhibition of bacterial protein production by polyvalent oligonucleotide modified nanoparticle conjugates
AU2010203517B2 (en) 2009-01-09 2012-08-16 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
WO2010088387A1 (en) 2009-01-28 2010-08-05 Novozymes, Inc. Polypeptides having beta-glucosidase activity and polynucleotides encoding same
WO2010088463A2 (en) 2009-01-30 2010-08-05 Novozymes, Inc. Polypeptides having expansin activity and polynucleotides encoding same
US8309530B2 (en) * 2009-02-04 2012-11-13 Washington State University Compositions and methods for modulating ghrelin-mediated conditions
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
EP2395996A1 (en) 2009-02-13 2011-12-21 Indiana University Research and Technology Corporation Compounds and methods for inhibiting mmp2 and mmp9
EP2395831B1 (en) 2009-02-13 2017-04-12 The Regents of The University of California Control of plant stress tolerance, water use efficiency and gene expression using novel aba receptor proteins and synthetic agonists
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
CA2754043A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
US20120029054A1 (en) 2009-03-19 2012-02-02 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
AU2010226604A1 (en) 2009-03-19 2011-10-13 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
US20120035247A1 (en) 2009-03-19 2012-02-09 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
CN102361987A (zh) * 2009-03-20 2012-02-22 巴斯夫植物科学有限公司 抗线虫的转基因植物
WO2010105311A1 (en) 2009-03-20 2010-09-23 Angioblast Systems, Inc. Production of reprogrammed pluripotent cells
EP2408455B1 (en) 2009-03-20 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibitors of cathepsin S for prevention or treatment of obesity-associated disorders
US20110045080A1 (en) * 2009-03-24 2011-02-24 William Marsh Rice University Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto
US20120022142A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US20120010272A1 (en) 2009-03-27 2012-01-12 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411517A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP6010458B2 (ja) * 2009-04-03 2016-10-19 ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物
US20100257634A1 (en) * 2009-04-03 2010-10-07 Venganza Inc. Bioassay for gene silencing constructs
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
WO2010118243A2 (en) 2009-04-08 2010-10-14 Genentech, Inc. Use of il-27 antagonists to treat lupus
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
US8283332B2 (en) 2009-04-17 2012-10-09 University Of Louisville Research Foundation, Inc. PFKFB4 inhibitors and methods of using the same
AU2010239689A1 (en) * 2009-04-21 2011-11-03 Selecta Biosciences, Inc. Immunonanotherapeutics providing a Th1-biased response
CA3020943A1 (en) 2009-04-22 2010-10-28 Basf Plant Science Company Gmbh Whole seed specific promoter
WO2010124231A2 (en) * 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
EP2243828A1 (en) 2009-04-24 2010-10-27 DKFZ Deutsches Krebsforschungszentrum Use of mixed lineage like kinase polypeptides (MLKL polypeptides) in cancer therapy
EP2427180B1 (en) 2009-05-05 2016-04-13 Beeologics Inc. Prevention and treatment of nosema disease in bees
MY186558A (en) * 2009-05-13 2021-07-27 Malaysian Palm Oil Board A constitutive promoter from oil palm type 2
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
US20100298697A1 (en) * 2009-05-19 2010-11-25 Medtronic, Inc. Method and devices for improved efficiency of rna delivery to cells
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
ES2432618T3 (es) 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
EP2432467B1 (en) 2009-05-20 2018-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
HUE030948T2 (en) 2009-05-21 2017-06-28 Basf Enzymes Llc Phytases, nucleic acids and processes encoding them for their production and use
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
ES2534078T3 (es) 2009-06-02 2015-04-17 Novozymes Inc. Polipéptidos con actividad de celobiohidrolasa y polinucleótidos que codifican los mismos
EP2258858A1 (en) 2009-06-05 2010-12-08 Universitätsklinikum Freiburg Transgenic LSD1 animal model for cancer
CN102458099B (zh) 2009-06-05 2015-08-19 佛罗里达大学研究基金公司 甘蔗木质素生物合成基因的分离和靶向抑制
BRPI1010843A2 (pt) 2009-06-08 2015-09-08 Nunhems Bv plantas tolerantes à seca
MX2011013224A (es) 2009-06-09 2012-06-01 Pioneer Hi Bred Int Promotor de endospermo temprano y metodos de uso.
NZ597504A (en) 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
EP2266550A1 (en) 2009-06-15 2010-12-29 Institut Curie Antagonists of ß-catenin for preventing and/or treating neurodegenerative disorders
US20100323018A1 (en) * 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Branched DNA/RNA monomers and uses thereof
US20100324124A1 (en) * 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Compositions and methods relating to DNA-based particles
EP2445334A1 (en) 2009-06-26 2012-05-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Non human animal models for increased retinal vascular permeability
AU2010273756A1 (en) 2009-06-30 2011-11-24 E. I. Du Pont De Nemours And Company Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding cytosolic pyrophosphatase
CA2767169A1 (en) 2009-07-07 2011-01-13 Novozymes, Inc. Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
AU2010270337B2 (en) 2009-07-09 2016-09-22 Biontech Delivery Technologies Gmbh Amphoteric liposomes comprising imino lipids
CN102471777B (zh) 2009-07-10 2014-09-24 巴斯夫植物科学有限公司 用于在植物中胚乳-特异性表达的表达盒
SI2453923T1 (sl) 2009-07-14 2016-04-29 Mayo Foundation For Medical Education And Research S peptidi posredovana ne-kovalentna dostava aktivnih učinkovin preko krvno možganske bariere
EA036343B1 (ru) 2009-07-20 2020-10-29 Серес, Инк. Увеличение биомассы трансгенных растений
PT2769737T (pt) 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
US9409983B2 (en) 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
JP5755647B2 (ja) 2009-07-24 2015-07-29 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア αｖβ５インテグリンに関連する疾患の処置および予防のための方法および組成物
WO2011014458A1 (en) 2009-07-28 2011-02-03 Novozymes, Inc. Polypeptides having phytase activity and polynucleotides encoding same
NZ598457A (en) * 2009-08-03 2014-06-27 Recombinetics Inc Methods and compositions for targeted gene modification
CA2806295A1 (en) 2009-08-03 2011-02-10 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating insects
US9029338B2 (en) 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011021177A2 (en) 2009-08-19 2011-02-24 Rosetta Genomics Ltd. Compositions and methods for prognosis and treatment of prostate cancer
EP2467159A1 (en) 2009-08-20 2012-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
WO2011021171A1 (en) 2009-08-21 2011-02-24 Beeologics, Llc Preventing and curing beneficial insect diseases via plant transcribed molecules
US8039613B2 (en) 2009-08-28 2011-10-18 Promega Corporation Methods of purifying a nucleic acid and formulation and kit for use in performing such methods
US8222397B2 (en) * 2009-08-28 2012-07-17 Promega Corporation Methods of optimal purification of nucleic acids and kit for use in performing such methods
CA2772619C (en) 2009-09-04 2019-07-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for enhancing genome stability and telomere elongation in embryonic stem cells
EP2475388B1 (en) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
WO2011032100A1 (en) 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibitors of kshv vil6 and human il6
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
DK3269804T3 (da) 2009-09-17 2020-11-23 Novozymes Inc Polypeptider med cellulolyseforbedrende aktivitet og polynukleotider, som koder for dem
EP2478095A1 (en) 2009-09-18 2012-07-25 Novozymes Inc. Polypeptides having beta-glucosidase activity and polynucleotides encoding same
EP2480573A1 (en) * 2009-09-22 2012-08-01 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
CA2775347A1 (en) 2009-09-29 2011-04-07 Novozymes A/S Polypeptides having xylanase activity and polynucleotides encoding same
WO2011041397A1 (en) 2009-09-29 2011-04-07 Novozymes, Inc. Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
BR112012007375A2 (pt) 2009-09-30 2016-11-22 Novozymes As polipeptídeo isolado, polinucleotídeo isolado, métodos para produzir um polipeptídeo, para produzir um mutante de uma célula precursora, para inibir a expressão de um polipeptídeo, para produzir uma proteína, para degradar ou converter um material celulósico, para produzir um produto de fermentação e para fermentar um material celulósico, planta transgênica, parte de planta ou célula de planta transformada, molécula de rna inibitória de filamento duplo, e, composição detergente
WO2011039319A1 (en) 2009-09-30 2011-04-07 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
US20150025122A1 (en) 2009-10-12 2015-01-22 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
UA111708C2 (uk) 2009-10-16 2016-06-10 Бандж Ойлз, Інк. Спосіб рафінування олії
UA109884C2 (uk) 2009-10-16 2015-10-26 Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування
US20120219543A1 (en) 2009-10-20 2012-08-30 Raphael Scharfmann Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
BR112012009044A2 (pt) 2009-10-26 2015-09-01 Pioneer Hi Bred Int Molécula de ácido nucléico isolada, cassete de expressão, vetor, célula vegetal, planta, semente transgênica, método para expressão de um polinucleotídeo em uma planta ou célula vegetal e método para expressão de um polinucleotídeo, preferencialmente em tecidos somáticos de óvulo de uma planta
WO2011059740A1 (en) 2009-10-29 2011-05-19 Novozymes, Inc. Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
CN103068976A (zh) 2009-11-06 2013-04-24 诺维信股份有限公司 具有纤维二糖水解酶活性的多肽和编码该多肽的多核苷酸
DK2496692T3 (en) 2009-11-06 2016-06-27 Novozymes Inc POLYPEPTIDES WITH xylanase AND POLYNUCLEOTIDES ENCODING THEM
WO2011054916A1 (en) 2009-11-06 2011-05-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of atherosclerosis
US9799416B2 (en) * 2009-11-06 2017-10-24 Terrapower, Llc Methods and systems for migrating fuel assemblies in a nuclear fission reactor
CN102666856B (zh) 2009-11-08 2016-04-06 夸克制药公司 定向至RhoA靶基因的双链RNA化合物在制造治疗神经性疼痛的药物中的用途
EP2322927A1 (en) 2009-11-16 2011-05-18 Deutsches Krebsforschungszentrum Compounds inhibiting CD95 signaling for the treatment of pancreatic cancer
EP2501414B1 (en) 2009-11-17 2018-01-10 The Trustees Of The University Of Pennsylvania Smndelta7 degron: novel compositions and methods of use
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
EP2322619A1 (en) 2009-11-17 2011-05-18 Deutsches Krebsforschungszentrum Inhibitors of centrosomal clustering
TW201124160A (en) 2009-11-26 2011-07-16 Quark Pharmaceuticals Inc SiRNA compounds comprising terminal substitutions
US9090932B2 (en) 2009-11-27 2015-07-28 Japan Science And Technology Agency Method for screening of therapeutic agent for hyperlipemia
DE112010005958T5 (de) 2009-12-03 2013-08-14 Basf Plant Science Company Gmbh Expressionskassetten für die Embryo-spezifische Expression in Pflanzen
US9163240B2 (en) 2009-12-07 2015-10-20 The Johns Hopkins University SR-BI mutation as a predictor of low progesterone levels and poor fetal viability during pregnancy
CA2781896C (en) 2009-12-09 2021-03-30 Nitto Denko Corporation Modulation of hsp47 expression
WO2011069953A1 (en) 2009-12-09 2011-06-16 Basf Plant Science Company Gmbh Methods for increasing the resistance of plants to fungi by silencing the fungal smt1-gene
WO2011072091A1 (en) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
WO2011070049A1 (en) 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
EP2509590B1 (en) 2009-12-10 2019-10-30 The Trustees of Columbia University in the City of New York Histone acetyltransferase activators and uses thereof
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
MX339050B (es) 2009-12-18 2016-05-09 Novartis Ag Composiciones organicas para tratar las enfermedades relacionadas con hsf1.
CN108295087B (zh) 2009-12-23 2021-01-15 格兰达利斯有限公司 弗林蛋白酶敲减和gm-csf增强的(fang)癌症疫苗
SG181881A1 (en) 2009-12-23 2012-07-30 Gradalis Inc Furin-knockdown bi-functional rna
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2011080261A1 (en) 2009-12-28 2011-07-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for improved cardiomyogenic differentiation of pluripotent cells
JP2013515500A (ja) 2009-12-29 2013-05-09 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 炎症性の病気の改善または予防のための、ショウガが含まれる組成物
US9109227B2 (en) 2010-01-05 2015-08-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
JP5914357B2 (ja) 2010-01-15 2016-05-11 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 自閉症の治療のための化合物
MX344543B (es) 2010-01-26 2016-12-19 Nat Jewish Health Metodos y composiciones para prediccion de riesgo, diagnosis, prognosis y tratamiento de desordenes pulmonares.
US9255259B2 (en) 2010-02-09 2016-02-09 Sangamo Biosciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
MX2012009318A (es) 2010-02-10 2012-09-07 Novartis Ag Metodos y compuestos para el crecimiento muscular.
CA2788036A1 (en) 2010-02-23 2011-09-01 Basf Plant Science Company Gmbh Nematode-resistant transgenic plants
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2542682A2 (en) 2010-03-03 2013-01-09 E.I. Du Pont De Nemours And Company Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding oxidoreductase motif polypeptides
KR101982126B1 (ko) 2010-03-08 2019-05-27 몬산토 테크놀로지 엘엘씨 식물에서 유전자 조절을 위한 폴리뉴클레오타이드 분자
EP2548025A4 (en) * 2010-03-17 2013-09-25 Univ Michigan USE OF PHOTOEPITOPES FOR PROFILING AN IMMUNE REACTION
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
CA2794189C (en) 2010-03-24 2022-01-11 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
WO2011120023A1 (en) 2010-03-26 2011-09-29 Marina Biotech, Inc. Nucleic acid compounds for inhibiting survivin gene expression uses thereof
EP2552460A1 (en) 2010-03-29 2013-02-06 Universite De Strasbourg Polymers for delivering molecules of interest
US20130281510A1 (en) 2010-03-29 2013-10-24 Kumamoto University siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
CN102971337B (zh) 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
EP3578657B1 (en) 2010-04-06 2024-03-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
WO2011133584A2 (en) 2010-04-19 2011-10-27 Marina Biotech, Inc. Nucleic acid compounds for inhibiting hras gene expression and uses thereof
WO2011133931A1 (en) 2010-04-22 2011-10-27 Genentech, Inc. Use of il-27 antagonists for treating inflammatory bowel disease
US20130190383A1 (en) 2010-04-26 2013-07-25 Marina Biotech, Inc. Nucleic acid compounds with conformationally restricted monomers and uses thereof
WO2011139842A2 (en) 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
KR20130107203A (ko) 2010-05-04 2013-10-01 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
WO2011140329A1 (en) 2010-05-06 2011-11-10 Ceres, Inc. Transgenic plants having increased biomass
EP2568986B1 (en) 2010-05-10 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
KR20130080007A (ko) 2010-05-11 2013-07-11 다우 아그로사이언시즈 엘엘씨 Ｓｐｎｋ 균주
US8658780B2 (en) 2010-05-18 2014-02-25 California Institute Of Technology Triggered covalent probes for imaging and silencing genetic expression
KR101223660B1 (ko) 2010-05-20 2013-01-17 광주과학기술원 ＨＩＦ－２α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물
JP6033218B2 (ja) 2010-05-21 2016-11-30 ペプティメド， インコーポレイテッド がんを治療するための試薬および方法
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
EA030460B1 (ru) 2010-05-28 2018-08-31 Нунхемс Б.Ф. Растения с увеличенным размером плода
WO2011151321A1 (en) 2010-05-31 2011-12-08 Institut Curie Asf1b as a prognosis marker and therapeutic target in human cancer
EP3456827A3 (en) 2010-06-02 2019-05-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
DE102010022937A1 (de) 2010-06-04 2011-12-08 Universitätsklinikum Jena Zellspezifisch aktivierbare biologisch wirksame Moleküle auf Grundlage von siRNA, Verfahren zu deren Aktivierung sowie Applikationskit zur Verabreichung
GB201009601D0 (en) 2010-06-08 2010-07-21 Devgen Private Ltd Method for down-grading gene expression in fungi
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
AU2011271094B2 (en) 2010-06-21 2015-01-22 Novozymes, Inc. Aspergillus aculeatus derived polypeptides having C4-dicarboxylic acid transporter activity and polynucleotides encoding same
US9168297B2 (en) 2010-06-23 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (NRG-1)
US9095591B2 (en) 2010-06-28 2015-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Pharmaceutical composition for use in the treatment of glaucoma
EP2588604B1 (en) 2010-06-30 2016-06-29 Novozymes, Inc. Polypeptides having beta-glucosidase activity and polynucleotides encoding same
BR112012033668A2 (pt) 2010-07-01 2017-06-13 Du Pont planta e semente transgênica, método para a produção de um planta transgênica, produto e/ou subproduto obtido a partir da semente transgênica, polinucleotídeo isolado e planta ou semente compreendendo uma cosntrução de dna recombinante
US9512188B2 (en) 2010-07-12 2016-12-06 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Isolated polynucleotides and methods and plants using same for regulating plant acidity
US8877438B2 (en) 2010-07-20 2014-11-04 California Institute Of Technology Self-assembled polynucleotide structure
US8962241B2 (en) 2010-07-20 2015-02-24 California Institute Of Technology Triggered molecular geometry based bioimaging probes
US9834439B2 (en) 2010-07-20 2017-12-05 California Institute Of Technology Biomolecular self-assembly
EP2596025B1 (en) 2010-07-23 2018-06-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
WO2012019991A1 (en) 2010-08-09 2012-02-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of hiv-1 infections
CA2805941A1 (en) 2010-08-13 2012-02-16 Pioneer Hi-Bred International, Inc. Methods and compositions for targeting sequences of interest to the chloroplast
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2606152B2 (en) 2010-08-18 2025-03-12 Fred Hutchinson Cancer Center Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
JP6106085B2 (ja) 2010-08-24 2017-03-29 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 内部非核酸スペーサーを含む一本鎖ＲＮＡｉ剤
WO2012027467A1 (en) 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9267126B2 (en) 2010-08-30 2016-02-23 Novozymes, Inc. Polypeptides having endoglucanase activity and polynucleotides encoding same
WO2012030849A1 (en) 2010-08-30 2012-03-08 Novozymes A/S Polypeptides having xylanase activity and polynucleotides encoding same
WO2012030811A1 (en) 2010-08-30 2012-03-08 Novozymes A/S Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
WO2012030858A2 (en) 2010-08-30 2012-03-08 Novozymes A/S Polypeptides having hemicellulolytic activity and polynucleotides encoding same
US8629325B2 (en) 2010-08-30 2014-01-14 Novozymes A/S Polypeptides having beta-glucosidase activity and polynucleotides encoding same
US9303074B2 (en) 2010-08-30 2016-04-05 Novoyzmes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
WO2012028703A1 (en) 2010-09-02 2012-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for the prognosis of the progression of cancer
WO2012042289A1 (en) 2010-09-28 2012-04-05 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of bone density related diseases
US20140079769A1 (en) 2010-10-01 2014-03-20 Fabiola Terzi Methods for predicting the progression and treating a chronic kidney disease in a patient
CA2811787A1 (en) 2010-10-06 2012-04-19 Bp Corporation North America Inc. Variant cbh i polypeptides
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
WO2012051491A1 (en) 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
CN103391784A (zh) 2010-10-15 2013-11-13 纽约市哥伦比亚大学理事会 肥胖症-相关的基因和它们的蛋白和其用途
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
BR112013010278B1 (pt) 2010-10-27 2020-12-29 Ceres, Inc método para produzir uma planta, método para modular a composição de biomassa em uma planta, ácido nucleico isolado e método para alterar a composição de biomassa em uma planta
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
US10738326B2 (en) 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
US20120107355A1 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2632943A1 (en) 2010-10-29 2013-09-04 Novozymes A/S Polypeptides having succinyl-coa:aceto acetate transferase activity and polynucleotides encoding same
SG10201508981YA (en) 2010-11-01 2015-11-27 Peptimed Inc Compositions Of A Peptide-Based System For Cell-Specific Targeting
PT2635299T (pt) 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
EP2635594B1 (en) 2010-11-04 2017-01-11 Novozymes Inc. Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
NZ610181A (en) 2010-11-04 2015-03-27 Arista Cereal Technologies Pty Ltd High amylose wheat
CA2816763A1 (en) 2010-11-05 2012-05-10 Transbio Ltd Markers of endothelial progenitor cells and uses thereof
US9339513B2 (en) 2010-11-09 2016-05-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
BR112013009026A2 (pt) 2010-11-12 2016-07-12 Novozymes Inc polipeptídeo isolado, célula hospedeira recombinante, métodos para produzir um polipeptídeo, um mutante de uma célula precursora, uma proteína, e um produto de fermentação, para inibir a expressão de um polipeptídeo, para degradar ou converter um material celulósico, e método para fermentar um material celulósico, planta transgênica, parte de planta ou célula de planta, molécula de rna inibidora de filamento duplo, polinucleotídeo isolado, e, formulação de caldo integral ou composição de cultura de célula
EP2455456A1 (en) 2010-11-22 2012-05-23 Institut Curie Use of kinesin inhibitors in HIV infection treatment and a method for screening them
WO2012072681A1 (en) 2010-12-01 2012-06-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Diagnostic and treatment of chronic heart failure
US9533041B2 (en) 2010-12-03 2017-01-03 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of heart failure
CA2820706C (en) 2010-12-03 2018-05-22 Ms Technologies, Llc Optimized expression of glyphosate resistance encoding nucleic acid molecules in plant cells
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
CA2818024C (en) 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
WO2012102793A2 (en) 2010-12-10 2012-08-02 Zirus, Inc. Mammalian genes involved in toxicity and infection
US8575328B2 (en) 2010-12-14 2013-11-05 The United States Of America, As Represented By The Secretary Of Agriculture Formicidae (ant) control using double-stranded RNA constructs
US9969677B2 (en) 2010-12-22 2018-05-15 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase modulators and uses thereof
BR112013014988A2 (pt) 2010-12-22 2017-06-27 Du Pont molécula de ácido nucléico isolada, constructo de dna, vetor, célula vegetal, planta, semente transgênica proveniente da planta, método para expressão de uma sequência de nucleotídeos em uma planta, método para expressão de uma sequência de nucleotídeos em uma célula vegetal, método para expressar seletivamente uma sequência de nucleotídeos em tecidos vegetais verdes de milho
EP2655632A1 (en) 2010-12-22 2013-10-30 Pioneer Hi-Bred International Inc. Viral promoter, truncations thereof, and methods of use
US8883757B2 (en) 2011-01-03 2014-11-11 Rosetta Genomics Ltd. Compositions and methods for treatment of ovarian cancer
KR20200023495A (ko) 2011-01-10 2020-03-04 더 리젠츠 오브 더 유니버시티 오브 미시간 줄기 세포 인자 억제제
MX2013007720A (es) 2011-01-26 2013-08-09 Novozymes As Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican para los mismos.
US9157075B2 (en) 2011-01-26 2015-10-13 Novozymes, Inc. Polypeptides having cellobiohydrolase activity and polynucleotides encoding same
EP2487242A1 (en) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
EP2675901B1 (en) 2011-02-14 2018-05-30 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
WO2012112411A1 (en) 2011-02-15 2012-08-23 Pioneer Hi-Bred International, Inc. Root-preferred promoter and methods of use
WO2012116040A1 (en) 2011-02-22 2012-08-30 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2681314B1 (en) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
AU2012223366B2 (en) 2011-03-03 2017-02-23 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
EP2684045B2 (en) 2011-03-09 2023-03-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods to characterize patients suffering from hemolysis
WO2012122477A1 (en) 2011-03-10 2012-09-13 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
BR112013023724A2 (pt) 2011-03-15 2019-09-24 Univ Utah Res Found métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
US8648230B2 (en) 2011-03-18 2014-02-11 Ms Technologies, Llc Regulatory regions preferentially expressing in non-pollen plant tissue
CN105886506A (zh) 2011-04-13 2016-08-24 Isis制药公司 Ptp1b 表达的反义调节
ES2607616T3 (es) 2011-04-13 2017-04-03 Institut National de la Santé et de la Recherche Medicale (INSERM) Modelo animal no humano para la colitis ulcerosa y sus principales complicaciones
KR101291668B1 (ko) 2011-04-21 2013-08-01 서울대학교산학협력단 미코박테리아―대장균용 셔틀 벡터 및 이의 용도
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
DK2702153T3 (en) 2011-04-28 2019-03-18 Novozymes Inc Polypeptides with endoglucanase activity and polynucleotides encoding them
WO2012146702A1 (en) 2011-04-28 2012-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing accessory cells and uses thereof for preparing activated nk cells
BR112013027860A2 (pt) * 2011-04-29 2016-11-29 Pioneer Hi Bred Int ácido nucleico isolado, planta ou célula vegetal, método para aumentar a capacidade do dreno, acelerar a remobilização e/ou a senescência e a secagem de grão em uma planta, método para aumentar a tolerância a seca na ausência de uma penalidade de produtividade sob condições sem seca, cassete de expressão e método para reduzir a expressão de zmme293 ou a atividade de zmme293 em uma planta
EP2998399A1 (en) 2011-05-03 2016-03-23 Dow AgroSciences LLC Enhancing spinosyn production with oxygen binding proteins
EP2704688B1 (en) 2011-05-05 2019-07-10 Matinas BioPharma Nanotechnologies, Inc. Cochleate compositions and methods of making and using same
EP2527448A1 (en) 2011-05-23 2012-11-28 Novozymes A/S Simultaneous site-specific integrations of multiple gene-copies in filamentous fungi
EP2527432A1 (en) 2011-05-23 2012-11-28 Novozymes A/S Bi-directional cytosine deaminase-encoding selection marker
BR112013029857A2 (pt) 2011-05-24 2017-11-28 Mor Research Applic Ltd métodos e composições para determinação de insuficiência cardíaca ou risco de insuficiência cardíaca
EP2714037B1 (en) 2011-05-25 2016-07-13 Université Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
US9920327B2 (en) 2011-06-02 2018-03-20 The Regents Of The University Of California Plants with elevated levels of glucan
EP2714094B1 (en) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
GB201109966D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer
GB201109965D0 (en) 2011-06-10 2011-07-27 Cancer Res Inst Royal Materials and methods for treating estrogen receptor alpher(ER) positive cancer
DK2718442T3 (en) 2011-06-10 2017-08-14 Temasek Life Sciences Laboratory Ltd GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR SUBPHYLA OF PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
CA2839896A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
EP2723351B1 (en) 2011-06-21 2018-02-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein c (proc) genes
EP2723861A4 (en) 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
EP2723756B1 (en) 2011-06-21 2020-03-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes
US20140235693A1 (en) 2011-06-23 2014-08-21 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
WO2012175711A1 (en) 2011-06-24 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the responsiveness of a patient affected with an osteosarcoma to a chemotherapy
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
RS55088B1 (sr) 2011-07-06 2016-12-30 Sykehuset Sorlandet Hf Egfr ciljana terapija
US9441255B2 (en) 2011-07-21 2016-09-13 The Regents Of The University Of California Transcription factors for cellulosic enzyme production
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US20140189895A1 (en) 2011-07-22 2014-07-03 Yoshindo Inc. TECHNIQUE FOR CLEAVING OUT PART OF POLY(A) CHAIN AND/OR 3'-TERMINAL SEQUENCE OF mRNA TO INHIBIT TRANSLATION REACTION
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
EP2742129B1 (en) 2011-08-10 2017-08-02 Novozymes A/S Polypeptides having peroxygenase activity and polynucleotides encoding same
WO2013021059A1 (en) 2011-08-10 2013-02-14 Novozymes A/S Polypeptides having peroxygenase activity and polynucleotides encoding same
WO2013021064A1 (en) 2011-08-10 2013-02-14 Novozymes A/S Polypeptides having peroxygenase activity and polynucleotides encoding same
US9506044B2 (en) 2011-08-10 2016-11-29 Novozymes A/S Polypeptides having peroxygenase activity and polynucleotides encoding same
WO2013021065A1 (en) 2011-08-10 2013-02-14 Novozymes A/S Polypeptides having peroxygenase activity and polynucleotides encoding same
WO2013021062A1 (en) 2011-08-10 2013-02-14 Novozymes A/S Polypeptides having peroxygenase activity and polynucleotides encoding same
US9487761B2 (en) 2011-08-10 2016-11-08 Novozymes A/S Polypeptides having peroxygenase activity and polynucleotides encoding same
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
WO2013023992A1 (en) * 2011-08-12 2013-02-21 Bayer Cropscience Nv Guard cell-specific expression of transgenes in cotton
EP2748314B1 (en) 2011-08-24 2016-12-28 Novozymes, Inc. Aspergillus fumigatus cellulolytic enzyme compositions and uses thereof
DK2748305T3 (en) 2011-08-24 2017-02-06 Novozymes Inc CELLULOLYTIC ENZYME COMPOSITIONS AND APPLICATIONS THEREOF
SG2014011316A (en) 2011-08-31 2014-06-27 Genentech Inc Diagnostic markers
JP2014531425A (ja) 2011-09-02 2014-11-27 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク 肥満の代謝異常を治療するためのＣａＭＫＩＩ、ＩＰ３Ｒ、カルシニューリン、ｐ３８、およびＭＫ２／３阻害剤
US20160032284A1 (en) 2011-09-02 2016-02-04 Arrowhead Research Corportation Organic compositions to treat hsf1-related diseases
HK1201471A1 (en) 2011-09-07 2015-09-04 Deutsches Krebsforschungszentrum Means and methods for treating and/or preventing natural ahr ligand-dependent cancer
EP2753631A1 (en) 2011-09-07 2014-07-16 Marina Biotech, Inc. Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
WO2013036799A2 (en) 2011-09-09 2013-03-14 Fred Hutchinson Cancer Research Center Methods and compositions involving nkg2d inhibitors and cancer
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US9644241B2 (en) 2011-09-13 2017-05-09 Interpace Diagnostics, Llc Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
MX350775B (es) * 2011-09-13 2017-09-15 Monsanto Technology Llc Métodos y composiciones para el control de malezas.
BR112014005975A8 (pt) 2011-09-13 2017-09-12 Monsanto Technology Llc Método de controle de planta, método de redução de expressão de um gene pds em uma planta, cassete de expressão microbiana, método de fazer um polinucleotídeo, método de identificação de polinucleotídeos, e composições para controle de erva daninha
EP3434780A1 (en) 2011-09-13 2019-01-30 Monsanto Technology LLC Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
BR112014005958A2 (pt) 2011-09-13 2020-10-13 Monsanto Technology Llc métodos e composições químicas agrícolas para controle de planta, método de redução de expressão de um gene accase em uma planta, cassete de expressão microbiana, método para fazer um polinucleotídeo, método de identificação de polinucleotídeos úteis na modulação de expressão do gene accase e composição herbicida
CA2848685A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control comprising topical application of a glutamine synthetase polynucleotide
AU2012308660B2 (en) * 2011-09-13 2017-05-25 Monsanto Technology Llc Methods and compositions for weed control
CN103930549B (zh) * 2011-09-13 2020-09-18 孟山都技术公司 用于杂草控制的方法和组合物
WO2013040005A1 (en) * 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
US20140308705A1 (en) 2011-09-20 2014-10-16 Novozymes A/S Polypeptides Having Cellulolytic Enhancing Activity And Polynucleotides Encoding Same
US9352312B2 (en) 2011-09-23 2016-05-31 Alere Switzerland Gmbh System and apparatus for reactions
JP2014531213A (ja) 2011-09-30 2014-11-27 ジェネンテック， インコーポレイテッド 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるｅｇｆｒキナーゼ阻害薬に対する応答
WO2013050405A1 (en) 2011-10-03 2013-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of th2 mediated diseases
UA115132C2 (uk) 2011-10-04 2017-09-25 Байєр Інтелекчуал Проперті Гмбх Спосіб боротьби з грибами та ооміцетами шляхом інгібування гена сахаропіндегідрогенази
PE20141562A1 (es) 2011-10-14 2014-11-12 Genentech Inc Anticuerpos anti-htra1 y metodos de uso
EP2766733A2 (en) 2011-10-14 2014-08-20 Inserm Biomarkers of renal disorders
AU2012325997C1 (en) 2011-10-18 2018-07-05 Dicerna Pharmaceuticals, Inc. Amine cationic lipids and uses thereof
EP2768971A1 (en) 2011-10-20 2014-08-27 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the detection and the treatment of cardiac remodeling
WO2013067128A1 (en) 2011-11-02 2013-05-10 Ceres, Inc. Transgenic plants having increased tolerance to aluminum
EP2773758B1 (en) 2011-11-03 2017-06-07 Quark Pharmaceuticals, Inc. Compositions for use in neuroprotection
EP2773183B1 (en) 2011-11-04 2024-10-09 Arista Cereal Technologies Pty Ltd High amylose wheat - ii
EP2776130A1 (en) 2011-11-07 2014-09-17 Institut National de la Sante et de la Recherche Medicale (INSERM) A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis
US20140323549A1 (en) 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
EP2782933A1 (en) 2011-11-22 2014-10-01 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for reducing airway hyperresponse
DK2782998T3 (en) 2011-11-22 2018-04-16 Novozymes Inc POLYPEPTIDES WITH BETA-XYLOSIDASE ACTIVITY AND POLYNUCLEOTIDES CODING THEM
US9624481B2 (en) 2011-12-01 2017-04-18 Novozymes, Inc. Polypeptides having beta-xylosidase activity and polynucleotides encoding same
US9404093B2 (en) 2011-12-02 2016-08-02 Novozymes A/S Polypeptides having peroxygenase activity and polynucleotides encoding same
US9169469B2 (en) 2011-12-02 2015-10-27 Novozymes A/S Polypeptides having peroxygenase activity and polynucleotides encoding same
BR112014013853A2 (pt) 2011-12-09 2020-01-14 Ceres, Inc. uso de um ácido nucleico isolado, método de obtenção de uma célula vegetal transgênica, método de obtenção de uma planta transgênica, método de produção de uma planta, método de produção de biomassa, método de processamento de biomassa, método de alteração da composição de biomassa, método de modulação de composição de biomassa, método de produção de um produto de forragem
UA116097C2 (uk) 2011-12-11 2018-02-12 Зе Стейт Оф Ізраел, Міністрі Оф Агрікалче Енд Руерал Девелопмент, Агрікалчерал Рісьоч Організейшн, (А.Р.О.), Волкані Сентре Спосіб модуляції провідності устячка рослини
WO2013087027A1 (en) 2011-12-16 2013-06-20 Novozymes, Inc. Polypeptides having laccase activity and polynucleotides encoding same
PH12014501474B1 (en) 2011-12-27 2024-01-19 Nuseed Global Innovation Ltd Processes for producing lipids
EP2798065B1 (en) 2011-12-27 2019-06-05 Commonwealth Scientific and Industrial Research Organisation Simultaneous gene silencing and supressing gene silencing in the same cell
CA2860416C (en) 2011-12-27 2024-04-30 Commonwealth Scientific And Industrial Research Organisation Production of dihydrosterculic acid and derivatives thereof
WO2013101783A2 (en) 2011-12-30 2013-07-04 Bio-Rad Laboratories, Inc. Methods and compositions for performing nucleic acid amplification reactions
EP2800760A1 (en) 2012-01-06 2014-11-12 Pioneer Hi-Bred International Inc. Compositions and methods for the expression of a sequence in a reproductive tissue of a plant
US9006515B2 (en) 2012-01-06 2015-04-14 Pioneer Hi Bred International Inc Pollen preferred promoters and methods of use
WO2013103371A1 (en) 2012-01-06 2013-07-11 Pioneer Hi-Bred International, Inc. Ovule specific promoter and methods of use
BR112014016870A2 (pt) 2012-01-09 2017-06-27 Huesken Dieter composições orgânicas para tratar doenças relacionadas com beta-catenina
CA2860864A1 (en) 2012-01-11 2013-07-18 The Australian National University Method for modulating plant root architecture
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
WO2013113762A1 (en) 2012-01-31 2013-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cutaneous melanoma in a subject
US9506077B2 (en) 2012-02-01 2016-11-29 Dow Agrosciences Llc Synthetic chloroplast transit peptides
WO2013121034A1 (en) 2012-02-17 2013-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing adipose tissue inflammation
PT2817325T (pt) 2012-02-20 2019-10-01 Novozymes As Polipéptidos que têm atividade da endoglucanase e polinucleotídeos codificando mesmos
US9663560B2 (en) * 2012-02-28 2017-05-30 The United States Of America, As Represented By The Secretary Of Agriculture Cotton PHYA1 RNAi improves fiber quality, root elongation, flowering, maturity and yield potential in Gossypium hirsutum L
HK1200093A1 (en) 2012-03-16 2015-07-31 霍夫曼-拉罗奇有限公司 Methods of treating melanoma with pak1 inhibitors
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2650013A1 (en) 2012-04-10 2013-10-16 Deutsches Krebsforschungszentrum Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for use in treating and/or preventing inflammation- and/or damage-induced cancer
EP2839007B1 (en) 2012-04-19 2017-12-27 Temasek Life Sciences Laboratory Limited Methods for increasing cotton fiber length
BR112014025983A2 (pt) 2012-04-20 2018-07-03 Futuragene Israel Ltd molécula de ácido ribonucleico, dsrna, vetor, célula hospedeira, tecido vegetal, ácido nucleico e métodos de produção de plantas e de inibição de infestação de pragas
EP2841570B1 (en) 2012-04-23 2017-12-20 Novozymes A/S Polypeptides having glucuronyl esterase activity and polynucleotides encoding same
BR112014026363A2 (pt) 2012-04-23 2017-06-27 Futuragene Israel Ltd molécula de ácido ribonucleico, dsrna, vetor, célula hospedeira, tecido vegetal, ácido nucleico isolado, método de produção de planta resistente a pragas e método de inibição de infestação de pragas
US9446102B2 (en) 2012-04-23 2016-09-20 Novozymes A/S Polypeptides having alpha-glucuronidase activity and polynucleotides encoding same
HK1207938A1 (en) 2012-04-25 2016-02-19 Commonwealth Scientific And Industrial Research Organisation High oleic acid oils
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
EP2844668A1 (en) 2012-05-03 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
WO2013167582A1 (en) 2012-05-09 2013-11-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease
WO2013171296A1 (en) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of sarcoidosis
WO2013174834A1 (en) 2012-05-22 2013-11-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating focal segmental glomerulosclerosis
CN104619843B (zh) 2012-05-24 2020-03-06 A.B.种子有限公司 用于使基因表达沉默的组合物和方法
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
WO2013187556A1 (en) 2012-06-14 2013-12-19 Scripps Korea Antibody Institute Novel antibody specific for clec14a and uses thereof
EP2864485A4 (en) 2012-06-22 2016-03-02 Univ California COMPOSITIONS AND METHODS FOR IMPROVING PLANT STATE DEVELOPMENT AS A RESPONSE TO CARBON DIOXIDE AND APPLICATIONS FOR MANIPULATING THE NON-RESISTANCE OF PLANTS
JP6282642B2 (ja) 2012-06-27 2018-02-21 メタノミクス ヘルス ゲーエムベーハー 糖尿病薬を同定する方法
WO2014006025A2 (en) 2012-07-02 2014-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Marker of pathogenicity in salmonella
EP2875049B1 (en) 2012-07-18 2018-12-26 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for preventing and treating chronic kidney disease (ckd)
ES2817897T3 (es) 2012-07-23 2021-04-08 La Jolla Inst Allergy & Immunology PTPRS y proteoglicanos en enfermedad autoinmune
CA2883130A1 (en) 2012-08-31 2014-03-06 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
MX375442B (es) 2012-09-21 2025-03-06 Intensity Therapeutics Inc Un agente terapéutico y un agente mejorador de la permeación intracelular para usarse en el tratamiento de cáncer.
CN104903449A (zh) 2012-10-03 2015-09-09 富优基尼以色列股份有限公司 瘿蜂防治剂
WO2014055825A1 (en) 2012-10-04 2014-04-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services A formulation of mycobacterial components as an adjuvant for inducing th17 responses
WO2014053871A1 (en) 2012-10-04 2014-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for screening a compound capable of inhibiting the notch1 transcriptional activity
US20150259690A1 (en) 2012-10-05 2015-09-17 Bioneer Corporation Amphiregulin-specific double-helical oligo-rna, double-helical oligo-rna structure comprising double-helical oligo-rna, and composition for preventing or treating respiratory diseases containing same
EP3677310A1 (en) 2012-10-08 2020-07-08 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
EP3586610B1 (en) 2012-10-08 2024-09-25 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
US20150259403A1 (en) 2012-10-10 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and Pharmaceutical Compositions for Treatment of Gastrointestinal Stromal Tumors
CA2887571A1 (en) 2012-10-11 2014-04-17 Pioneer Hi-Bred International, Inc. Guard cell promoters and uses thereof
EP2906686B1 (en) 2012-10-12 2018-08-29 Novozymes A/S Polypeptides having peroxygenase activity
EP2906685B1 (en) 2012-10-12 2018-08-15 Novozymes A/S Polypeptides having peroxygenase activity
EP2906689B1 (en) 2012-10-12 2018-12-12 Novozymes A/S Polypeptides having peroxygenase activity
US9404094B2 (en) 2012-10-12 2016-08-02 Novozymes A/S Polypeptides having peroxygenase activity
CN104718287B (zh) 2012-10-12 2018-02-06 诺维信公司 具有过氧合酶活性的多肽
US9453207B2 (en) 2012-10-12 2016-09-27 Novozymes A/S Polypeptides having peroxygenase activity
WO2014056916A2 (en) 2012-10-12 2014-04-17 Novozymes A/S Polypeptides having peroxygenase activity
BR112015008706A2 (pt) 2012-10-18 2018-02-06 Monsanto Technology Llc métodos e composições para controle de praga de plantas
CN104918639B (zh) 2012-10-22 2018-01-26 萨拜格Rfa公司 用于将治疗剂递送到活细胞和细胞核中的系统
JP2015536933A (ja) 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路結合剤を用いて神経内分泌腫瘍を処置する方法
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
WO2014066141A2 (en) 2012-10-24 2014-05-01 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
US20150246118A1 (en) 2012-10-26 2015-09-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
WO2014064192A1 (en) 2012-10-26 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
EP2917347B1 (en) 2012-11-08 2019-01-02 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of bone metastases
EP2732815A1 (en) 2012-11-16 2014-05-21 Neurochlore Modulators of intracellular chloride concentration for treating fragile X syndrome
BR112015013105B1 (pt) 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
WO2014090765A1 (en) 2012-12-12 2014-06-19 Bayer Cropscience Ag Use of 1-[2-fluoro-4-methyl-5-(2,2,2-trifluoroethylsulfinyl)phenyl]-5-amino-3-trifluoromethyl)-1 h-1,2,4 tfia zole for controlling nematodes in nematode-resistant crops
US9486473B2 (en) 2012-12-13 2016-11-08 Ymir Genomics, Llc MicroRNAs and uses thereof
WO2014091466A2 (en) 2012-12-14 2014-06-19 Indian Agricultural Research Institute A method for the control of nematodes in plants
US9765373B2 (en) 2012-12-14 2017-09-19 Novozymes A/S Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
WO2014099798A1 (en) 2012-12-19 2014-06-26 Novozymes A/S Polypeptides having cellulolytic enhancinc activity and polynucleotides encoding same
KR102228358B1 (ko) 2012-12-21 2021-03-16 쉬케후세트 솔란데트 에이치에프 신경 장애 및 통증의 ｅｇｆｒ 표적 치료
EP2938628A4 (en) 2012-12-24 2016-10-19 Novozymes As POLYPEPTIDES WITH ENDOGLUCANASE ACTIVITY AND POLYNUCLEOTIDES FOR CODING THEREOF
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
UY35251A (es) 2013-01-01 2014-07-31 Seeds Ltd Ab MOLÉCULAS DE dsRNA AISLADAS Y MÉTODOS PARA USARLAS PARA SILENCIAR MOLÉCULAS DIANA DE INTERÉS
WO2014113541A1 (en) 2013-01-16 2014-07-24 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Attenuated chlamydia vaccine
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
US20150377888A1 (en) 2013-02-01 2015-12-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for Predicting and Preventing Metastasis in Triple Negative Breast Cancers
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
WO2014122199A1 (en) 2013-02-06 2014-08-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of chronic intestinal pseudo-obstruction
EP2767594A1 (en) 2013-02-19 2014-08-20 Deutsches Krebsforschungszentrum The signature of Wnt/ß-catenin signaling in Cancer
WO2014128127A1 (en) 2013-02-19 2014-08-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of prostate cancer
AU2014223548A1 (en) 2013-02-26 2015-10-15 Triact Therapeutics, Inc. Cancer therapy
EP2961853B1 (en) 2013-02-28 2018-09-19 The Board of Regents of The University of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
WO2014135655A1 (en) 2013-03-06 2014-09-12 Institut Curie Compositions and methods for treating muscle-invasive bladder cancer
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US9243258B2 (en) 2013-03-12 2016-01-26 Pioneer Hi Bred International Inc Root-preferred promoter and methods of use
US9273322B2 (en) 2013-03-12 2016-03-01 Pioneer Hi Bred International Inc Root-preferred promoter and methods of use
CA2905027A1 (en) 2013-03-13 2014-10-09 Monsanto Technology Llc Methods and compositions for weed control
BR112015023108A8 (pt) 2013-03-13 2018-01-23 Geneweave Biosciences Inc sistema de acondicionamento de célula bacteriana, método para acondicionamento de uma molécula de ácido nucléico repórter, composição, método para detectar uma presença ou uma ausência de uma célula bacteriana em uma amostra, vetor, método para detectar um transcrito alvo em uma célula, método para detectar a presença de uma célula bacteriana em uma amostra e kit.
AU2014248958A1 (en) 2013-03-13 2015-10-01 Monsanto Technology Llc Methods and compositions for weed control
WO2014140167A1 (en) 2013-03-14 2014-09-18 Dsm Ip Assets B.V. Cell wall deconstruction enzymes of malbranchea cinnamomea and uses thereof
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
WO2014140165A1 (en) 2013-03-14 2014-09-18 Dsm Ip Assets B.V. Cell wall deconstruction enzymes of paecilomyces byssochlamydoides and uses thereof
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
AU2014233198B2 (en) 2013-03-15 2019-06-27 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
US9688767B2 (en) 2013-03-15 2017-06-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
US9546364B2 (en) 2013-03-15 2017-01-17 Carnegie Mellon University Synthetic lariat RNA for RNA interference
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
WO2014151734A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20160051556A1 (en) 2013-03-21 2016-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and Pharmaceutical Composition for use in the Treatment of Chronic Liver Diseases Associated with a Low Hepcidin Expression
WO2014170712A1 (en) 2013-04-15 2014-10-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Rac-1 inhibitors or pi3k inhibitors for preventing intestinal barrier dysfunction
JP2016523818A (ja) 2013-04-18 2016-08-12 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル それを必要とする被験体におけるｔ細胞増殖を阻害するための方法及び医薬組成物（ｃｔｐｓ１阻害剤、例えばノルロイシン）
US20160083424A1 (en) 2013-04-26 2016-03-24 Oslo Universitetssykehus Hf Compositions and methods for targeting antigen-presenting cells
EP2810952A1 (en) 2013-06-03 2014-12-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel pest control methods
JP7102096B2 (ja) 2013-06-13 2022-07-19 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 非常に低レベルのホルデインを有するオオムギ
US10155001B2 (en) 2013-06-14 2018-12-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) RAC1 inhibitors for inducing bronchodilation
US20160145628A1 (en) 2013-06-18 2016-05-26 Ramot At Tel-Aviv University Ltd. Nanocarrier system for micrornas and uses thereof
KR20160030099A (ko) 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
US9856472B2 (en) 2013-07-01 2018-01-02 California Institute Of Technology Small conditional RNAs
WO2015001053A1 (en) 2013-07-03 2015-01-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the screening of substances that may be useful for the prevention and treatment of infections by enterobacteriaceae family
CA2917102A1 (en) 2013-07-03 2015-01-08 City Of Hope Anticancer combinations
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
ES2776353T3 (es) 2013-07-17 2020-07-30 Univ Columbia Inhibidores de la fosfodiesterasa novedosos y usos de los mismos
MX359191B (es) 2013-07-19 2018-09-18 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
EP3027222A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Sphingolipid-polyalkylamine-oligonucleotide compounds
EP3027223A1 (en) 2013-07-31 2016-06-08 QBI Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
EP2835423A1 (en) 2013-08-09 2015-02-11 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Ligase E3 RNF185 inhibitors and uses thereof
WO2015035410A1 (en) 2013-09-09 2015-03-12 Triact Therapeutic, Inc. Cancer therapy
EA201690560A1 (ru) 2013-09-11 2016-10-31 Пайонир Хай-Бред Интернэшнл, Инк. Регуляторные элементы растений и способы их применения
WO2015036618A1 (en) 2013-09-16 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of epilepsy
CA2924343C (en) 2013-09-17 2025-09-16 Bolt Threads, Inc. PROCESSES AND COMPOSITIONS FOR SYNTHESIZING IMPROVED SILK FIBERS
WO2015049365A2 (en) 2013-10-03 2015-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof
EP3722277A3 (en) 2013-10-04 2021-01-20 Novartis AG 3'end caps for rna-interferring agents for use in rna
WO2015051366A2 (en) 2013-10-04 2015-04-09 Novartis Ag Novel formats for organic compounds for use in rna interference
WO2015051044A2 (en) 2013-10-04 2015-04-09 Novartis Ag Novel formats for organic compounds for use in rna interference
WO2015050871A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compounds to treat hepatitis b virus
EP3055426B1 (en) 2013-10-09 2019-06-19 The United States of America as represented by The Secretary Department of Health and Human Services Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
WO2015054670A1 (en) 2013-10-11 2015-04-16 Genentech, Inc. Nsp4 inhibitors and methods of use
EP3057434A4 (en) 2013-10-16 2017-05-03 The Australian National University Method for modulating plant growth
EP2862928A1 (en) 2013-10-18 2015-04-22 Université de Strasbourg Dynamin 2 inhibitor for the treatment of centronuclear myopathies
WO2015066643A1 (en) 2013-11-04 2015-05-07 Dow Agrosciences Llc Optimal soybean loci
EP3066110B1 (en) 2013-11-04 2021-12-29 Corteva Agriscience LLC Optimal maize loci
AR098295A1 (es) 2013-11-04 2016-05-26 Monsanto Technology Llc Composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos
JP6633532B2 (ja) 2013-11-04 2020-01-22 ダウ アグロサイエンシィズ エルエルシー 最適なトウモロコシ遺伝子座
WO2015069459A1 (en) 2013-11-05 2015-05-14 Novartis Ag Organic compounds
US20170002064A1 (en) 2013-11-08 2017-01-05 The Board Of Regents Of The University Of Texas System Vh4 antibodies against gray matter neuron and astrocyte
US10004814B2 (en) 2013-11-11 2018-06-26 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety
WO2015073922A2 (en) 2013-11-15 2015-05-21 Northwestern University Inhibition of oxidative stress in atrial fibrillation
EP3074513A1 (en) 2013-11-26 2016-10-05 Novozymes A/S Enzyme compositions and uses thereof
TR201900665T4 (tr) 2013-11-28 2019-02-21 B Creative Sweden Ab Diyabetik nefropatinin tedavi yöntemi.
ES2895977T3 (es) 2013-11-28 2022-02-23 Bavarian Nordic As Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus
JP6772062B2 (ja) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
CN105979780A (zh) 2013-12-11 2016-09-28 斯隆-凯特林癌症研究院 治疗前列腺癌的糖皮质激素抑制剂
CN105979965B (zh) 2013-12-18 2021-07-09 杰特有限公司 治疗伤口的方法
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
WO2015091857A1 (en) 2013-12-20 2015-06-25 Fondazione Istituto Italiano Di Tecnologia Modulators of intracellular chloride concentration for treating down syndrome
US9274117B2 (en) 2013-12-21 2016-03-01 Catholic University Industry Academic Use of SIRT7 as novel cancer therapy target and method for treating cancer using the same
WO2015098113A1 (ja) 2013-12-27 2015-07-02 独立行政法人医薬基盤研究所 悪性腫瘍の治療薬
TW201527314A (zh) 2013-12-31 2015-07-16 Dow Agrosciences Llc 新穎玉米泛素啓動子（三）
TW201527312A (zh) 2013-12-31 2015-07-16 Dow Agrosciences Llc 新穎玉米泛素啓動子（一）
TW201527313A (zh) 2013-12-31 2015-07-16 Dow Agrosciences Llc 新穎玉米泛素啓動子（二）
TW201527316A (zh) 2013-12-31 2015-07-16 Dow Agrosciences Llc 新穎玉米泛素啓動子（五）
ES2728932T3 (es) 2014-01-09 2019-10-29 Intra Cellular Therapies Inc Compuestos orgánicos
AU2015206585A1 (en) 2014-01-15 2016-07-21 Monsanto Technology Llc Methods and compositions for weed control using EPSPS polynucleotides
ES2796090T3 (es) 2014-02-10 2020-11-25 Inst Curie Uso de moduladores MCOLN-1 para regular la migración celular
TW201538518A (zh) 2014-02-28 2015-10-16 Dow Agrosciences Llc 藉由嵌合基因調控元件所賦予之根部特異性表現
RU2752933C2 (ru) 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
WO2015140351A1 (en) 2014-03-21 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing myelination
JP6752151B2 (ja) 2014-03-25 2020-09-09 アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー
US9856475B2 (en) 2014-03-25 2018-01-02 Arcturus Therapeutics, Inc. Formulations for treating amyloidosis
JP6771387B2 (ja) 2014-03-25 2020-10-21 アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー
EP3420809A1 (en) 2014-04-01 2019-01-02 Monsanto Technology LLC Compositions and methods for controlling insect pests
WO2015152693A2 (ko) 2014-04-04 2015-10-08 (주)바이오니아 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물
US10272135B2 (en) 2014-04-16 2019-04-30 Philippe Rouet Apolipoprotein O and fragments thereof for inducing apoptosis in a cancerous cell
EP2932969A1 (en) 2014-04-17 2015-10-21 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Pancreatic cancer therapy and diagnosis
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
US9101100B1 (en) 2014-04-30 2015-08-11 Ceres, Inc. Methods and materials for high throughput testing of transgene combinations
US9545417B2 (en) 2014-05-01 2017-01-17 The Johns Hopkins University Methods of inhibiting cancer stem cells with HMGA1 inhibitors
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
KR101633881B1 (ko) 2014-05-08 2016-06-28 고려대학교 산학협력단 도파민 의존성 신경장애 치료를 위한 REV-ERBα 유전자의 용도
KR101633876B1 (ko) 2014-05-08 2016-06-28 고려대학교 산학협력단 정서장애 및 중독질환 치료를 위한 REV-ERBα 유전자의 용도
EP3152315B1 (en) 2014-06-06 2018-08-15 Novozymes A/S Enzyme compositions and uses thereof
US10988764B2 (en) 2014-06-23 2021-04-27 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
CN106460022B (zh) 2014-06-24 2018-06-05 加州大学董事会 木糖甙木糖醇寡聚物的生产方法
EP3161138A4 (en) 2014-06-25 2017-12-06 Monsanto Technology LLC Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
MY204560A (en) 2014-07-07 2024-09-04 Nuseed Global Innovation Ltd Process for producing industrial products from plant lipids
EP3167063B1 (en) 2014-07-09 2019-03-06 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and compositions for treating neuropathic pain
AU2015289691B2 (en) 2014-07-15 2020-12-24 Ceres, Inc. Methods of increasing crop yield under abiotic stress
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
JP2017524739A (ja) 2014-07-17 2017-08-31 アンセルムＩｎｓｅｒｍ 神経筋接合部関連疾患の処置方法
CN114009454A (zh) 2014-07-29 2022-02-08 孟山都技术公司 用于控制昆虫害虫的组合物和方法
WO2016022947A1 (en) 2014-08-07 2016-02-11 The Johns Hopkins University Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
CA2955828A1 (en) 2014-08-08 2016-02-11 Pioneer Hi-Bred International, Inc. Ubiquitin promoters and introns and methods of use
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
CN115054687A (zh) 2014-08-22 2022-09-16 广州英恩迈生物医药科技有限公司 治疗和/或预防与ifp35蛋白家族的异常水平和/或活性相关的疾病或不适的方法和组合物
EP3188799B1 (en) 2014-09-05 2022-07-06 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US11219670B2 (en) 2014-09-05 2022-01-11 The Johns Hopkins University Targeting CAPN9/CAPNS2 activity as a therapeutic strategy for the treatment of myofibroblast differentiation and associated pathologies
WO2016044271A2 (en) 2014-09-15 2016-03-24 Children's Medical Center Corporation Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation
CN107106544B (zh) 2014-09-19 2021-09-24 纪念斯隆-凯特琳癌症中心 用于治疗脑转移瘤的方法
RU2017110868A (ru) 2014-09-25 2018-10-25 Колд Спринг Харбор Лаборатори Лечение синдрома ретта
EP3197446A2 (en) 2014-09-26 2017-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
EP3197270B1 (en) 2014-09-26 2025-12-03 Pioneer Hi-Bred International, Inc. Wheat ms1 polynucleotides, polypeptides, and methods of use
WO2016050680A1 (en) 2014-09-29 2016-04-07 Novozymes A/S Yoqm-inactivation in bacillus
US9705501B2 (en) * 2014-10-01 2017-07-11 Maxim Integrated Products, Inc. Systems and methods for enhancing confidentiality via logic gate encryption
CA2964155A1 (en) 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
EP3009147A1 (en) 2014-10-16 2016-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant glioblastoma
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
WO2016064347A1 (en) 2014-10-22 2016-04-28 Temasek Life Sciences Laboratory Limited Terpene synthases from ylang ylang (cananga odorata var. fruticosa)
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
WO2016066671A1 (en) 2014-10-29 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating resistant cancers using progastrin inhibitors
AU2015346281B2 (en) 2014-11-12 2021-12-02 Nmc, Inc. Transgenic plants with engineered redox sensitive modulation of photosynthetic antenna complex pigments and methods for making the same
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
AU2015360794B2 (en) 2014-12-08 2021-07-08 The Board Of Regents Of The University Of Texas System Lipocationic polymers and uses thereof
EP3865576A1 (en) 2014-12-15 2021-08-18 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
EP3925979A3 (en) 2014-12-23 2022-03-23 The Trustees of Columbia University in the City of New York Fgfr-tacc fusion proteins and methods thereof
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
KR102360028B1 (ko) * 2014-12-26 2022-02-08 삼성전자주식회사 Smurf2의 저해제를 포함하는 세포 또는 개체의 노화를 감소시키기 위한 조성물 및 그의 용도
US9434947B2 (en) * 2015-01-20 2016-09-06 Oregon Health & Science University Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
RU2723049C2 (ru) 2015-01-22 2020-06-08 Монсанто Текнолоджи Ллс Композиции и способы борьбы с leptinotarsa
WO2016128523A1 (en) 2015-02-12 2016-08-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease
WO2016131944A1 (en) 2015-02-20 2016-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cardiovascular diseases
WO2016140921A1 (en) 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an il-33 antagonist
MA41629A (fr) 2015-03-04 2018-01-09 Center For Human Reproduction Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
WO2016139331A1 (en) 2015-03-05 2016-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of melanoma
US10781446B2 (en) 2015-03-09 2020-09-22 University Of Kentucky Research Foundation RNA nanoparticle for treatment of gastric cancer
US10584144B2 (en) 2015-03-09 2020-03-10 University Of Kentucky Research Foundation RNA nanoparticles for brain tumor treatment
CN107429251A (zh) 2015-03-09 2017-12-01 肯塔基大学研究基金会 用于治疗乳腺癌的miRNA
WO2016142427A1 (en) 2015-03-10 2016-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method ank kit for reprogramming somatic cells
WO2016146587A1 (en) 2015-03-13 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Hepcidin antagonists for use in the treatment of inflammation
KR101797569B1 (ko) 2015-03-18 2017-11-22 한국교통대학교산학협력단 금속 나노입자 기반 간 표적성 핵산 전달체 및 이의 제조방법
US10519447B2 (en) 2015-04-01 2019-12-31 Arcturus Therapeutics, Inc. Therapeutic UNA oligomers and uses thereof
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
ES2841437T3 (es) 2015-04-13 2021-07-08 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de enfermedades hemorrágicas
WO2016168784A2 (en) 2015-04-17 2016-10-20 University Of Kentucky Research Foundation Rna nanoparticles and method of use thereof
WO2016170027A1 (en) 2015-04-22 2016-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of th17 mediated diseases
EP3085785A1 (en) 2015-04-22 2016-10-26 Université de Strasbourg Dynamin 2 inhibitor for the treatment of duchenne's muscular dystrophy
WO2016170382A1 (en) 2015-04-23 2016-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions comprising a bradykinin 2 receptor antagonist for prevention or treatment of impaired skin wound healing
WO2016176617A2 (en) 2015-04-29 2016-11-03 New York University Method for treating high-grade gliomas
HK1251488A1 (zh) 2015-05-05 2019-02-01 The University Of Louisville Research Foundation, Inc. 作为放射致敏剂以及mri和/或x光造影剂的结合纳米粒子的抗核仁素剂
US20180148793A1 (en) 2015-05-19 2018-05-31 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting pancreas cancer intervention
EP3297615A1 (en) 2015-05-20 2018-03-28 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for modulation polarization and activation of macrophages
EP3303391A1 (en) 2015-05-26 2018-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions (ntsr1 inhibitors) for the treatment of hepatocellular carcinomas
WO2016191734A1 (en) 2015-05-28 2016-12-01 University Of California Berkeley Monofunctional aldehyde and alcohol dehydrogenases for production of fuels and commodity chemicals
ES2968199T3 (es) 2015-05-29 2024-05-08 Arcadia Biosciences Inc Granos con gluten disminuido y composiciones de los mismos
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
US10655136B2 (en) 2015-06-03 2020-05-19 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
AU2016276981B2 (en) 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
CN107771218B (zh) 2015-06-17 2021-12-31 先锋国际良种公司 植物调节元件及其使用方法
CA2989324A1 (en) 2015-06-19 2016-12-22 Arcadia Biosciences, Inc. Wheat with reduced lipoxygenase activity
JP6980534B2 (ja) 2015-06-25 2021-12-15 ザ チルドレンズ メディカル センター コーポレーション 造血幹細胞の増大、富化、および維持に関する方法および組成物
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
US11001845B2 (en) 2015-07-06 2021-05-11 Phio Pharmaceuticals Corp. Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017015671A1 (en) 2015-07-23 2017-01-26 Arcturus Therapeutics, Inc. Compositions for treating amyloidosis
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
MX2018002090A (es) 2015-08-24 2018-09-12 Halo Bio Rnai Therapeutics Inc Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
US10072065B2 (en) 2015-08-24 2018-09-11 Mayo Foundation For Medical Education And Research Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
US10889813B2 (en) 2015-09-02 2021-01-12 Alnylam Pharmaceuticals, Inc. Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
CA2996806A1 (en) 2015-09-04 2017-03-09 Keygene N.V. Diplospory gene
WO2017042238A1 (en) * 2015-09-08 2017-03-16 Sylentis Sau Sirna and their use in methods and compositions for inhibiting the expression of the nrarp gene
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
KR102764250B1 (ko) 2015-09-14 2025-02-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 지질양이온성 덴드리머 및 이의 용도
US10086063B2 (en) 2015-09-23 2018-10-02 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
US10383935B2 (en) 2015-09-23 2019-08-20 Regents Of The University Of Minnesota Methods of making and using live attenuated viruses
WO2017059118A1 (en) 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
WO2017067944A1 (en) 2015-10-19 2017-04-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from triple negative breast cancer
SG11201803567XA (en) 2015-10-29 2018-05-30 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
BR112018007703A2 (pt) 2015-10-30 2018-11-06 Genentech Inc anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
WO2017083920A1 (en) 2015-11-18 2017-05-26 Commonwealth Scientific And Industrial Research Organisation Rice grain with thickened aleurone
WO2017085566A1 (en) 2015-11-20 2017-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increase/induction of immune responses
EP3384031A1 (en) 2015-11-30 2018-10-10 Pioneer Hi-Bred International, Inc. Plant regulatory elements and methods of use thereof
WO2017093354A1 (en) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nmdar antagonists for the treatment of diseases associated with angiogenesis
CN115109850A (zh) 2015-11-30 2022-09-27 谢彦晖 Akt2在诊断和治疗肿瘤中的用途
WO2017093350A1 (en) 2015-12-01 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of darier disease
WO2017096165A1 (en) 2015-12-03 2017-06-08 Agios Pharmaceuticals, Inc. Mat2a inhibitors for treating mtap null cancer
AU2016371624B2 (en) 2015-12-13 2020-08-27 Nitto Denko Corporation siRNA structures for high activity and reduced off target
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
BR112018012887B1 (pt) 2015-12-22 2024-02-06 Pioneer Hi-Bred International, Inc Cassete de expressão, vetor, métodos de obtenção de célula vegetal e planta transgênica, métodos para expressar um polinucleotídeo
WO2017129558A1 (en) 2016-01-25 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases and sepsis
US12447166B2 (en) 2016-02-25 2025-10-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
EP3419629A4 (en) 2016-02-25 2019-10-30 Applied Biological Laboratories, Inc. COMPOSITIONS AND PROCEDURES FOR PROTECTION AGAINST AIRBORNE PATHOGENES AND IRRITATES
EP3423568A4 (en) 2016-03-04 2019-11-13 University Of Louisville Research Foundation, Inc. METHOD AND COMPOSITIONS FOR EX-VIVO REPRODUCTION OF VERY SMALL EMBRYONAL STEM CELLS (VSELS)
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
PL3779447T3 (pl) 2016-03-15 2023-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Sposób aktywowania przeciwnowotworowej odpowiedzi komórek t cd8+ u pacjenta dotknego nowotworem
WO2017158396A1 (en) 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
US20190086392A1 (en) 2016-03-21 2019-03-21 Inserm (Institut National De La Sante Et De La Recherch Medicale) Methods for diagnosis and treatment of solar lentigo
WO2017162798A1 (en) 2016-03-23 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the neuronal calcium sensor 1 for treating wolfram syndrome
US11525140B2 (en) 2016-03-24 2022-12-13 Universiteit Leiden Methods for transfecting plants and for reducing random integration events
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
US10876121B2 (en) 2016-04-01 2020-12-29 Avidity Biosciences, Inc. EGFR nucleic acids and uses thereof
US10858656B2 (en) 2016-04-01 2020-12-08 Avidity Biosciences, Inc. KRAS nucleic acids and uses thereof
WO2017173297A1 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Beta-catenin nucleic acids and uses thereof
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
WO2017182834A1 (en) 2016-04-19 2017-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating resistant glioblastoma
DK3445776T3 (da) 2016-04-19 2021-04-19 Novozymes As RLMA-inaktiveret filamentøs svampeværtscelle
EP3448369B1 (en) 2016-04-29 2025-06-25 The Regents of The University of Colorado, A Body Corporate Inhibition or degradation of hdac11 for treating obesity, hyperlipidemia, type ii diabetes, metabolic syndrome or insulin resistance, for promoting weight loss, and/or ameliorating or preventing weight gain
WO2017197355A2 (en) 2016-05-13 2017-11-16 4D Molecular Therapeutics Inc. Adeno-associated virus variant capsids and methods of use thereof
CN114656378A (zh) 2016-05-16 2022-06-24 得克萨斯州大学系统董事会 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
IL263232B2 (en) 2016-05-22 2024-04-01 Weedout Ltd Compositions, kits and methods for weed control
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
PT109454A (pt) 2016-06-14 2017-12-14 Phyzat Biopharmaceuticals Lda Ácidos nucleicos de interferência e composições que os compreendem
WO2017216352A1 (en) 2016-06-16 2017-12-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of gut inflammatory diseases such as inflammatory bowel diseases (ibd) or irritable bowel syndrome (ibs)
CN109642237B (zh) 2016-06-24 2022-09-30 先锋国际良种公司 植物调节元件及其使用方法
EP3478321A4 (en) 2016-06-30 2020-04-22 Oncorus, Inc. PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES
ES2908919T3 (es) 2016-07-05 2022-05-04 California Inst Of Techn Reacción en cadena de hibridación de iniciador fraccionario
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US11279935B2 (en) 2016-07-08 2022-03-22 Tak-Circulator Co, Ltd Method for screening prophylactic or therapeutic agents for diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5
EP3476939A4 (en) * 2016-07-08 2019-06-05 Tak-Circulator Co., Ltd. NUCLEIC ACID FOR INHIBITING THE EXPRESSION OF THE MEX3B GENE, MEX3B GENE EXPRESSION INHIBITOR, METHOD FOR INHIBITING MEX3B GENE EXPRESSION, PROPHYLACTIC ACID OR THERAPEUTIC FOR DISEASES THROUGH MEX3B GENE EXPRESSION
CA3070146A1 (en) 2016-07-19 2018-01-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oncolytic viruses targeting stat3
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
EP3491387A1 (en) 2016-07-28 2019-06-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods of treatement of cancer disease by targetting tumor associated macrophage
EP3519582A1 (en) 2016-07-29 2019-08-07 Danmarks Tekniske Universitet Methods for decoupling cell growth from production of biochemicals and recombinant polypeptides
EP3493670A1 (en) 2016-08-05 2019-06-12 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and compositions for the preservation of organs
AU2017321492A1 (en) 2016-08-30 2019-03-14 California Institute Of Technology Immunohistochemistry via hybridization chain reaction
EP3510407A1 (en) 2016-09-08 2019-07-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating nephrotic syndrome
EP3516062A1 (en) 2016-09-21 2019-07-31 Alnylam Pharmaceuticals, Inc. Myostatin irna compositions and methods of use thereof
EP3516071B1 (en) 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018069232A1 (en) 2016-10-10 2018-04-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of having cardiac hypertrophy
WO2018078083A1 (en) 2016-10-28 2018-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating multiple myeloma
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018089772A1 (en) 2016-11-10 2018-05-17 Memorial Sloan-Kettering Cancer Center Inhibition of kmt2d for the treatment of cancer
EP3538140A1 (en) 2016-11-14 2019-09-18 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
EP3541938A1 (en) 2016-11-17 2019-09-25 Deutsches Krebsforschungszentrum Heidelberg Stiftung des öffentlichen Rechts (DKFZ) Cancer treatment by glycerol-3-phosphate dehydrogenase 1 inhibition
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US11147249B2 (en) 2016-12-08 2021-10-19 Alector Llc Siglec transgenic mice and methods of use thereof
US20200054660A1 (en) 2016-12-09 2020-02-20 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy
EP3554345A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
US20200315540A1 (en) 2016-12-14 2020-10-08 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
WO2018112232A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor released using an ingestible device
AU2017378393B2 (en) 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
CA3045666A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
CN116712540A (zh) 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3555138A1 (en) 2016-12-16 2019-10-23 Université de Bordeaux Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
WO2018115083A1 (en) 2016-12-21 2018-06-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of gut diseases such as irritable bowel syndrome (ibs)
WO2018115477A1 (en) 2016-12-23 2018-06-28 Universite De Strasbourg Dynamin 2 inhibitor for the treatment of myotonic dystrophy
JP7215716B2 (ja) 2017-01-13 2023-01-31 学校法人自治医科大学 肝臓ゲノム上の凝固関連因子遺伝子を破壊するためのａａｖベクター
WO2018134386A1 (en) 2017-01-23 2018-07-26 Novozymes A/S Host cells and methods for producing double-stranded rna
WO2018138106A1 (en) 2017-01-27 2018-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
WO2018141753A1 (en) 2017-01-31 2018-08-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating squamous cell carcinomas
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
WO2018162676A1 (en) 2017-03-08 2018-09-13 Université De Strasbourg DISINTEGRATABLE POROUS ORGANOSILICA OR ORGANOMETALOXIDE NANOPARTICLES AND USES THEREOF AS VEHICLE FOR CONTROLLED DELIVERY OF siRNA
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018172155A1 (en) 2017-03-23 2018-09-27 Novozymes A/S Improved filamentous fungal host cells
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018183934A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
WO2018189403A1 (en) 2017-04-14 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancer
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
WO2018193393A1 (en) 2017-04-19 2018-10-25 St. Jude Children's Research Hospital Tumor suppression by modulation of non-canonical autophagy (lap) in myeloid cells
CN106942162A (zh) * 2017-04-25 2017-07-14 遵义医学院 一种适用于白背飞虱饲喂法rna干扰实验的装置及其使用方法
CN111201247A (zh) 2017-04-28 2020-05-26 奥克兰联合服务有限公司 治疗方法和新颖构建体
US20200190541A1 (en) 2017-04-28 2020-06-18 Precision Biosciences, Inc. Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells
JP7170666B2 (ja) 2017-05-08 2022-11-14 プレシジョン バイオサイエンシズ，インク． 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法
EP3625258A1 (en) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
WO2018211018A1 (en) 2017-05-17 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Flt3 inhibitors for improving pain treatments by opioids
EP3630740B1 (en) 2017-05-25 2026-07-01 The Governors of the University of Alberta SPECIFIC HUMAN NEURAMINIDASE ISOENZYME INHIBITORS USED IN THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS
EP3412288A1 (en) 2017-06-08 2018-12-12 Galderma Research & Development Vegf inhibitors for use for preventing and/or treating acne
EP3641739A1 (en) 2017-06-20 2020-04-29 Institut Curie Inhibitor of suv39h1 histone methyltransferase for use in cancer combination therapy
CN110997902B (zh) 2017-06-20 2021-11-30 居里研究所 Suv39h1缺陷的免疫细胞
WO2018234538A1 (en) 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) ANTAGONIST OR AGONIST OF HEPCIDINE FOR USE IN THE TREATMENT OF DYSREGULATION OF MO AND / OR MN METABOLISM
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
US12054711B2 (en) 2017-07-14 2024-08-06 City Of Hope Meta-stable oligonucleotides junctions for delivery of therapeutics
MY205541A (en) 2017-08-03 2024-10-25 Alector Llc Anti-cd33 antibodies and methods of use thereof
WO2019033083A1 (en) 2017-08-10 2019-02-14 City Of Hope CONDITIONAL RNAIDS AND THEIR USES IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA
CN111630166B (zh) 2017-08-10 2024-04-19 希望之城 条件性-siRNA及其在治疗心肌肥大中的用途
EP3444347A1 (en) 2017-08-18 2019-02-20 Universität Heidelberg Use of anti-crispr polypeptides for specific activation of cas nucleases
EP4768033A2 (en) 2017-09-07 2026-07-01 Beijing Tide Pharmaceutical Co., Ltd. DOUBLE-STRANDED RNA MOLECULE TARGETING CKIP-1 AND ITS USE
CN119506283A (zh) 2017-09-15 2025-02-25 联邦科学技术研究组织 Rna分子
DK3684423T5 (da) 2017-09-20 2024-08-26 4D Molecular Therapeutics Inc Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
BR112020006045A2 (pt) 2017-09-25 2020-10-06 Pioneer Hi-Bred International, Inc. molécula de ácido nucleico, cassete de expressão, vetor, célula vegetal, planta, semente da planta, método para produzir uma planta transgênica, planta transgênica, semente da planta transgênica, método para aprimorar a eficiência de maturação de embrião somático e método para produzir uma planta dicotiledônea transgênica ou uma planta gimnosperma transgênica
US20200237864A1 (en) 2017-10-10 2020-07-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating fibrotic interstitial lung disease
WO2019072885A1 (en) 2017-10-11 2019-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) MAGNETIC NANOPARTICLES FOR THE TREATMENT OF CANCER
JP2021500371A (ja) 2017-10-26 2021-01-07 レ ラボラトワール セルヴィエ チューブリンカルボキシペプチダーゼ関連疾患を処置するための方法及び医薬組成物
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
SG11202003082UA (en) 2017-11-13 2020-05-28 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages
US11618884B2 (en) 2017-11-14 2023-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof
EP3713603A1 (en) 2017-11-23 2020-09-30 Institut National de la Sante et de la Recherche Medicale (INSERM) New method for treating dengue virus infection
US11766489B2 (en) 2017-11-27 2023-09-26 4D Molecular Therapeutics, Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
WO2019108835A1 (en) 2017-11-29 2019-06-06 The Trustees Of Columbia University In The City Of New York Delta-2-tubulin as a biomarker and therapeutic target for peripheral neuropathy
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
WO2019106126A1 (en) 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mdm2 modulators for the diagnosis and treatment of liposarcoma
CN118638787A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
EP3502259A1 (en) 2017-12-19 2019-06-26 Universiteit Leiden A combinational strategy for reducing random integration events when transfecting plants
WO2019121872A1 (en) 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
UA128937C2 (uk) 2018-01-09 2024-12-04 Сайбас Юес Ллс Рослина brassica napus, що має знижену сприйнятливість до розстріскування плодів до збирання урожаю, та спосіб її одержання
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2019155387A1 (en) 2018-02-07 2019-08-15 St. Jude Children's Research Hospital Epigenetic histone regulation mediated by cxorf67
WO2019158512A1 (en) 2018-02-13 2019-08-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prognosis and the treatment of glioblastoma
WO2019170727A1 (en) 2018-03-06 2019-09-12 Institut Curie Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
WO2019177976A1 (en) 2018-03-12 2019-09-19 Pioneer Hi-Bred International, Inc. Methods for plant transformation
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
WO2019185683A1 (en) 2018-03-28 2019-10-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
CA3095134A1 (en) 2018-03-28 2019-10-03 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in dna isolated from exosomes
US11649455B2 (en) 2018-03-30 2023-05-16 University Of Geneva Micro RNA expression constructs and uses thereof
EA202092382A1 (ru) 2018-04-04 2021-02-02 САЙБАС ЮЭс ЛЛС Гены fad2 и мутации
WO2019199673A1 (en) 2018-04-09 2019-10-17 President And Fellows Of Harvard College Modulating nuclear receptors and methods of using same
WO2019207066A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of sjögren's syndrome
WO2019211370A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019211369A1 (en) 2018-05-03 2019-11-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cancer
WO2019226508A1 (en) 2018-05-22 2019-11-28 Pioneer Hi-Bred International, Inc. Plant regulatory elements and methods of use thereof
JP7512207B2 (ja) 2018-05-24 2024-07-08 サーナオミクス インコーポレイテッド 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法
US12478588B2 (en) 2018-05-25 2025-11-25 The Penn State Research Foundation Nanoparticle for protein delivery
GB201808927D0 (en) 2018-05-31 2018-07-18 Institute Of Cancer Res Royal Cancer Hospital Materials and methods for monitoring the development of resistance of cancers to treatment
WO2019234099A1 (en) 2018-06-06 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, predicting the outcome and treating a patient suffering from heart failure with preserved ejection fraction
CN119841953A (zh) 2018-06-08 2025-04-18 艾利妥 抗siglec-7抗体及其使用方法
WO2019234221A1 (en) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2019246271A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
EP3810085A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3833747A1 (en) 2018-06-28 2021-06-16 Pioneer Hi-Bred International, Inc. Methods for selecting transformed plants
WO2020016160A1 (en) 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
WO2020016377A1 (en) 2018-07-19 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination for treating cancer
EP3823663A4 (en) 2018-07-19 2022-03-09 Children's Medical Center Corporation COMPOSITIONS AND METHODS FOR GENERATING A PHYSIOLOGICAL X-CHROMOSOME INACTIVATION
SG11202100555PA (en) 2018-07-27 2021-02-25 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
JPWO2020026968A1 (ja) 2018-07-30 2021-08-12 株式会社遺伝子治療研究所 Ａａｖベクターによる遺伝子発現を増強する方法
JP7566741B2 (ja) 2018-08-10 2024-10-15 シティ・オブ・ホープ プログラム可能なｓｉＲＮＡ及びその使用
AR119259A1 (es) 2018-08-31 2021-12-09 Alector Llc Anticuerpos anti-cd33 y métodos de uso de los mismos
CN112654397B (zh) 2018-09-05 2025-01-03 国家医疗保健研究所 用于治疗哮喘和过敏性疾病的方法和组合物
JP2022501388A (ja) 2018-09-19 2022-01-06 ラホヤ インスティチュート フォー イミュノロジー 関節リウマチにおけるｐｔｐｒｓ及びプロテオグリカン
EP3864136A1 (en) 2018-10-09 2021-08-18 Novozymes A/S Modified filamentous fungal host cell
WO2020078865A1 (en) 2018-10-16 2020-04-23 F. Hoffmann-La Roche Ag Use of akt inhibitors in ophthalmology
CN112955462B (zh) 2018-10-18 2024-05-07 国家医疗保健研究所 用于治疗实体瘤的βIG-H3拮抗剂和免疫检查点抑制剂的组合
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
CN113614535B (zh) 2018-10-31 2024-08-16 亚利桑那大学评议会 用于辐射诱导的肺损伤的生物标志物和使用方法
US20220000893A1 (en) 2018-10-31 2022-01-06 |Nserm (Institut National De La Santé Et De La Recherche Médicale) Method for treating t-helper type 2 mediated disease
EP3874050A1 (en) 2018-10-31 2021-09-08 Pioneer Hi-Bred International, Inc. Compositions and methods for ochrobactrum-mediated plant transformation
EP3650040A1 (en) 2018-11-07 2020-05-13 Galderma Research & Development Vegf inhibitors for use for preventing and/or treating atopic dermatitis
EP4365289A3 (en) 2018-11-16 2024-07-10 Nitto Denko Corporation Rna interference delivery formulation and methods for malignant tumors
US20220025423A1 (en) 2018-11-28 2022-01-27 Novozymes A/S Modified Filamentous Fungal Host Cells
CN114144423B (zh) 2018-12-27 2025-04-04 圣诺制药公司 使用与免疫检查点抑制剂组合递送的siRNA沉默TGF-BETA 1和COX2以治疗癌症
US11883401B2 (en) 2019-01-08 2024-01-30 Duke University Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same
EP3911957A1 (en) 2019-01-17 2021-11-24 F. Hoffmann-La Roche AG E3 ubiquitin ligase (ube3a) protein targets
WO2020152122A1 (en) 2019-01-21 2020-07-30 Singapore Health Services Pte. Ltd. Treatment of hepatotoxicity
BR112021015159A2 (pt) 2019-02-01 2021-09-28 Universität Basel Células imunológicas resistentes a inibidores de calcineurina para uso em terapia de transferência de células adotivas
US20220117911A1 (en) 2019-02-04 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
US20220136011A1 (en) 2019-02-08 2022-05-05 Board Of Regents, The University Of Texas System Telomerase-containing exosomes for treatment of diseases associated with aging and age-related organ dysfunction
WO2020169707A1 (en) 2019-02-21 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Foxo1 inhibitor for use in the treatment of latent virus infection
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
CN113412333B (zh) 2019-03-11 2025-04-08 先锋国际良种公司 用于克隆植物生产的方法
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
JP7743308B2 (ja) 2019-03-27 2025-09-24 パイオニア ハイ－ブレッド インターナショナル， インコーポレイテッド 植物外稙片の形質転換
WO2020193740A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
CA3127173A1 (en) 2019-03-28 2020-10-01 Pioneer Hi-Bred International, Inc. Modified agrobacterium strains and use thereof for plant transformation
WO2020208082A1 (en) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating cmv related diseases
CN114096313A (zh) 2019-04-19 2022-02-25 索邦大学 用于预防或治疗亨廷顿氏病的p16INK4a抑制剂
KR20220050087A (ko) 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
IL287801A (en) 2019-05-07 2022-07-01 Immunicom Inc Increasing responses to checkpoint inhibitors by extracorporeal apheresis
EP3969472A1 (en) 2019-05-16 2022-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat type 2 inflammation or mast-cell dependent disease
WO2020249769A1 (en) 2019-06-14 2020-12-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating ocular diseases related to mitochondrial dna maintenance
US11473086B2 (en) 2019-06-19 2022-10-18 Ut-Battelle, Llc Loss of function alleles of PtEPSP-TF and its regulatory targets in rice
WO2021001539A1 (en) 2019-07-04 2021-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy to detect and treat eosinophilic fasciitis
US20220251567A1 (en) 2019-07-10 2022-08-11 Inserm (Institut National De La Santè Et De La Recherche Médicale) Methods for the treatment of epilepsy
JP7371954B2 (ja) 2019-07-12 2023-10-31 株式会社遺伝子治療研究所 ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン
US20220251581A1 (en) 2019-07-26 2022-08-11 Novozymes A/S Modified filamentous fungal host cell
CA3148950A1 (en) 2019-07-30 2021-02-04 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (A.R.O.), Volcani Center Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
JP7645553B2 (ja) 2019-08-14 2025-03-14 ヴァナリックス エスエー 硝子軟骨組織のｉｎ ｖｉｔｒｏでの産生のための方法
CN115176011B (zh) 2019-08-27 2025-11-11 赛诺菲 用于抑制pcsk9的组合物和方法
US20220340975A1 (en) 2019-09-05 2022-10-27 INSERM (Institute National de la Santé et de la Recherche Médicale) Method of treatment and pronostic of acute myeloid leukemia
GB201913030D0 (en) 2019-09-10 2019-10-23 Francis Crick Institute Ltd Treatment of hr deficient cancer
KR102100163B1 (ko) 2019-09-24 2020-04-13 테고사이언스 (주) 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
WO2021058744A1 (en) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of müllerian inhibiting substance inhibitors for treating cancer
WO2021099394A1 (en) 2019-11-19 2021-05-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Antisense oligonucleotides and their use for the treatment of cancer
EP3825408A1 (en) 2019-11-19 2021-05-26 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Methods of multi-species insect pest control
WO2021105384A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Targeting the nls region of nupr1 protein to treat cancer
WO2021105391A1 (en) 2019-11-27 2021-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination comprising nupr1 inhibitors to treat cancer
PH12022551482A1 (en) 2019-12-18 2023-11-29 Novartis Ag 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7846007B2 (ja) 2019-12-18 2026-04-14 ノバルティス アーゲー 異常ヘモグロビン症の治療用組成物及び方法
IL294611B1 (en) 2020-01-08 2026-05-01 Regeneron Pharma Treatment of fibrodysplasia ossificans progressive
US12178902B1 (en) 2020-01-12 2024-12-31 University Of Southern California Methods and compositions for fluid drainage by Piezo ion channel activation
US20210222128A1 (en) 2020-01-22 2021-07-22 Massachusetts Institute Of Technology Inducible tissue constructs and uses thereof
WO2021156329A1 (en) 2020-02-05 2021-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of cancer disease by targeting an epigenetic factor
EP4103699A1 (en) 2020-02-10 2022-12-21 BioMarin Pharmaceutical Inc. Virus-free cell cultures
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
KR20230005244A (ko) 2020-04-20 2023-01-09 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 생물학적 활성 건조 분말 조성물 및 이의 제조 및 사용 방법
EP4139440B1 (en) 2020-04-22 2026-08-19 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
CN115552021A (zh) 2020-04-27 2022-12-30 4D分子治疗有限公司 用于肺递送的腺相关变体、制剂和方法
US20210332364A1 (en) 2020-04-28 2021-10-28 Phyzat Biopharmaceuticals, Lda siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
JP2023524679A (ja) 2020-04-30 2023-06-13 フィジーン、エルエルシー 癌線維芽細胞を標的化するための免疫療法の方法および組成物
WO2021224401A1 (en) 2020-05-07 2021-11-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for determining a reference range of β-galactose exposure platelet
US20210348167A1 (en) 2020-05-09 2021-11-11 Phyzat Biopharmaceuticals, Lda siNA MOLECULES, METHODS OF PRODUCTION AND USES THEREOF
EP4149512A4 (en) 2020-05-12 2024-06-05 Board of Regents, The University of Texas System Methods for treating glioblastoma
JP7869149B2 (ja) 2020-05-19 2026-06-02 アンスティテュ・クリー サイトカイン放出症候群の診断及び処置の方法
AU2021278356A1 (en) 2020-05-27 2022-11-03 Antion Biosciences Sa Adapter molecules to re-direct CAR T cells to an antigen of interest
EP3919062A1 (en) 2020-06-02 2021-12-08 Institut Gustave-Roussy Modulators of purinergic receptors and related immune checkpoint for treating acute respiratory distress syndrom
US20230302031A1 (en) 2020-06-02 2023-09-28 Institut Gustave-Roussy Modulators Of Purinergic Receptors and Related Immune Checkpoint For Treating Acute Respiratory Distress Syndrome
AU2021283380B2 (en) 2020-06-03 2025-06-12 Alexis Bio, Inc. Selection and monitoring methods for xenotransplantation
CN115768475A (zh) 2020-06-04 2023-03-07 Csl创新私人有限公司 治疗或预防急性呼吸窘迫综合征的方法
US20230235326A1 (en) 2020-06-05 2023-07-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating ocular diseases
CN116194474A (zh) 2020-06-09 2023-05-30 吉尼松公司 遗传性扩张型心肌病的治疗
CA3185499A1 (en) 2020-06-09 2021-12-16 Genethon Cilp-1 inhibitors for use in the treatment of dilated cardiomyopathies
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
WO2021255204A1 (en) 2020-06-18 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy for treating pancreatic cancer
WO2021260139A1 (en) 2020-06-25 2021-12-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment and diagnostic of pathological conditions associated with intense stress
US20230266325A1 (en) 2020-06-30 2023-08-24 Lunglife Ai, Inc. Methods for detecting lung cancer
KR20230050336A (ko) 2020-07-10 2023-04-14 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) 뇌전증을 치료하기 위한 방법과 조성물
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
JP7886313B2 (ja) 2020-07-30 2026-07-07 アンスティテュ・クリー Ｓｏｃｓ１に欠陥のある免疫細胞
US20230340149A1 (en) 2020-09-07 2023-10-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of treatment of inflammatory bowel diseases
EP4222165A2 (en) 2020-09-30 2023-08-09 Pioneer Hi-Bred International, Inc. Rapid transformation of monocot leaf explants
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
MX2023004299A (es) 2020-10-13 2023-07-07 Univ Pennsylvania Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
WO2022107106A2 (en) 2020-11-23 2022-05-27 Phyzat Biopharmaceuticals, Lda Sina molecules, methods of production and uses thereof
US20240052000A1 (en) 2020-12-15 2024-02-15 Novozymes A/S Mutated host cells with reduced cell motility on
JP2023554395A (ja) 2020-12-17 2023-12-27 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｔｌａ－４及びｐｄ－１阻害剤と併用した腫瘍浸潤リンパ球療法による治療
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
EP4284925A4 (en) 2021-01-26 2025-08-13 California Inst Of Techn ALLOSTERIC CONDITIONAL GUIDE RNAS FOR SELECTIVE REGULATION OF CRISPR/CAS CELLS
WO2022162015A1 (en) 2021-01-26 2022-08-04 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof
WO2022165111A1 (en) 2021-01-28 2022-08-04 Precision Biosciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
EP4291898A1 (en) 2021-02-12 2023-12-20 Institut National de la Santé et de la Recherche Médicale (INSERM) Method for prognosis and treating a patient suffering from cancer
EP4314253A2 (en) 2021-03-25 2024-02-07 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
WO2022218998A1 (en) 2021-04-13 2022-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating hepatitis b and d virus infection
EP4322938A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve nk cells cytotoxicity
US20240190993A1 (en) 2021-04-14 2024-06-13 INSERM (Institut National de la Santé et de la Recherche Médicale) New method to improve the anti-tumoral activity of macrophages
EP4328313A4 (en) 2021-04-21 2025-06-25 Jichi Medical University Adeno-associated virus virion for treating ornithine transcarbamylase deficiency
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
EP4349852A4 (en) 2021-05-28 2025-09-03 Shanghai Regenelead Therapies Co Ltd RECOMBINANT ADENO-ASSOCIATED VIRUS HAVING A VARIANT CAPSID, AND ITS APPLICATION
WO2022253910A1 (en) 2021-06-02 2022-12-08 INSERM (Institut National de la Santé et de la Recherche Médicale) A new method to treat an inflammatory skin disease
US20250127809A1 (en) 2021-06-23 2025-04-24 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US11593428B2 (en) 2021-07-08 2023-02-28 Bank Of America Corporation System and method for detecting errors in a task workflow from a video stream
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
EP4381069A1 (en) 2021-08-02 2024-06-12 Universite De Montpellier Compositions and methods for treating cmt1a or cmt1e diseases with rnai molecules targeting pmp22
EP4380691A1 (en) 2021-08-06 2024-06-12 Institut Régional du Cancer de Montpellier (ICM) Methods for the treatment of cancer
WO2023020980A1 (en) 2021-08-16 2023-02-23 F. Hoffmann-La Roche Ag E3 ubiquitin ligase (ube3a) protein targets
US20240316061A1 (en) 2021-09-17 2024-09-26 Institut Curie Bet inhibitors for treating pab1 deficient cancer
EP4405680A1 (en) 2021-09-20 2024-07-31 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
US20240401146A1 (en) 2021-10-06 2024-12-05 Institut National de la Santé et de la Recherche Médicale Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
WO2023073099A1 (en) 2021-10-28 2023-05-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
EP4427044A1 (en) 2021-11-03 2024-09-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023078906A1 (en) 2021-11-03 2023-05-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating acute myeloid leukemia
WO2023081767A1 (en) 2021-11-05 2023-05-11 Precision Biosciences, Inc. Methods for immunotherapy
WO2023089032A1 (en) 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023089159A1 (en) 2021-11-22 2023-05-25 INSERM (Institut National de la Santé et de la Recherche Médicale) New strategy targeting stroma/tumor cell crosstalk to treat a cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
JPWO2023106261A1 (enExample) 2021-12-06 2023-06-15
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
WO2023111173A1 (en) 2021-12-16 2023-06-22 INSERM (Institut National de la Santé et de la Recherche Médicale) An ezh2 degrader or inhibitor for use in the treatment of resistant acute myeloid leukemia
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method
WO2023118546A2 (en) 2021-12-23 2023-06-29 Boehringer Ingelheim International Gmbh METHODS AND MOLECULES FOR RNA INTERFERENCE (RNAi)
EP4215614A1 (en) 2022-01-24 2023-07-26 Dynacure Combination therapy for dystrophin-related diseases
US12004476B2 (en) 2022-01-26 2024-06-11 Monsanto Technology Llc. Cotton variety 20R750B3XF
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
GB202206507D0 (en) 2022-05-04 2022-06-15 Antion Biosciences Sa Expression construct
EP4532772A1 (en) 2022-05-24 2025-04-09 Lunglife Ai, Inc. Methods for detecting circulating genetically abnormal cells
WO2024003350A1 (en) 2022-06-30 2024-01-04 Universite De Strasbourg Combination therapy for melanoma
EP4299742A1 (en) 2022-06-30 2024-01-03 Université de Strasbourg Combination therapy for melanoma
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
EP4311546A1 (en) 2022-07-26 2024-01-31 Dynacure Combination therapy for myopathies
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
WO2024028476A1 (en) 2022-08-05 2024-02-08 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of th2-mediated diseases
WO2024037910A1 (en) 2022-08-17 2024-02-22 Institut National de la Santé et de la Recherche Médicale Syk inhibitors for use in the treatment of cancer
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
WO2024047110A1 (en) 2022-08-31 2024-03-07 Institut National de la Santé et de la Recherche Médicale Method to generate more efficient car-t cells
EP4584291A1 (en) 2022-09-08 2025-07-16 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to ltbp2 and uses thereof
WO2024056659A1 (en) 2022-09-13 2024-03-21 Institut National de la Santé et de la Recherche Médicale Method for treating prostate cancer and other epithelial cancers
CR20250095A (es) 2022-09-13 2025-09-01 Arsenal Biosciences Inc Células inmunitarias que coexpresan arnhc de tgfbr
JP2025532585A (ja) 2022-09-16 2025-10-01 アーセナル バイオサイエンシズ インコーポレイテッド 組み合わせ遺伝子摂動を有する免疫細胞
WO2024074713A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
JP2026513101A (ja) 2022-10-25 2026-04-23 アブリンクス エン．ヴェー． エフェクター機能が強化された糖鎖改変Ｆｃ変異ポリペプチド
WO2024112571A2 (en) 2022-11-21 2024-05-30 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
WO2024110458A1 (en) 2022-11-22 2024-05-30 Institut Curie Lnc-znf30-3 as cancer biomarker and therapeutic target
GB202219829D0 (en) 2022-12-29 2023-02-15 Ivy Farm Tech Limited Genetically manipulated cells
WO2024161015A1 (en) 2023-02-03 2024-08-08 Institut National de la Santé et de la Recherche Médicale Method to treat age-related diseases
JP2026506602A (ja) 2023-02-13 2026-02-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 鉄過剰関連疾患の処置方法
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向ｐｓｍａ及ｃａ９之系統
CN120858176A (zh) 2023-03-07 2025-10-28 居里研究所 Brca相关癌症中的ung/udg抑制
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders
WO2024184479A1 (en) 2023-03-08 2024-09-12 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of food allergy
WO2024191808A1 (en) 2023-03-10 2024-09-19 University Of Rochester Etiological therapeutics for fragile x syndrome
GB202303784D0 (en) 2023-03-15 2023-04-26 Institute Of Cancer Res Royal Cancer Hospital Cancer treatment
EP4683630A1 (en) 2023-03-21 2026-01-28 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
EP4702132A1 (en) 2023-04-26 2026-03-04 Institut National de la Santé et de la Recherche Médicale Method for modulating the differentiation and functions of human dendritic cells
GB202306619D0 (en) 2023-05-04 2023-06-21 Antion Biosciences Sa Cell
WO2024236131A1 (en) 2023-05-17 2024-11-21 Institut National de la Santé et de la Recherche Médicale Stratificate and method to treat a patient suffering from a cancer
EP4713003A1 (en) 2023-05-17 2026-03-25 Institut National de la Santé et de la Recherche Médicale Lipc variant in the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease
EP4719423A1 (en) 2023-05-30 2026-04-08 Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of focal cortical dysplasia
EP4727570A1 (en) 2023-06-13 2026-04-22 Institut National de la Santé et de la Recherche Médicale Use of a cxcl 10 inhibitor for the treatment of transplant vasculopathy
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
EP4735019A1 (en) 2023-06-30 2026-05-06 Institut National de la Santé et de la Recherche Médicale Methods of treatment of metabolic disorders
WO2025008406A1 (en) 2023-07-04 2025-01-09 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of cancer
EP4739706A1 (en) 2023-07-05 2026-05-13 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
WO2025021839A1 (en) 2023-07-25 2025-01-30 Institut National de la Santé et de la Recherche Médicale Method to treat metabolic disorders
EP4757808A1 (en) 2023-08-08 2026-06-17 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of type 2-mediated diseases
GB202313465D0 (en) 2023-09-04 2023-10-18 Univ Court Univ Of Glasgow Methods for the treatment of heart failure with preserved ejection fraction
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response
NL2035852B1 (en) 2023-09-21 2025-03-28 Academisch Ziekenhuis Leiden Enhancement of t cell mediated therapies
WO2025068157A1 (en) 2023-09-25 2025-04-03 Stromacare COMBINATION OF A βIG-H3 ANTAGONIST AND A PDFG-AA ANTAGONIST FOR THE TREATMENT OF CANCER
WO2025068180A1 (en) 2023-09-25 2025-04-03 Institut National de la Santé et de la Recherche Médicale Methods of treatment of cancer by targetting cancer - associated fibroblasts
WO2025068418A1 (en) 2023-09-27 2025-04-03 Institut National de la Santé et de la Recherche Médicale Inhibitor of the transcription factor ap-1 for use in the treatment of age-related diseases
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
EP4788839A1 (en) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025078851A1 (en) 2023-10-11 2025-04-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of treating cognitive deficit
WO2025082944A1 (en) 2023-10-16 2025-04-24 Institut National de la Santé et de la Recherche Médicale Inhibitor of the low-density lipoprotein receptor family (ldl-r family) and/or apolipoprotein e (apoe) for use in the treatment of crimean-congo hemorrhagic fever virus (cchfv) infection
WO2025088546A1 (en) 2023-10-25 2025-05-01 Ablynx N.V. Fc domain variants with enhanced fc receptor binding
WO2025114512A1 (en) 2023-11-29 2025-06-05 Cnrs Dsi Therapeutic use of surf2 modulators
WO2025114453A1 (en) 2023-11-30 2025-06-05 Institut National de la Santé et de la Recherche Médicale Method of prevention and/or treatment of nairoviridae family infections
WO2025162980A1 (en) 2024-01-30 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of breast cancer using a jnk-1 inhibitor
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
WO2025176679A1 (en) 2024-02-19 2025-08-28 Institut National de la Santé et de la Recherche Médicale Inhibitor of the flavin-containing monooxygenase (fmo) for use in the treatment of cancer
WO2025176777A1 (en) 2024-02-20 2025-08-28 Institut Curie Dut inhibition in homologous recombination deficiency cancer
GB202402745D0 (en) 2024-02-27 2024-04-10 Antion Biosciences Sa Cell
WO2025191002A1 (en) 2024-03-12 2025-09-18 National University Of Singapore Treatment and prevention of disease by il-7r inhibition
WO2025191018A1 (en) 2024-03-13 2025-09-18 Institut National de la Santé et de la Recherche Médicale Mrgpre binding agent for use in the treatment of inflammatory and pain disorders
TW202544044A (zh) 2024-03-20 2025-11-16 美商亞森諾生物科學公司 靶向ｓｌｃ３４ａ２及ｔｍｐｒｓｓ４之系統及其使用方法
WO2025213127A1 (en) 2024-04-05 2025-10-09 Indapta Therapeutics, Inc. Treatment of autoimmune diseases or conditions with natural killer cells
WO2025215354A1 (en) 2024-04-08 2025-10-16 Ivy Farm Technologies Limited Method of culturing an animal cell
WO2025217379A1 (en) 2024-04-10 2025-10-16 University Of Rochester Drug treatment for macular degeneration
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025237990A1 (en) 2024-05-14 2025-11-20 Institut National de la Santé et de la Recherche Médicale Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
WO2025245399A1 (en) 2024-05-23 2025-11-27 Indapta Therapeutics, Inc. Method of treating cancer with natural killer cells
WO2025248505A1 (en) 2024-05-31 2025-12-04 Wayne State University Methods for treating endometrial and ovarian hyperproliferative disorders
WO2026002934A1 (en) 2024-06-25 2026-01-02 Institut National de la Santé et de la Recherche Médicale Combination of a slc16a1 inhibitor and a smad3 inhibitor for treating cancer
WO2026003239A2 (en) 2024-06-28 2026-01-02 Institut National de la Santé et de la Recherche Médicale Method to improve macrophages functions
WO2026013153A1 (en) 2024-07-10 2026-01-15 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from myc-high tumors
EP4681722A1 (en) 2024-07-18 2026-01-21 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of inflammatory skin diseases with urocanase inhibitor
WO2026052851A2 (en) 2024-09-09 2026-03-12 Institut National de la Santé et de la Recherche Médicale Inhibitor of ciliogenesis for use in a method of preventing therapeutic resistance in cancer
WO2026062222A1 (en) 2024-09-20 2026-03-26 Institut Curie Novel protein isoforms and uses
WO2026076425A1 (en) 2024-10-04 2026-04-09 Biodrive, Inc. Oral biodelivery platform
GB202415862D0 (en) 2024-10-28 2024-12-11 Antion Biosciences Sa Intronic mirna
WO2026093738A1 (en) 2024-10-28 2026-05-07 Institute Of Cancer Research: Royal Cancer Hospital Cancer treatment
WO2026125263A1 (en) 2024-12-09 2026-06-18 Institut National de la Santé et de la Recherche Médicale Inhibitor of the heterochromatin protein 1 (hp1) for modulating th cells
WO2026136848A2 (en) 2024-12-20 2026-06-25 Juno Therapeutics, Inc. Cd70-targeted cars and engineered cells comprising same and related methods
WO2026151965A1 (en) 2025-01-10 2026-07-16 Arsenal Biosciences, Inc. Shrna targeting fas and tgfbrii genes

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931397A (en) 1971-11-05 1976-01-06 Beecham Group Limited Biologically active material
US4024222A (en) 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US4283393A (en) 1979-03-13 1981-08-11 Merck & Co., Inc. Topical application of interferon inducers
US6130206A (en) 1980-07-07 2000-10-10 Hem Research, Inc. Treating viral infections associated with chronic fatigue with dsRNA
US4511713A (en) 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US4605394A (en) 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
JPS5936698A (ja) 1982-08-20 1984-02-28 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えｄｎａおよび形質転換動物細胞
US5208149A (en) 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5272065A (en) 1983-10-20 1993-12-21 Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5173410A (en) 1984-02-15 1992-12-22 Lubrizol Genetics Inc. Transfer vector
US4766072A (en) 1985-07-17 1988-08-23 Promega Corporation Vectors for in vitro production of RNA copies of either strand of a cloned DNA sequence
CA1326450C (en) 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)
US4820696A (en) 1985-08-26 1989-04-11 Hem Research, Inc. Modulation of aids virus-related events by double-stranded RNAS
US4795744A (en) 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
US4945082A (en) 1985-08-26 1990-07-31 Hem Research, Inc. Controlled dsRNA therapy for human viral infections
US5063209A (en) 1985-08-26 1991-11-05 Hem Research, Inc. Modulation of aids virus-related events by double-stranded RNAs
US5107065A (en) 1986-03-28 1992-04-21 Calgene, Inc. Anti-sense regulation of gene expression in plant cells
US5453566A (en) 1986-03-28 1995-09-26 Calgene, Inc. Antisense regulation of gene expression in plant/cells
US5120657A (en) * 1986-12-05 1992-06-09 Agracetus, Inc. Apparatus for genetic transformation
PH24467A (en) 1987-03-03 1990-07-18 Hem Res Inc Synergistics interplay of lymphokines and dsrnas
US4950652A (en) 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
US5091374A (en) 1987-07-17 1992-02-25 Hem Research Inc. Double-stranded RNA correction of abnormalities in circulating immune complexes and monocyte function
US5906980A (en) 1987-07-17 1999-05-25 Hem Research Inc. Treatment of hepatitis with mismatched dsRNA
AU1820588A (en) 1987-07-17 1989-01-19 Hem Research, Inc. Double-stranded rna correction of abnormalities in circulating immune complexes and monocyte function
IE72103B1 (en) 1987-08-12 1997-03-12 Hem Res Inc Promotion of host defense by systemic dsRNA treatment
US5683986A (en) 1987-08-12 1997-11-04 Hemispherx Biopharma Inc. Elaboration of host defense mediators into biological fluids by systemic dsRNA treatment
IE66830B1 (en) 1987-08-12 1996-02-07 Hem Res Inc Topically active compositions of double-stranded RNAs
US5712257A (en) 1987-08-12 1998-01-27 Hem Research, Inc. Topically active compositions of mismatched dsRNAs
US5593973A (en) 1987-09-04 1997-01-14 Hemispherx Biopharma Inc. Treatment of viral hepatitis with mismatched dsRNA
EP0306347B1 (en) 1987-09-04 1995-05-10 Hem Pharmaceuticals Corp. Diagnosis of double-stranded RNA deficiency states
US5874555A (en) 1987-10-30 1999-02-23 California Institute Of Technology Triple helices and processes for making same
US4963532A (en) 1987-11-25 1990-10-16 Hem Research, Inc. dsRNA-based prevention of viral escape
PH25365A (en) 1987-12-23 1991-05-13 Hem Research Rhase l inhibitor as a marker for virus infections
US5922602A (en) 1988-02-26 1999-07-13 Biosource Technologies, Inc. Cytoplasmic inhibition of gene expression
US5789214A (en) 1988-03-08 1998-08-04 Novartis Finance Corporation Method of inducing gene transcription in a plant
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
CA1320446C (en) 1988-06-20 1993-07-20 William A. Carter Modulation of lymphokine-resistant cellular states by dsrnas
DE68914201T2 (de) 1988-07-07 1994-07-14 Hem Pharma Corp Diagnose und Behandlung chronischer Ermüdungserscheinungen.
US5258369A (en) 1988-08-29 1993-11-02 Hem Pharmaceuticals Corporation Treatment of chronic cerebral dysfunction by dsRNA methodology
ES2090049T3 (es) 1989-03-16 1996-10-16 Boehringer Ingelheim Int Unidades geneticas para la inhibicion de la funcion de arn.
US5034323A (en) 1989-03-30 1991-07-23 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
WO1990012488A2 (en) 1989-04-05 1990-11-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce A clone of double-stranded rna virus applied to antibody production, study of retrovirus-like frameshifting and production of proteins in yeast
WO1990012094A1 (en) 1989-04-05 1990-10-18 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce A clone of double-stranded rna virus and applications thereof
EP0473576A4 (en) 1989-05-19 1993-03-10 Hem Research, Inc. Short therapeutic dsrna of defined structure
GB8916213D0 (en) 1989-07-14 1989-08-31 Ici Plc Dna constructs,cells and plants derived therefrom
BR9007757A (pt) 1989-10-16 1992-08-11 Hem Res Inc Diagnostico e tratamento de disturbios neuro-cognitivos associados com disfuncoes imunologicas sistemicas
US5194245A (en) 1990-05-25 1993-03-16 Hem Research Inc. Diagnosis of viral hepatitis
US5132292A (en) 1990-05-25 1992-07-21 Hem Research, Inc. Treatment of viral hepatitis
US5639949A (en) 1990-08-20 1997-06-17 Ciba-Geigy Corporation Genes for the synthesis of antipathogenic substances
JP3234598B2 (ja) 1990-11-23 2001-12-04 プラント・ジエネテイツク・システムズ・エヌ・ベー 単子葉植物の形質転換方法
US5145323A (en) * 1990-11-26 1992-09-08 Tecumseh Products Company Liquid level control with capacitive sensors
CA2106386A1 (en) 1991-04-18 1992-10-19 Barbara C. F. Chu Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
US6010908A (en) 1992-08-21 2000-01-04 The Regents Of The University Of California Gene therapy by small fragment homologous replacement
US6136601A (en) 1991-08-21 2000-10-24 Epoch Pharmaceuticals, Inc. Targeted mutagenesis in living cells using modified oligonucleotides
CA2073630C (en) 1991-08-30 2007-12-11 Atsushi Ohshima Method for synthesizing single-stranded stem-loop dnas, the products and uses therefor
FR2685346B1 (fr) 1991-12-18 1994-02-11 Cis Bio International Procede de preparation d'arn double-brin, et ses applications.
DE4208107A1 (de) 1992-03-13 1993-09-16 Bayer Ag Pseudorabies-virus (prv)-polynukleotide und ihre verwendung zur herstellung von virusresistenten eukaryotischen zellen
US5593874A (en) 1992-03-19 1997-01-14 Monsanto Company Enhanced expression in plants
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
WO1994001550A1 (en) * 1992-07-02 1994-01-20 Hybridon, Inc. Self-stabilized oligonucleotides as therapeutic agents
US5489519A (en) * 1992-10-27 1996-02-06 Queen's University At Kingston Multidrug resistance protein
US6372965B1 (en) 1992-11-17 2002-04-16 E.I. Du Pont De Nemours And Company Genes for microsomal delta-12 fatty acid desaturases and hydroxylases from plants
DE69434931T2 (de) 1993-04-02 2007-11-22 Rigel Pharmaceuticals, Inc., South San Francisco Methode zur selektiven inaktivierung der viralen replication
US5739309A (en) 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
JPH09500787A (ja) 1993-07-19 1997-01-28 ジェン−プローブ・インコーポレイテッド 蛋白生産、細胞増殖および／または感染症病原体の増殖に対するオリゴヌクレオチド阻害の促進
US5514546A (en) 1993-09-01 1996-05-07 Research Corporation Technologies, Inc. Stem-loop oligonucleotides containing parallel and antiparallel binding domains
US5808036A (en) 1993-09-01 1998-09-15 Research Corporation Technologies Inc. Stem-loop oligonucleotides containing parallel and antiparallel binding domains
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5908779A (en) 1993-12-01 1999-06-01 University Of Connecticut Targeted RNA degradation using nuclear antisense RNA
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
FR2714383B1 (fr) 1993-12-29 1996-02-09 Centre Nat Rech Scient Contrôle de l'expression de gènes.
WO1995018854A1 (en) 1994-01-05 1995-07-13 Gene Shears Pty., Ltd. Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US5583034A (en) * 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
AU706417B2 (en) 1994-02-23 1998-06-17 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting the expression of disease related genes
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
US6054299A (en) 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US6291742B1 (en) 1994-09-26 2001-09-18 Carnegie Institution Of Washington Production of hydroxylated fatty acids in genetically modified plants
US5674683A (en) * 1995-03-21 1997-10-07 Research Corporation Technologies, Inc. Stem-loop and circular oligonucleotides and method of using
AU5741396A (en) 1995-05-11 1996-11-29 Hybridon, Inc. Pyrimidine targeting hairpin triplex-forming oligonucleotide s
US5691140A (en) 1995-05-18 1997-11-25 New England Biolabs, Inc. Bidirectional in vitro transcription vectors utilizing a single RNA polymerase for both directions
US5693773A (en) 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
EP0850318A1 (en) 1995-09-13 1998-07-01 Chiron Corporation Method and construct for screening for inhibitors of transcriptional activation
CA2239976A1 (en) 1995-09-20 1997-03-27 Paul A. Zamecnik Antisense oligonucleotide chemotherapy for benign hyperplasia or cancer of the prostate
JPH09110894A (ja) 1995-10-17 1997-04-28 Soyaku Gijutsu Kenkyusho:Kk ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤
JP3847366B2 (ja) 1996-02-22 2006-11-22 アンジェスＭｇ株式会社 アンチセンスオリゴヌクレオチドを用いた固定性分裂終了細胞増殖剤
US5693512A (en) 1996-03-01 1997-12-02 The Ohio State Research Foundation Method for transforming plant tissue by sonication
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
US5850026A (en) 1996-07-03 1998-12-15 Cargill, Incorporated Canola oil having increased oleic acid and decreased linolenic acid content
CN1189562C (zh) 1996-08-02 2005-02-16 吉倪塞思技术公司 针对核糖核苷酸还原酶r1和r2组分的抗肿瘤反义序列
DE19631919C2 (de) 1996-08-07 1998-07-16 Deutsches Krebsforsch Anti-Sinn-RNA mit Sekundärstruktur
US5747338A (en) 1996-08-15 1998-05-05 Chiron Corporation Method and construct for screening for inhibitors of transcriptional activation
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
GB9703146D0 (en) 1997-02-14 1997-04-02 Innes John Centre Innov Ltd Methods and means for gene silencing in transgenic plants
EP0921195A1 (en) 1997-03-10 1999-06-09 Japan Tobacco Inc. Antisense base sequences
GB9710475D0 (en) 1997-05-21 1997-07-16 Zeneca Ltd Gene silencing
CA2300938A1 (en) 1997-08-20 1999-02-25 Somagenics, Inc. Antisense and antigene therapeutics with improved binding properties and methods for their use
GB9720148D0 (en) 1997-09-22 1997-11-26 Innes John Centre Innov Ltd Gene silencing materials and methods
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CN101818145A (zh) 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AU9522501A (en) 1998-03-20 2002-01-31 Benitec Australia Ltd Control of gene expression
DK1068311T3 (da) 1998-04-08 2011-08-08 Commw Scient Ind Res Org Fremgangsmåder og midler til opnåelse af modificerede fænotyper
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE69914770T2 (de) 1998-08-20 2005-05-12 The Johns Hopkins University School Of Medicine Mitochondriale, als tumormarker geeignete mutationen, die nur ein basenpaar betreffen
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US20040138168A1 (en) 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
IL145778A0 (en) 1999-04-21 2002-07-25 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
JP2003504061A (ja) 1999-07-09 2003-02-04 ワイス プラスミド配列の転写の間における異常型ｒｎａの形成を防止するための方法および組成物
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
GB9930691D0 (en) 1999-12-24 2000-02-16 Devgen Nv Improvements relating to double-stranded RNA inhibition
CN1426466A (zh) 2000-03-17 2003-06-25 贝尼泰克澳大利亚有限公司 遗传沉默
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
GB2362383B (en) 2000-05-19 2003-12-31 Devgen Nv Gene expression system
CA2408326A1 (en) 2000-06-23 2002-01-03 E.I. Dupont De Nemours And Company Recombinant constructs and their use in reducing gene expression
US7109393B2 (en) 2000-08-15 2006-09-19 Mendel Biotechnology, Inc. Methods of gene silencing using inverted repeat sequences
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US6506059B2 (en) 2001-03-29 2003-01-14 Avx Corporation Electrical connectors for display devices
BR0211111A (pt) 2001-07-12 2004-06-22 Univ Massachusetts Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula
CA2457282C (en) 2001-09-13 2015-01-13 California Institute Of Technology Method for expression of small antiviral rna molecules within a cell
WO2003027298A1 (en) 2001-09-27 2003-04-03 Timothy Albert Holton Stem-loop vector system
GB0130955D0 (en) 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
ES2267967T3 (es) * 2002-03-01 2007-03-16 Magnetek S.P.A. Circuito para la alimentacion de una pantalla de plasma.
US20040022748A1 (en) 2002-03-12 2004-02-05 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Method of enhancing skin lightening
AU2002951347A0 (en) 2002-09-09 2002-09-26 Benitec Australia Ltd Genetic silencing

Also Published As

Publication number Publication date
US10358653B2 (en) 2019-07-23
US20130230492A1 (en) 2013-09-05
US20030051263A1 (en) 2003-03-13
CA2311999C (en) 2016-02-23
US20130029425A1 (en) 2013-01-31
US8283329B2 (en) 2012-10-09
AU743798B2 (en) 2002-02-07
EP2267131B1 (en) 2017-04-19
US8580754B2 (en) 2013-11-12
US20140350083A1 (en) 2014-11-27
US20080050342A1 (en) 2008-02-28
US7622633B2 (en) 2009-11-24
US20030056235A1 (en) 2003-03-20
US20080248576A1 (en) 2008-10-09
JP2009291209A (ja) 2009-12-17
US7560438B2 (en) 2009-07-14
EP1042462A1 (en) 2000-10-11
JP2002516062A (ja) 2002-06-04
US6506559B1 (en) 2003-01-14
JP2013048629A (ja) 2013-03-14
US20080081373A1 (en) 2008-04-03
US9102939B2 (en) 2015-08-11
JP5148028B2 (ja) 2013-02-20
US20030055020A1 (en) 2003-03-20
JP2015133993A (ja) 2015-07-27
US20160208280A1 (en) 2016-07-21
US7538095B2 (en) 2009-05-26
AU1938099A (en) 1999-07-12
CA2311999A1 (en) 1999-07-01
JP5969889B2 (ja) 2016-08-17
WO1999032619A1 (en) 1999-07-01
EP2267131A1 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
US10358653B2 (en) Genetic inhibition by double-stranded RNA
US20050229272A1 (en) Compositions and methods for gene silencing
US20170096667A1 (en) INHIBITING GENE EXPRESSION WITH dsRNA
CN113840925A (zh) 修饰非编码rna分子对于在真核细胞中的沉默基因的特异性
GB2383330A (en) Expression system
US20070020652A1 (en) Methods and compositions for RNA interference
WO2004001013A2 (en) Inhibition of gene expression in vertebrates using double-stranded rna (rnai)
Bhatia Characterization of systemic RNAi mutants in Caenorhabditis elegans
Wurmthaler Influence of ribozyme cleavage in E. coli expression systems and the utilization of ligand-dependent ribozymes for conditional genetic control in C. elegans
Seng Investigating the Mechanism of Tissue-Specific RNA Interference in Caenorhabditis elegans
Grishok Analysis of RNA Interference in C. elegans: A Dissertation
WO2003095652A2 (de) EXPRESSIONSKONSTRUKTE ZUR HERSTELLUNG VON DOPPELSTRANG (ds) RNA UND DEREN ANWENDUNG

Legal Events

Date Code Title Description
CB Opposition filed

Opponent name: PAUL JONES

ON Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing)

Free format text: OPPOSITION DISMISSED. NONE OF THE OPPONENT'S ARGUMENTS WERE FOUND TO BE TENABLE.

Opponent name: BENITEC AUSTRALIA LTD

Effective date: 20051103

MK14 Patent ceased section 143(a) (annual fees not paid) or expired